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SUMMARY 
This thesis examines factors influencing the outcomes of patients 
receiving multidisciplinary stage-directed treatment for oesophagogastric 
cancer. 
The hypotheses tested were:  1.The TNM7 staging system is a more 
accurate prognostic tool for oesophageal cancer (OC) than TNM6.  2.Use 
of CT-PET upstages a significant number of patients with occult 
metastases.  3.OC recurrence patterns differ following definitive 
chemoradiotherapy (dCRT) and surgery, but overall recurrence rates and 
survival are comparable for advanced stage disease.  4.An involved 
circumferential resection margin (CRM+) following oesophagectomy is 
associated with poorer survival and its incidence can be reduced with 
neoadjuvant chemoradiotherapy.  5.Early enteral nutrition improves clinical 
outcomes following upper GI cancer resection.  6.Centralisation of 
oesophagogastric cancer (OGC) surgery in S.E. Wales is feasible and 
associated with improved clinical outcomes. 
Reclassification with TNM7 resulted in stage re-categorisation of 11.9% of 
OC patients.  Multivariate analysis indicated only TNM7 prognostic group 
to be independently and significantly associated with survival.  CT-PET 
upstaged OC M stage in 24.0% of patients.  Loco-regional OC recurrence 
was commoner after dCRT (p<0.0001) but distant recurrence commoner 
after surgery (p=0.001).  Disease-free survival was better after surgery for 
stage I (p=0.069) and II (p=0.011) but comparable with dCRT for stage III 
4 
(p=0.878) and IV (p=0.710).  CRM+ occurred in 38.0% of all OC patients, 
and 62.4% of pT3 patients.  Multivariate analysis revealed lymphovascular 
invasion (p<0.0001) and CRM+ (p=0.002) were independently and 
significantly associated with disease-free survival.  Multivariate analysis 
revealed EUS T stage (p<0.0001) and neoadjuvant chemoradiotherapy 
(p<0.0001) were independently associated with CRM+.  Early enteral 
nutrition (EEN) was associated with reduced hospital stay (p=0.023) and 
less operative morbidity (p=0.044) than control management, due to fewer 
wound infections (p=0.017), chest infections (p=0.036) and anastomotic 
leaks (p=0.055).  Following centralisation, OGC critical care (p<0.0001) 
and total hospital stay (p=0.037) were significantly reduced.  Serious 
operative morbidity (Dindo-Clavien grade III+) decreased from 33.3% to 
16.7% (p=0.066). 
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1.1 EPIDEMIOLOGY 
Oesophageal carcinoma is the eighth commonest cancer worldwide 
(Parkin 2001), and the ninth commonest cancer in the UK, where it 
accounted for more than 8000 new diagnoses and more than 7600 deaths 
in 2008 (Cancer Research UK 2011).  The incidence for men and women 
in the UK is 17.5 and 8.8 per 100,000 respectively (Cancer Research UK 
2011).  The reported incidence of oesophageal cancer in Wales is higher 
still at 20.9 and 10.6 per 100,000 respectively (Welsh Cancer Intelligence 
and Surveillance Unit 2009).  Oesophageal cancer has an almost two-fold 
male predominance overall, however for adenocarcinoma of the 
oesophagus specifically it is even higher (Cancer Research UK 2011).  
This male predominance is one of the highest sex differentials of any non-
occupational cancer (Cancer Research UK 2011).  Oesophageal cancer 
remains predominantly a disease of old age, with two thirds of cases 
diagnosed in people over the age of 65 (Cancer Research UK 2011).  The 
last 30 years have seen a marked increase in the UK incidence of 
oesophageal cancer for both sexes, but particularly males, in whom the 
incidence has almost doubled between 1975 and 2007.  
The epidemiology of oesophageal cancer differs significantly by 
histological subtype.  Squamous cell carcinoma remains the dominant 
type worldwide, with the highest incidences reported in developing 
countries, particularly in the so called Asian ‘oesophageal cancer belt’, 
extending from Northern Iran through Central Asia to Northern China, 
where incidence is as high as 200 per 100,000.  However, in developed 
1 Introduction 
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countries the incidence of squamous cell carcinoma has remained fairly 
stable or even decreased, while that of adenocarcinoma has increased 
substantially in recent decades, particularly in men.  Adenocarcinoma is 
now the predominant histological subtype for Caucasian men in the UK.  
Furthermore, in the UK reported rates of adenocarcinoma are the highest 
in the world (Bollschweller et al 2001, Wild et al 2003).  The same time 
period has seen a parallel increase in the incidence of adenocarcinoma of 
the gastric cardia, which now accounts for more than 50% of gastric 
cancers, suggesting possible aetiological similarities. 
1.2 AETIOLOGY 
The aetiology of oesophageal cancer differs for the two predominant 
histological cell types. 
1.2.1 Squamous cell carcinoma 
Smoking and alcohol consumption are the predominant risk factors for 
oesophageal squamous cell carcinoma in Western countries.  Smoking 
and alcohol together have a synergistic effect in promoting the 
developement of oesophageal squamous cell carcinoma, with the risk 
ranging from 20 to 130-fold higher for various combinations of heavy 
drinking and smoking (Castellsague et al 1999, Zambon et al 2000, 
Freedman et al 2007).  Alcohol also increases the risk independently of 
smoking.  Estimates of the increase in the risk of oesophageal squamous 
cell carcinoma associated with alcohol consumption range from 18% for 
men and 35% for women per 10g/day alcohol consumption, (Weikert et al 
1 Introduction 
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2009) to 5-fold for those drinking more than three drinks per day 
(Freedman et al 2007), up to almost 25-fold higher in men drinking 84 or 
more drinks per week (Zambon et al 2000).  The mechanism of action of 
alcohol in the development of oesophageal squamous cell carcinoma 
remains unclear, although possibilties include direct damage to the 
oesophageal mucosa, an increase in mucosal susceptibility to other 
carcinogens, or a secondary effect via associated dietary deficiencies.  
The third main risk factor for squamous cell carcinoma in the developed 
world is a diet lacking in fruit and vegetables.  Risk reductions have been 
demonstrated for increased consumption of both fruit and vegetables, 
although in all studies of these effects there exist the confounding effects 
of smoking and alcohol (Key 2011). 
Other dietary and lifestyle factors influencing the risk of squamous cell 
carcinoma include nutritional deficiencies at a young age, particularly 
riboflavin, vitamin A and vitamin C, diets rich in nitrosamines, and the 
consumption of very hot drinks (Iran – IARC Study Group 1979, 
Pourshams et al 2005, Mosavi-Jarrahi and Mohagheghi 2006).  It is 
postulated that these factors cause an asymptomatic chronic oesophagitis, 
different from that seen in Western society-related gastro-oesophageal 
reflux disease, which is thought to be a precursor to squamous cell 
carcinoma.  These aetiological factors are the most important in the high 
incidence developing countries, where poverty and malnutrition are 
prevalent.  
1 Introduction 
 9 
Oesophageal strictures associated with the ingestion of corrosive agents, 
particularly in childhood, are associated with a 1000-fold increase in the 
risk of carcinoma.  There is a similarly increased risk in patients with 
achalasia.  The exact size of the increased risk is uncertain but has been 
estimated as 140-fold with long-standing achalasia, compared with the 
general population (Brucher et al 2001).  The Plummer-Vinson syndrome 
(dysphagia, iron-deficiency anaemia, koilonychia and oropharyngeal 
mucosal atrophy) is associated with an increased risk of cervical 
oesophageal cancer (Ribeiro Jr et al 1996).  Finally the rare autosomal 
dominant condition tylosis palmarum is associated with a very high 
incidence of squamous cell carcinoma (Varela et al 2011). 
1.2.2 Adenocarcinoma 
Gastro-oesophageal reflux disease (GORD) and obesity are the principal 
risk factors for oesophageal adenocarcinoma.  It has been estimated that 
4-9% of the population experience daily heartburn, and up to 20% 
experience symptoms on a weekly basis (Cameron 1997).  Lagargen et al 
(1999) stratified the risk of developing oesophageal cancer according to 
the symptoms of GORD.  The risk of cancer is estimated to be 7.7 times 
higher in those with recurrent symptomatic reflux compared to those 
without symptoms, with even greater risk (44-fold) for those with more 
frequent, more severe or longer lasting symptoms.  However others have 
found that GORD is not an indendent risk factor for oesophageal cancer. 
(Solaymani-Dodaran et al 2004).  The cancer risk associated with reflux is 
due to the development of Barrett’s metaplasia.  Barrett’s oesophagus was 
1 Introduction 
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first described in 1950 and is defined as the replacement of the squamous 
epithelium by a columnar-lined mucosa in the lower oesophagus (Barrett 
1950).  The exact prevalence of Barrett’s oesophagus is unclear as many 
patients are asymptomatic.  Post-mortem studies estimate it may be as 
high as 5% (Cameron et al 1990), but endoscopy studies suggest it is 
found in approximately 1% of unselected patients undergoing endoscopy 
(Cameron et al 1992), but in 12% of those with symptoms of reflux 
(Winters Jr et al 1987).  The metaplasia arises as a result of chronic reflux, 
with subsequent changes through increasing grades of epithelial dysplasia 
to invasive adenocarcinoma (Fitzgerald 2006).  The natural history of 
Barrett’s oesophagus remains poorly understood with considerable 
uncertainty regarding the overall risk of developing cancer within a 
Barrett’s segment, the risk of progression from low grade dysplasia, and 
the risk of progression to cancer from high grade dysplasia.  Numerous 
studies over the last few decades have estimated the incidence of 
adenocarcinoma in Barrett’s oesophagus, with risk per patient year 
ranging from 1 in 56 to 1 in 315 (Robertson et al 1988, Miros et al 1991, 
Katz et al 1998, Oberg et al 2005).  Additionally there is geographical 
variation in incidence between Western countries, with incidence rates in 
the UK and USA of 1% and 0.5% respectively per year (Jankowski et al 
2002).  The most notable risk factor for malignant transformation of 
Barrett’s metaplasia is the segment length (Menke-Pluymers et al 1993), 
but other factors include male sex, age over 45, Caucasian ethnicity, 
severe reflux symptoms, obesity and heavy smoking (Watson et al 2005).  
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The obesity epidemic in the Western world, most notably in the USA and 
UK, has paralleled the rising incidence of oesophageal adenocarcinoma in 
these countries over the last 30 years.  There is a three to six-fold 
increased risk of oesophageal adenocarcinoma in the overweight (Cheng 
et al 2000), which is attributed at least in part to the increased reflux and 
increased incidence of hiatus hernia that is associated with excess intra-
abdominal adiposity.  However, evidence is also accumulating that the 
obesity effect is independent of reflux (Lindbald et al 2005).  In addition 
there is a marked sex difference to the obesity effect, with the male 
(abdominal) fat distribution being particularly associated with cancer risk 
(Vaughan et al 2002).  The role of Helicobacter pylori (H. pylori) infection 
in the aetiology of junctional cancer remains unclear but there is evolving 
evidence of a reduced risk of junctional adenocarcinoma conferred by H. 
pylori infection (Whiteman et al 2010).  It is postulated that gastric H. pylori 
infection paradoxically protects the lower oesophagus, by virtue of 
hypochlorhydria due to gastric atrophy, and ammonia production from the 
action of bacterial urease, changing the contents of the refluxing gastric 
juice.  The increase in junctional cancer incidence has mirrored a 
decrease in H. pylori incidence in developed countries, and H. pylori 
eradication has become widespread over the last 20 years.  Socio-
economic deprivation has an adverse effect on adenocarcinoma risk, but 
this is less strong than for squamous cell carcinoma, and may be 
confounded by social class related differences in obesity, smoking and 
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alcohol, the latter two of which both increase reflux by reducing the lower 
oesophageal sphincter pressure. 
It is known that a small proportion of cases of Barrett’s oesophagus and 
oesophageal adenocarcinoma display familial aggregation (Ash et al 
2011). However, the exact genetic basis for this remains uncertain, and 
the vast majority of such cases arise sporadically.  Orloff et al (2011) from 
the Cleveland Clinic, USA, have recently identified three major genes 
(MSR1, ASCC1 and CTHRC1) that are associated with Barrett’s 
oesophagus related adenocarcinoma.  Just over 11% of siblings studied 
had a germline mutation in one of these three genes, most frequently 
involving MSR1 (Orloff et al 2011).  A further validation series of unrelated 
patients with Barrett’s oesophagus related adenocarcinoma confirmed that 
two of fifty-eight cases (3.4%) carried a germline mutation in the MSR1 
gene (Orloff et al 2011).  The genetic basis of Barrett’s oesophagus and 
the risk of malignant transformation into adenocarcinoma is clearly in it’s 
infancy at present, and further larger cohort studies are needed to confirm 
the findings of Orloff et al (2011).  However, it is very probable that 
developments in this area will play a role in risk stratification and 
premorbid diagnosis in the future. 
1.3 DIAGNOSIS 
1.3.1 Symptoms 
The cardinal symptom of oesophageal cancer is dysphagia, usually 
progressive, and often accompanied by the vomiting of undigested food.  
1 Introduction 
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However, this symptom occurs as a consequence of tumour mass effect in 
advanced stage disease, and this explains the late presentation of 
oesophageal cancer. 
1.3.2 Endoscopy 
Endoscopy and biopsy remains the investigation of choice for diagnosing 
oesophageal cancer.  In addition to providing histological confirmation of 
the oesophageal malignancy, endoscopy also allows some assessment to 
be made of the local extent of the tumour.  Some of the factors which can 
be appreciated endoscopically include the proximal and distal extent of the 
tumour, the length of the tumour, the relationship to the oesophagogastric 
junction, and whether the lesion can be crossed endoscopically.  Barium 
studies are an alternative diagnostic modality, often reserved for those 
who cannot tolerate endoscopy, although clearly this technique is 
disadvantaged by the inability to take biopsies.  Arguably the most difficult 
lesions to diagnose endoscopically are very early cancers arising within a 
Barrett’s segment.  Studies have demonstrated failure to diagnose 
oesophagogastric malignancy at the patient’s first endoscopy in as many 
as 10%, and a further 10-20% require a further endoscopy (Bramble et al 
2000, Yalamarthi et al 2004).  The principal factors responsible for these 
deficiencies are failure to suspect malignancy, and consequently the 
retrieval of inadequate numbers of biopsies.  When six or more biopsies 
are taken from a segment of Barrett’s oesophagus, the diagnostic yield to 
detect high risk premalignant lesions reaches 100% (Fitzgerald RC et al 
2001).  The current recommendation for Barrett’s sampling is four 
1 Introduction 
 14 
quadrant biopsies at 2cm intervals along the length of the segment, which 
has been shown to increase diagnostic accuracy and aid differentiation of 
high grade dysplasia form adenocarcinoma, particularly when visible 
mucosal abnormalities are present (Lal et al 1992, Levine et al 1993).     
1.3.3 Open access endoscopy referral 
Recent UK referral guidelines for suspected cancer from the National 
Institute for Health and Clinical Excellence (2005) state that patients of any 
age with alarm symptoms (chronic GI bleeding, dysphagia, progressive 
unintentional weight loss, persistent vomiting, iron deficiency anaemia, 
epigastric mass, suspicious barium meal result) or those aged 55 and 
older with unexplained dyspepsia should be referred urgently for 
endoscopy or to a specialist.  The guidelines also state “In patients aged 
less than 55 years, endoscopic investigation of dyspepsia is not necessary 
in the absence of alarm symptoms”.  These guidelines have caused 
concern amongst many upper GI surgeons, as the alarm symptoms 
prioritising urgent endoscopy are largely markers of advanced, possibly 
incurable, oesophagogastric cancer (Stephens et al 2005, Bowrey et al 
2006).  Indeed, the possibility to detect early oesophagogastric cancers in 
younger patients, the group most likely to benefit from curative treatment, 
is either delayed or lost altogether if applied rigidly.  Furthermore, Sundar 
et al (2006) reviewed local open access endoscopy results and found that 
of 228 patients diagnosed with oesophagogastric cancer over a 4 year 
period, 5 patients who presented with uncomplicated dyspepsia under the 
age of 55 years had operable cancers. 
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1.3.4 Screening and surveillance 
At present there is no role for screening of the general population for 
oesophageal cancer in the UK.  Neither is there any proven benefit in the 
endoscopic screening of patients with symptomatic reflux, as the absolute 
risk of cancer in such patients has been shown to be less than 1 in 1000 
per annum (Shaheen and Ransohoff 2002), and consequently this is not 
recommended in the UK (Watson et al 2005).  Endoscopic surveillance of 
patients with known Barrett’s metaplasia, with the aim of detecting cancer 
or high grade dysplasia, is widely practiced in the UK, Europe and the 
USA.  The presumed benefits of surveillance are the earlier detection of 
oesophageal adenocarcinoma, with an increased opportunity for curative 
treatment, and consequently better outcomes.  However, this practice 
remains contentious as the benefits have never been proven in a 
randomised controlled trial, although many non-randomised studies have 
demonstrated better survival rates with surveillance detected cancers than 
non surveillance detected cancers (Pera et al 1992, Levine at el 1993, 
Peters et al 1994, Fountoulakis et al 2004).  The current recommendation 
in the UK guidelines is for surveillance endoscopy to be undertaken every 
2 years, for patients with non dysplastic Barrett’s (Watson et al 2005).  
This recommendation has been derived from computer modelling, based 
on the assumption of a 1% risk of cancer per annum in the UK.  In the 
past, patients were considered eligible for surveillance if their performance 
status made them potentially suitable for oesophagectomy.  However the 
increasing use of endoscopic treatment modalities for early oesophageal 
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cancers means that this is no longer necessarily the case.  The Barrett’s 
Oesophagus Surveillance Study (BOSS) is a large multicentre UK 
randomised controlled trial of surveillance vs. questionnaire follow-up for 
Barrett’s.  It is envisaged that the results of this study which recruited more 
than 3400 patients when it closed in 2011 will improve future surveillance 
practice.   
1.4 STAGE CLASSIFICATIONS 
In 1986, following an agreement between the American Joint Committee 
on Cancer (AJCC), the Japanese Joint Committee (JJC) and the 
International Union Against Cancer (IUCC), the TNM staging classification 
system was introduced.  This is the gold standard staging system used 
globally.  Its objectives are to inform the planning of treatment, to help 
determine prognosis and to allow comparison of outcomes between 
centres.  Periodic updates are published to incorporate the expanding 
evidence base.  The TNM system has recently been revised in a 7th 
edition (Sobin et al 2009), with effect from 2010.  This incorporates major 
modifications for oesophageal cancer, based for the first time on a 
mathematical data driven approach (Rice et al 2010).  Staging can be 
based on a combination of clinical (radiological) and surgical findings, but 
ultimately the final stage is set histopathologically by analysis of the 
resected specimen.   
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1.4.1 Anatomical site 
The TNM classification of the anatomical site of the primary tumour is 
derived from the original description by the Japanese Society for 
Esophageal Diseases (1976), and divides the oesophagus into four parts.  
The cervical oesophagus from the lower border of the cricoid cartilage to 
the thoracic inlet at the suprasternal notch.  The upper thoracic portion  
from the thoracic inlet to the level of the tracheal bifurcation.  The mid 
thoracic portion, which is the proximal half of the oesophagus between the 
tracheal bifurcation and the oesophagogastric junction and the lower 
thoracic portion which is the distal half. (Sobin at al 2009).  
1.4.2 Tumour stage 
The T stage is based on the depth of invasion of the tumour through the 
different layers of the oesophageal wall.  Changes in T stage in TNM7 
include the inclusion of high grade dysplasia, along with carcinoma in situ, 
in the Tis category.  In addition T1 has been subdivided into T1a and T1b 
components to reflect tumour extension confined to the mucosa, or 
extending into the submucosa respectively.  Stage T4 denotes tumour 
invasion of adjacent structures, and has now been subdivided into T4a 
and T4b components.  The former describes structures that can be 
resected surgically, in part if necessary, including pleura, pericardium and 
diaphragm, whereas the latter describes non-resectable structures, such 
as aorta, trachea and vertebral body.  Depth of tumour invasion is 
established as one of the most consistent negative prognostic indicators 
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(Ide et al 1994, Lieberman et 1995, Paraf et al 1995, Lozac’h et al 1997, 
Khan et al 2003). 
1.4.3 Nodal stage 
The regional lymph nodes are defined according to the anatomical location 
of the primary tumour.  In the cervical oesophagus the regional lymph 
nodes are the scalene, internal jugular, upper and lower cervical, 
paraoesophageal and supraclavicular.  With regard to the intrathoracic 
oesophagus the regional lymph nodes are the internal jugular, 
tracheobronchial, superior mediastinal, paratracheal, perigastric (excluding 
coeliac), carinal, pulmonary hilar, perioesophageal, left gastric, pericardial, 
nodes of the lesser curve of the stomach and posterior mediastinal nodes.  
Lymph node status has long been recognised as one of the most 
important prognostic markers (Khan et al 2003, Lozac’h et al 1997, Paraf 
et al 1995).  Furthermore, the number of lymph node metastases is also a 
widely reported prognostic indicator (Ide et al 1994, Lieberman et al 1995, 
Kawahara et al 1998, Zafirellis et al 2002, Kunisaki et al 2005, Mariette et 
al 2008).  A major update was incorporated into TNM7 (Sobin et al 2009, 
Rice et al 2012) to take account of the number of lymph node metastases, 
with N stage sub classifications of N1 (1-2 nodes), N2 (3-6 nodes), or N3 
(>6 nodes). 
1.4.4 Metastasis stage 
The M stage is the assessment of distant metastases.  In the previous 6th 
edition of TNM (Sobin and Wittekind 2002) there were M1a and M1b sub 
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classifications, dependent on the position of the primary tumour and the 
location of metastases.  However in TNM7 this had been simplified to M0 
denoting the absence of distant metastases and M1 where there is 
evidence of metastases. 
1.4.5 Stage groupings 
Patients are also allocated a stage group ranging from I to IV.  These 
groups were previously defined on the basis of anatomical T, N and M 
stages under TNM6.  The updated TNM7 contains revised grouping 
definitions to incorporate the new N stage system, but also contains a new 
system of prognostic groupings.  The latter differ for adenocarcinoma and 
squamous cell carcinoma, and incorporate additional factors of prognostic 
relevance for early stage (I and II) tumours.  For both histological subtypes 
these definitions include tumour grade, and for squamous cell carcinoma, 
site within the oesophagus is also specified.  A summary of TNM7 is 
provided in Appendix 2. 
1.4.6 Siewert classification 
In response to the increasing incidence of junctional oesophagogastric 
tumours, Siewert and Stein (1998) proposed a classification of such 
tumours into three groups based on endoscopic, radiological and 
histopathological findings.  Type I are adenocarcinomas of the distal 
oesophagus, with an epicentre 2-5 cm above the cardia which may 
infiltrate the oesophagogastric junction from above.  Type II are true 
junctional cancers, with an epicentre within 2 cm of the cardia.  Type III 
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are sub-cardial gastric cancers, with an epicentre 2-5 cm below the cardia 
which may infiltrate the oesophagogastric junction and distal oesophagus 
from below.  These tumours pose a particular difficulty in staging, and 
there is debate as to which TNM system should be used for each type.  In 
the TNM7 classification, Type I and II are staged with the oesophageal 
system, and Type III are staged with the gastric system, provided the 
epicentre is at least 2 cm below the cardia and there is no extension into 
the oesophagus (Sobin et al 2009).  
1.4.7 Histopathological specimen reporting 
High quality histopathological assessment of oesophagectomy specimens 
facilitates accurate prognostic information for patients and clinicians, 
provides feedback to surgeons on the quality of resection and the effects 
of neoadjuvant therapy, and provides feedback for radiologists on the 
accuracy of staging information (Mapstone 2007).  A minimum core data 
set is defined by the Royal College of Pathologists, and includes TNM 
stage, along with other pathological markers of prognostic value. 
1.4.8 Margin status  
Proximal and distal resection margin status must be assessed as there is 
good evidence that tumour involvement of either increases the risk of 
recurrence, although the evidence is stronger for proximal than distal 
margins (Robey-Cafferty et al 1991, Paraf et al 1995, Mariette et al 2003, 
Casson et al 2000).  Circumferential margin (CRM) status remains an area 
of contention.  Since the seminal study of Sagar et al (1993), 
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demonstrating the prognostic significance of a positive CRM, a number of 
other studies of heterogeneous design have sought to clarify the issue 
(Dexter et al 2001, Khan et al 2003, Griffiths et al 2006, Sujendran et al 
2008, Scheepers et al 2009, Saha et al 2009, Mirzenami et al 2010).  
Many, but not all, (Khan et al 2003) have found some degree of prognostic 
significance for CRM status.  Given this uncertainty, some have suggested 
CRM status should not be routinely reported following oesophagectomy 
(Khan et al 2003), but it remains in the core data set until a consensus can 
be reached, and to provide surgical and radiological feedback (Mapstone 
2007). 
1.4.9 Tumour differentiation 
Increasing tumour grade has an established negative association with 
survival in both squamous cell carcinoma and adenocarcinoma of the 
oesophagus (Robey-Cafferty et al 1991, Paraf et al 1995, Lieberman et al 
1995).  Where areas of different grades are present, differentiation is 
taken as that of the highest grade present in a tumour. 
1.4.10 Vascular invasion 
Vascular invasion, either venous or lymphatic, has an established 
prognostic association in oesophageal cancer, using both univariate and 
multivariate analysis (Robey-Cafferty et al 1991, Ide et al 1994, Paraf et al 
1995, Zafirellis et al 2002).  Invasion of any venous or lymphatic space 
should be recorded as vascular invasion (Mapstone 2007). 
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1.4.11 Response to neoadjuvant treatment 
Oesophageal resection specimens frequently demonstrate 
histopathological evidence of the effects of chemotherapy or radiotherapy.  
Several schemes have been suggested for the classification of response 
to neoadjuvant therapy (Mandard et al 1994, Chirieac et al 2005), but 
none are universally accepted and their use is largely restricted to the 
research setting.  TNM stage following neoadjuvant therapy is prefixed by 
‘y’, with complete pathological response designated ypT0N0. 
1.5 PRE-OPERATIVE STAGING 
Accurate radiological staging of patients with oesophageal cancer is 
crucial, as it allows the most appropriate stage-directed management to be 
tailored to individual patients, and avoids aggressive surgery with no 
chance of cure in those with disseminated disease.  All staging modalities 
should define stage in accordance with the TNM classification.  The 
general principles of staging are first to identify those patients who have 
metastatic disease (M1) at presentation and for whom further staging and 
curative treatment is inappropriate.  Following this, precise locoregional 
staging is undertaken to establish not only T and N stage, but also the 
precise margins of the disease and the position of lymph node metastases.  
The principal modalities used in contemporary staging include computed 
tomography (CT), endoluminal ultrasonography (EUS), endoscopic 
mucosal resection (EMR), CT-positron emission tomography (CT-PET) 
and laparoscopy, all of which have complementary roles.  
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1.5.1 Computed tomography (CT) 
Computed tomography is usually the first radiological modality undertaken.  
The main purpose of CT is to establish the presence or absence of distant 
metastases, and consequently determine the need to progress to further 
staging modalities.  CT technology has developed considerably over the 
last decade, with the most recent scanner hardware advances relating 
mainly to x-ray detectors.  Contemporary scanners utilise multiple rows of 
detectors, arranged along the longitudinal axis of the patient, allowing the 
acquisition of multiple sets of projection data for each rotation of the gantry 
assembly (Cody and Mahesh 2007).  Such progress has resulted in the 
findings of many studies of CT accuracy becoming outdated, as many 
involved older generation scanning technology. 
The T stage accuracy of CT compared with histopathology has been 
variably reported from 43 to 92%, with increased accuracy attributed to 
new techniques including virtual endoscopy (3D reconstruction from an 
endoluminal perspective, Kim et al 2006, Panebianco et al 2006, Onbas et 
al 2006), and hydro-CT (water loading with gas forming granules to 
enhance oesophageal distension, Ba-Ssalamah et al 2011).  One 
particular area of controversy relating to CT is the loss of the 
perioesophageal fat plane.  When present, invasion is unlikely, but when 
absent it cannot be taken as definite evidence of such, and this may 
explain CT overestimation of tracheal, bronchial and aortic invasion.  
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Meta-analysis derived CT N stage sensitivity and specificity are 50% and 
83% respectively (van Vliet et al 2008).  However, many of the included 
studies involved CT technology outdated by contemporary standards, and 
the criteria used to identify malignant lymph nodes are an area of 
considerable controversy.  It is very difficult on CT to differentiate 
abnormally enlarged lymph nodes that contain tumour, from those 
enlarged for benign reasons, and size criteria are therefore important.  
Lymph nodes greater than 1cm in size are likely to be malignant, although 
size criteria for such involvement have been reported by various authors 
from 0.5 to 1.5 cm (Fekette et al 1988).  Furthermore, mediastinal lymph 
nodes greater than 1cm diameter can be normal, and conversely normal 
sized nodes can contain tumour deposits.  One study of 23,000 lymph 
nodes assessed histopathologically following gastric cancer resection, 
found the mean diameter of a metastatic node was 7.8 mm, and if a cut off 
of 5 mm was applied, then 38% of metastatic nodes would be missed 
(Noda et al 1998).    
The principal strength of CT is in the assessment of distant metastases, 
for which meta-analysis derived sensitivity and specificity have been 
reported as 52% and 91% respectively (van Vliet et al 2008).  The main 
weaknesses of CT with regard to M stage are the assessment of very 
small lesions and the detection of small volume peritoneal disease.  For 
the latter reason there remains a need for staging laparoscopy for tumours 
with a component below the diaphragm.  
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1.5.2 Endosonography (EUS) 
The principal strength of EUS is in locoregional staging, for which it is the 
established gold standard, and is recommended for all patients with 
oesophageal cancer potentially suitable for curative treatment (Allum et al 
2011).  EUS has been shown to reduce the incidence of open and closed 
oesophageal surgery (Fockens et al 1998).  EUS also allows guided fine 
needle aspiration (FNA) of suspicious lymph node metastases where 
indicated.  A further benefit of EUS is the accurate determination of the 
margins and length of disease, which are important from both surgery and 
radiotherapy perspectives.  The main weakness of EUS is that failure to 
cross stenotic tumours is reported in as many as third of patients (Vrieze 
et al 2004), which is associated with a poor prognosis (Vickers and 
Alderson 1998), although valuable staging information can still be obtained 
using blind endoscopic probes (Twine et al 2009a). 
EUS is known to be more accurate at determining T stage than CT (Kienle 
et al 2002).  Reported accuracy ranges from 33 to 90% for T1 tumours, 
but for T2, T3 and T4 tumours there is less disparity between studies and 
generally greater accuracy of 75 to 93% (Rosch et al 1992, Grimm et al 
1993, Dittler and Siewert 1993, Catalano et al 1995).   
For the assessment of lymph nodes EUS provides more information than 
CT.  In addition to size, EUS can determine shape, border demarcation, 
echo intensity and texture of lymph nodes.  The same studies show 
variation in accuracy for nodal disease, ranging from 42 to 94% for N0 
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tumours and 74 to 89% for N1 tumours (TNM6 stages) (Rosch et al 1992, 
Grimm et al 1993, Dittler and Siewert 1993, Catalano et al 1995).  Meta-
analysis derived EUS N stage sensitivity and specificity are 80% and 70% 
respectively (van Vliet et al 2008). 
Although EUS is not generally suitable for the assessment of distant 
metastases, it can identify coeliac axis or cervical lymph metastases, and 
facilitate guided FNA if appropriate. 
A further consideration in the utilisation of EUS is the experience of the 
endosonographer, as results are highly operator dependant.  National UK 
guidelines have recently recommended that centres should perform at 
least 100 staging examinations annually, and each centre should have at 
least one fully trained endosonographer (Allum et al 2011).  Such 
guidance strengthens the current argument for centralising specialised 
staging services in high volume centres.   
1.5.3 Endoscopic Mucosal Resection (EMR) 
EMR is an emerging modality increasingly used for the staging and 
treatment of early oesophageal cancer.  EMR is indicated for the 
assessment of areas of Barrett’s oesophagus where invasive disease is 
suspected.  One particular advantage of EMR is the opportunity to obtain 
biopsies that extend deeper into the oesophageal wall than those obtained 
at standard endoscopy, and this is crucial in the accurate staging of T1 
cancers.  A recent study has shown submucosa is contained in 88% of 
EMR biopsies but only 1% of standard biopsies (Wani et al 2010).  
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Furthermore, there is significantly stronger interobserver agreement on the 
histopathological interpretation of specimens taken by EMR than standard 
mucosal biopsies (Mino-Kenudson et al 2007, Wani et al 2010).  It is now 
generally accepted that EMR is more accurate than EUS in staging T1 
cancers (Mino-Kenudson et al 2007, Peters FP et al 2008, Curvers WL et 
al 2008).   
1.5.4 CT-positron emission tomography (CT-PET) 
Medical imaging utilising positron emission was first reported at the 
Massachusetts General Hospital, Boston, USA in 1951.  A simple 
prototype scanner, incorporating two opposed detectors, was built in-
house and used for cranial imaging of patients with suspected brain 
tumours, with encouraging early results (Sweet 1951).  Progressive 
technological development over subsequent decades resulted in the sale 
by Siemens of the first commercial positron emission tomography (PET) 
scanner to UCLA, Los Angeles, USA in 1976.  As a nuclear medicine 
technique, PET provides functional rather than anatomical information. 
The underlying principle is based on positrons (positively charged electron 
counterparts) emitted by short half-life radionuclides interacting in body 
tissues with electrons, resulting in the production of gamma rays, which 
are detectable by conventional means.  The most commonly used 
radionuclide, 18F, is coupled to the glucose analogue fluorodeoxyglucose 
(FDG) and injected intravenously.  The rate of cellular tracer uptake is 
proportional to metabolic activity, and once intracellular, FDG cannot be 
immediately metabolised, unlike glucose, and therefore remains 
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intracellular until radioactive decay occurs.  Malignant tumours usually 
have higher metabolic rates than normal tissue, enabling their 
identification with CT-PET (Branstetter et al 2005).   
Traditionally PET information was software fused with separate CT data to 
provide anatomical localisation.  More recently integrated CT-PET 
hardware has been developed (Beyer et al 2000), with the first commercial 
clinical application in 2001, and since then more than 1000 installations 
have been established worldwide (Beyer and Townsend 2006).  The 
advantage of integrated scanning is attributable to more accurate co-
registration of the CT and PET datasets due to lack of patient movement 
artefact.  The technology is widely used for a raft of different cancers 
including lung, gastrointestinal, breast and lymphoma (Endo et al 2006). 
In oesophageal cancer the bulk of the published data on staging relates to 
separate CT and PET scans.  The role of CT-PET in assessing T stage is 
very limited.  Identification of a tumour on CT-PET relies upon adequate 
FDG uptake, and although 95-100% of large tumours demonstrate such 
uptake, this is less predictable for early stage tumours (T1 and T2) and 
poorly cellular mucinous tumours.  Conversely false positive results may 
occur due to gastro-oesophageal reflux disease.  Studies including 
adenocarcinoma and squamous cell carcinoma report a failure to detect 
rate of between 0 to 20% of oesophageal tumours (Rankin et al 1998, 
Kato et al 2005, Pfau et al 2007), with many of the undetected cancers 
being early stage lesions.  CT-PET has limited value in assessing the 
perioesophageal fat plane in T3/T4 tumours, although this is due to the CT 
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component, and the PET data adds nothing in this regard (Choudhary et al 
2008). 
The accuracy of N stage determination is reported variably.  Meta-analysis 
derived PET N stage sensitivity and specificity are 57% and 85%, 
representing an improvement over CT for both parameters, and poorer 
sensitivity yet better specificity compared with EUS (van Vliet et al 2008).  
Few studies have compared CT-PET compared with separate CT and 
PET scans, although Yuan et al (2006) have demonstrated 12 and 5% 
improvements in sensitivity and specificity respectively for the former.  N 
stage accuracy also differs for peritumoural lymph nodes compared with 
more distant regional nodes, with the former being most difficult to identify 
due to FDG uptake from the primary tumour (Flamen et al 2000, Yoon et 
al 2003). 
The principal strength of PET is in the detection of distant metastases, 
where meta-analysis derived sensitivity and specificity have been reported 
as 71 and 93% respectively (van Vliet et al 2008).  These sensitivity and 
specificity figures represent 19 and 2% improvements over CT in these 
parameters respectively (van Vliet et al 2008).  Recent UK studies of the 
use of CT-PET in oesophageal cancer, in Leicester and Leeds have 
reported a change of treatment type as a direct result of this imaging 
modality in 20 to 40% of patients.  This was mainly attributed to upstaging 
by the detection of occult metastases.  However, the caseloads studied 
were relatively small at 38 and 25 patients (Williams et al 2009, 
Salahudeen et al 2008). 
1 Introduction 
 30 
Additional applications of CT-PET in the treatment of oesophageal cancer 
include assessment of the response to neoadjuvant therapy, the planning 
of radiotherapy, and the identification of recurrent disease.  However, the 
role of CT-PET in these areas remains to be defined at present (Bruzzi et 
al 2007, Choudhary et al 2008, Mujis et al 2010). 
1.5.5 Staging Laparoscopy  
Current UK guidelines suggest staging laparoscopy for select patients with 
lower oesophageal or junctional tumours with a gastric component (Allum 
et al 2011).  The principal strengths are the identification of small 
peritoneal or liver metastases, undetectable by other modalities, and the 
option to cytologically sample the peritoneal cavity.  De Graff et al (2007) 
recently demonstrated that staging laparoscopy avoids inappropriate 
laparotomy in 17.1% and 17.2% of patient with lower oesophageal and 
junction carcinomas respectively.  Furthermore, the routine use of 
peritoneal cytology in patients without overt metastases on laparoscopy, 
has been found to upstage a further 5% and 9% of patients with 
oesophageal and junctional tumours respectively (Nath et al 2008). 
1.6 PRE-OPERATIVE PHYSIOLOGICAL ASSESSMENT 
The aims of physiological assessment are to inform decision making 
related to treatment type and to allow optimisation of performance status 
in patients selected for surgery in order to minimise operative risk.  
Oesophagectomy carries a substantial element of cardiopulmonary stress, 
and pulmonary complications in particular are a major cause of mortality 
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(Griffin et al 2002, Bailey et al 2003, NHS Information Centre 2010).  
Consequently, a raft of clinical risk predictors have emerged that are 
thought to have an association with surgical outcome, although the 
reliability of many remain controversial, and there is no consensus on 
selection criteria for upper GI resectional surgery.  Age alone is not an 
absolute contraindication to surgery, even though comorbidity and organ 
dysfunction increase with age.  It has been reported that in a specialist unit 
with appropriate case selection, good survival outcomes are achievable for 
patients over the age of 70 years compared to those under 70 years, 
although the risk of morbidity is higher (Alexiou et al 1998).  
1.6.1 Risk assessment 
The American Society of Anaesthesiologists’ (ASA) classification of pre-
operative physical status is familiar and frequently applied.  Although it is 
used globally the correlation of ASA grade with peri-operative risk has 
limitations. The Physiological and Operative Severity Score for the 
enumeration of Mortality and morbidity (POSSUM) was developed by 
Copeland et al (1991) to better predict surgical risk.  The strength of the 
POSSUM model is that it combines an assessment of physiological status 
(physiological score) with a measure of the magnitude of an operation 
(operative severity score).  POSSUM and models adapted from it, are 
widely used and validated in many surgical specialities.  Despite this, 
POSSUM has a poor predictive accuracy related to oesophagectomy 
(Zafirellis et al 2002).  A modified P-POSSUM version was developed in 
Portsmouth, in recognition of the general overestimation of mortality in low 
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risk patients, and has been found to have greater accuracy, although it is 
not specific to oesophagogastric surgery (Prytherch et al 1998).  A further 
O-POSSUM version was therefore derived specifically for 
oesophagogastric surgery (Tekkis et al 2004).  The value of the various 
POSSUM models in oesophagogastric surgery remains highly 
controversial, with studies finding both P-POSSUM (Nagabushan et al 
2007, Dutta et al 2010) and 0-POSSUM (Bosch et al 2011) to be of 
greater predictive accuracy.  Much of the debate relates to the degree of 
overestimation of mortality associated with each model (Nagabushan et al 
2007, Lagarde et al 2007, Dutta et al 2010, Bosch et al 2011). 
1.6.2 Cardiopulmonary exercise testing  
Cardiopulmonary exercise testing (CPET) is a dynamic and objective test 
that assesses the ability of a patient to adapt to the increased oxygen 
demand known to be precipitated during and following thoracic surgery 
(Saito et al 2007).  Increasing exercise results in oxygen consumption 
exceeding supply, and consequently a switch to anaerobic metabolism to 
supplement demands.  The value for oxygen consumption at this point is 
the anaerobic threshold, and a value below 11ml/kg/min has been 
reported to predict greater mortality following major abdominal surgery 
(Older et al 1999).  The other two CPET derived physiological variables of 
most interest are peak oxygen uptake (VO2 max) and ventilatory 
equivalent for carbon dioxide (VE/VCO2).  Few studies have investigated 
the association between CPET derived variables and outcome in 
oesophagogastric cancer surgery.  The most consistent data exists for 
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VO2 max, which has been reported to be significantly lower in those who 
experience cardiopulmonary morbidity following oesophagectomy 
(Nagamatsu et al 1994 and 2001, Forshaw et al 2008).  Only Nagamatsu 
et al (1994) found a similar association for anaerobic threshold.  A further 
finding was that the majority of resting lung function variables had no 
association with subsequent morbidity following oesophagectomy 
(Nagamatsu et al 1994 and 2001).  However, these studies had small 
sample sizes, and were therefore potentially underpowered to detect small 
differences, and also lacked clinician blinding to the CPET results.  There 
remains a need for a large-scale study of CPET in oesophagogastric 
surgery (Hennis et al 2011). 
1.7 SURGICAL TREATMENT 
The fundamental aim of surgery for oesophageal cancer is to remove all 
malignant tissue, and provide survival with acceptable quality of life.  Many 
controversies continue to surround the surgical management of 
oesophageal cancer, including the optimum operative approach, the role 
of neoadjuvant therapy, the peri-operative care and the configuration of 
surgical services.  
1.7.1 Operative approach 
The most appropriate operative approach in oesophageal cancer remains 
controversial and should preferably be determined by the histological 
tumour type, tumour location, the extent of the proposed 
lymphadenectomy, patient factors and the experience of the surgeon 
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(Allum et al 2011).  The main decision for Western patients with distal 
oesophageal or junction adenocarcinoma is between a transthoracic 
resection (Lewis 1946, Tanner 1947) with extended en bloc 
lymphadenectomy, or a transhiatal approach (Orringer 1984).  The 
transthoracic approach risks greater early morbidity in the hope of better 
long term survival.  The transhiatal procedure aims to reduce early 
pulmonary morbidity, lagely by avoiding a thoracotomy, but at the cost of 
potentially poorer long term survival. 
The Lewis Tanner procedure is a two stage approach via an upper midline 
laparotomy and right posterior lateral thoracotomy.  The thoracic stage 
consists of an en-bloc resection of the oesophagus, thoracic duct peri-
oesophageal tissue and mediastinal pleura up to the level of the carina.  A 
complete posterior mediastinal lymphadenectomy is performed to include 
the subcarinal lymph nodes. 
A transhiatal resection is performed via the abdomen and neck.  Gastric  
and oesophageal mobilisation is performed under direct vision up to the 
inferior pulmonary vein.  The remainder of the oesophageal dissection is 
performed using a blunt technique followed by reconstruction using a 
tubularised gastric conduit with a left cervical anastomosis.  Critics of this 
approach argue that it is an inferior oncological operation, principally due 
to the lack of a formal mediastinal lymphadenectomy (Hulscher et al 2001).  
However, proponents argue that long term survival is equivalent to the 
transthoracic approach (Morgan et al 2007a).  Occasionally, a three stage 
oesophagectomy is employed for middle or upper third tumours (McKeown 
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1985).  This procedure involves abdominal gastric mobilisation, right 
thoracotomy and cervical anastomosis, and was recommended by 
McKeown (1985) on the grounds that an anastomotic leak in the neck is 
less catastrophic than one in the thorax. 
In reality, in Western patients there is little evidence of the superiority of 
one procedure over another in terms of overall survival.  The best data 
was produced by a large Dutch randomised trial which compared 
transthoracic and transhiatal resection in patients with distal oesophageal 
and junctional tumours (Hulscher et al 2002, Omloo et al 2007).  Operative 
morbidity rates were significantly lower in the transhiatal group, but in-
hospital mortality was similar (Hulscher et al 2002).  There was no 
difference in survival related to operative approach for Siewert type II 
tumours, but for type I tumours transthoracic resection was associated 
with a non-significant 14% improvement in 5 year survival in comparison 
with transhiatal resection (Omloo et al 2007).  Transthoracic resection also 
showed a survival advantage over transhiatal resection for patients with 1 
to 8 lymph node metastases, but there was no difference for those who 
were node negative, or had more than 8 involved lymph nodes (Omloo et 
al 2007).  
1.7.2 Minimally invasive oesophagectomy 
A number of minimally invasive oesophageal resection techniques have 
been described, including thoracoscopic dissection, laparoscopic 
mobilisation of the stomach in the abdomen for utilisation as a conduit, 
1 Introduction 
 36 
and hybrid laparoscopic and thoracoscopic approaches.  No randomised 
trials have yet compared minimally invasive with open techniques.  
However, several published UK series, from highly regarded units, have 
raised concerns relating mainly to the high incidence of gastric conduit 
necrosis following minimally invasive oesophagectomy, for which the 
reasons are unclear (Safranek et al 2010, Blazeby et al 2011).  This 
presently remains very much an evolving area of practice. 
1.7.3 Lymphadenectomy 
The aims of lymphadenectomy are to optimise lymph node staging 
histopathologically, control locoregional disease and improve long term 
survival.  Single-field dissection involves upper abdominal 
lymphadenectomy only, two-field dissection also includes thoracic 
lymphadenectomy, and three field dissection includes abdominal, thoracic 
and cervical lymphadenectomy.  The improved accuracy of nodal staging 
associated with lymphadenectomy is well established (Lerut et al 1992, 
Dresner and Griffin 2000), but the impact of lymphadenectomy level on 
locoregional control and long term survival is less certain.  There is little 
justification for oesophagectomy without at least one-field 
lymphadenectomy.  The arguments for routine two-field lymphadenectomy 
are that more radical surgery increases the chance of R0 resection 
(microscopically clear margins) and that squamous cell carcinoma and 
adenocarcinoma of the upper, middle and lower thirds of the oesophagus 
have mediastinal lymph node metastases in over 70% of cases (Lerut et al 
1992, Akiyama et al 1994, Dresner and Griffin 2000).  The long term 
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outcomes of the Dutch trial, demonstrating survival benefit following 
transthoracic resection for tumours with 1 to 8 lymph node metastases, 
supports this argument (Omloo et al 2007). 
Three-field lymphadenectomy is advocated by the Japanese for squamous 
cell tumours.  Akiyama et el (1994) demonstrated cervical lymph node 
metastases were present in 25% of squamous cell carcinomas, yet no 
survival difference was identified for patients who had two or three field 
lymphadenectomy.  Three-field lymphadenectomy is not routine practice in 
the UK.  Indeed squamous cell carcinomas are far less common in the 
West and such patients are less likely to be surgical candidates owing to a 
combination of smoking related co-morbidity and high oesophageal 
tumours.  
1.8 PERI-OPERATIVE CARE 
1.8.1 Enhanced recovery after surgery (ERAS) 
Conventional peri-operative care following gastrointestinal resection and 
anastomosis was based on prolonged periods of gastrointestinal tract rest 
until the return of normal gut function, with an acceptance that the stress 
response was inevitable after major surgery.  The last decade has seen 
radical changes in practice.  The now familiar concept of Enhanced 
Recovery After Surgery (ERAS) was pioneered by Kehlet in Copenhagen, 
Denmark, following colorectal surgery and challenged many aspects of 
traditional peri-operative care (Basse et al 2000).  The ERAS group was 
established in 2001 as a European collaboration of university surgical 
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departments in the UK, Sweden, Denmark, Norway and The Netherlands.  
ERAS describes an evidence-based multidisciplinary package of 
measures for patients undergoing colorectal surgery, with the core aim of 
reducing the stress response to surgery and promoting the return of 
normal gut and body function (Fearon et al 2005).  The components of 
ERAS include pre-admission information and patient education, the 
avoidance of pre-operative bowel preparation, reduced pre-operative 
fasting, carbohydrate loading, anti-thrombotic and antibiotic prophylaxis, 
goal directed anaesthesia, small surgical incisions or minimal access 
surgery, avoidance of NG tubes and drains, avoidance of fluid and sodium 
overload, post-operative nutrition with early oral fluid and dietary intake, 
early mobilisation and clearly defined discharge criteria.  When used in 
combination, the protocol has been demonstrated in large meta-analyses 
to significantly reduce morbidity rates and shorten hospital stay following 
colorectal resection (Gouvas et al 2009, Varadhan et al 2010), and is 
consequently a mainstay of contemporary colorectal practice.  There is 
also some evidence for the role of ERAS in gynaecological surgery (Sjetne 
et al 2009) and urological oncology surgery (Arumainayagam et al 2008).  
In contrast, there is a distinct lack of published data for enhanced recovery 
in oesophagogastric surgery, with most of the current interest in improving 
outcomes focussed largely on service reconfiguration and minimally 
invasive surgery.  A single non-randomised Spanish study has recently 
reported reduced morbidity and mortality, and shortened hospital stay 
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associated with the use of written enhanced recovery protocols following 
oesophagectomy (Munitz et al 2010).   
1.8.2 Post-operative Nutrition 
An appreciation of the impact of nutritional status on surgical outcome 
dates back to the 1930s, and the work of Studley (1936).  It was 
demonstrated that patients who underwent partial gastrectomy for peptic 
ulcer disease, who had lost more than 20% of their pre-illness weight had 
a ten-fold increased operative mortality, compared with those who had lost 
less than 20% (Studley 1936).  Undoubtedly, advances in surgery, 
anaesthesia, antibiotics and post-operative care have reduced such high 
rates of complications in malnourished patients, but recent studies confirm 
significantly increased morbidity and prolonged hospital stay following 
gastrointestinal surgery in patients with protein depletion (Hill 1994).  In 
the 1980s, there was considerable interest in peri-operative total 
parenteral nutrition (TPN), with numerous trials in surgical and critically ill 
patients, many of which were performed in patients not specifically 
malnourished (Fearon et al 2003).  Meta-analysis failed to identify any 
improvement in operative morbidity or mortality associated with TPN 
(Heyland et al 1998).  There was a shift in emphasis from TPN to enteral 
nutrition (EN) during the 1990s, due predominantly to EN being more 
physiological, associated with fewer septic complications related to venous 
access, and reduced cost.  The specific benefits of EN include 
preservation of gut structure and function (Maxton et al 1989) and the 
enhancement of gut mediated immunity (Kudsk 2002).  The superiority of 
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EN over TPN in surgical patients has been demonstrated in randomised 
studies (Bozzetti et al 2001).  A recent meta-analysis of EN within 24 
hours of gastrointestinal surgery demonstrated significantly reduced 
mortality, with trends towards reduced operative morbidity and reduced 
length of hospital stay, but stressed the need for an adequately powered 
randomised trial to test these findings (Lewis et al 2009).  In 
oesophagogastric surgery, where oral intake is contraindicated, the route 
of administration of EN is controversial, with nasojejunal tubes being 
poorly tolerated and the possibility of major complications associated with 
surgical feeding jejunostomy placement (Hoffmann et al 2001).  
Consequently, jejunal feeding is not routine in all centres following 
oesophagogastric surgery in the UK.  The latest UK oesophagogastric 
cancer guidelines recommend nutritional support specifically for “patients 
who are malnourished or at risk of malnutrition, and have an inadequate 
oral intake defined as having eaten little or nothing for more than 5 days 
and/or likely to eat little or nothing for the next 5 days or longer” (Allum et 
al 2011).  This recommendation closely adheres to the 2006 National 
Institute for Health and Clinical Excellence adult nutrition guidance.  
1.8.3 Fluid management 
The dangers of excessive saline administration have been recognised for 
the last century (Evans 1911).  Although physiology has evolved highly 
efficient homeostatic mechanisms for maintaining fluid and electrolyte 
balance in situations of water deficit or excess, or sodium deficit, it is far 
less effective in dealing with sodium excess (Macafee et al 2005).  The 
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reasons for this may relate to the relatively recent occurrence of sodium 
excess, in evolutionary terms, due to dietary changes and medical therapy 
(Lobo 2004).  This situation is compounded by the stress response to 
surgery or critical illness, such that post-operative patients are even more 
vulnerable to fluid or sodium excesses than healthy individuals (Lobo 2004, 
Allison 2004).  The stress response causes anti-diuresis and oliguria, 
mediated by vasopressin, catecholamines and the renin-angiotensin-
aldosterone system.  Water and sodium are thus retained, even in 
situations of overload.  Moreover, the use of saline can result in 
hyperchloraemia, further compromising the ability to excrete sodium and 
water (Wilcox 1983). 
Fluid overload due to excess administration is recognised as a cause of 
delayed return to normal gut function (Lobo et al 2002), impaired wound or 
anastomotic healing and can potentially lead to prolonged hospitalisation 
and even increase mortality (Brandstrup et al 2003, Tambyraja et al 2004, 
Lobo 2006).  Despite these dangers, knowledge of recommended fluid 
and electrolyte requirements amongst UK surgeons of varying levels of 
seniority is poor, (Lobo et al 2001 and 2002), and intravenous fluid 
prescription is at best idiosyncratic (Stoneham et al 1997).  Indeed, the 
recent British guidelines on intravenous fluid therapy (GIFTASUP) 
highlighted the dangers of sodium and fluid excess, and in particular the 
overuse of normal saline (Powell-Tuck et al 2009).  Moreover, the 
establishment of ERAS programmes has subjected post-operative fluid 
management to even closer scrutiny.  Early post-operative resumption of 
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oral hydration, with a consequent reduced need for intravenous fluid 
therapy, is a simple but effective way of limiting fluid excess, and a core 
component of ERAS protocols in colorectal surgery (Basse et al 2000, 
Fearon et al 2005).  The situation in upper gastrointestinal surgery is more 
complex, with the oral route frequently unavailable in the immediate post-
operative period.  It has been postulated that the use of early jejunal 
nutrition after upper GI resection reduces the need for supplementary 
intravenous fluid and therefore limits the dangers of fluid and sodium 
excess, but this issue has not been studied to date. 
1.9 NEOADJUVANT AND ADJUVANT THERAPY 
1.9.1 Neoadjuvant therapy 
The majority of patients with oesophageal cancer present with advanced 
disease (stages III and IV).  Of the minority suitable for potentially curative 
surgery, most will eventually develop recurrence, supporting the theory 
that systemic micro metastases are present at diagnosis, but are not 
detectable by contemporary staging modalities.  Systemic disease 
requiring systemic treatment forms the basis of the argument in favour of 
neoadjuvant therapy, although the optimal regimen remains uncertain.  
The two largest randomised studies of neoadjuvant chemotherapy vs. 
surgery alone reported conflicting results.  The UK based OEO2 trial 
demonstrated a 9% improvement in 2-year survival with chemotherapy 
(Medical Research Council Oesophageal Cancer Working Group 2002), 
and this subsequently became the standard of care in the UK over the last 
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decade.  However, the corresponding US Intergroup trial failed to identify 
any survival difference (Kelson et al 1998).  The most comprehensive 
meta-analysis to date demonstrates significant survival benefits for both 
chemotherapy (HR 0.87, 95% CI 0.79-0.96, p=0.005) and 
chemoradiotherapy (HR 0.78, 95% CI 0.70-0.88, p<0.0001) when 
compared with surgery alone (Sjoquist et al 2011).  The largest 
randomised trial of neoadjuvant chemoradiotherapy vs. surgery alone, in 
363 patients with oesophageal cancer from the Netherlands, has recently 
reported substantially improved overall survival (median 49 vs. 26 months, 
2-year 67 vs 52%) and increased R0 resection rates (92.3 vs. 64.9%) for 
neoadjuvant chemoradiotherapy (Gaast et al 2010).  The benefits were 
applicable to both squamous cell carcinoma and adenocarcinoma, 
although were greater for the former. The evidence comparing 
neoadjuvant chemotherapy with chemoradiotherapy is weaker, with only 
two comparatively underpowered randomised trials reported, meta-
analysis of which showed a non-significant trend towards improved 
survival after chemoradiotherapy (HR 0.88, 95% CI 0.76-10.01, p=0.07).  
An adequately powered trial of these two differing neoadjuvant regimens is 
urgently needed (Hingorani et al 2011). 
1.9.2 Adjuvant therapy 
The recovery after oesophagectomy precludes the majority of patients with 
oesophageal cancer from receiving adjuvant therapy within an appropriate 
time frame.  Furthermore, the data are not supportive of this approach to 
treatment.  A recent meta-analysis of 1001 patients treated with adjuvant 
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chemotherapy for oesophageal squamous cell carcinoma in China failed 
to demonstrate any significant difference in outcome (Zhang et al 2008).  
Consequently adjuvant therapy is not currently recommended routinely in 
the UK (Allum et al 2011).   
1.10 NON SURGICAL TREATMENT OPTIONS 
1.10.1 Endoscopic techniques 
Endoscopic techniques play an integral role in the multidisciplinary staging 
and treatment of oesophageal cancer.  Current recommendations are that 
such procedures should only be considered when recommended by a 
specialist MDT, should be performed in high volume tertiary referral 
centres by trained clinicians, and the results carefully audited (Allum et al 
2011).  A number of techniques are used including endoscopic mucosal 
resection (EMR), endoscopic submucosal dissection (ESD), photodynamic 
therapy (PDT), and ablation using laser, argon plasma coagulation (APC), 
electrocoagulation, cryotherapy and radio frequency ablation (RFA).  
These techniques are used to remove dysplasia and early cancer, and 
also to address field change abnormalities such as Barrett’s metaplasia.  
However, it is also important that patients have adequate control of reflux 
and helicobacter pylori eradication.  The major limitation of all these 
modalities is the failure to treat regional lymph nodes.  The risk of lymph 
node metastases relates to the depth of tumour invasion and the 
histological cell type, being more likely in squamous cell carcinoma than 
adenocarcinoma (Kodama et al 1998, Curvers et al 2008, Griffin et al 
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2011).  The differentiation of mucosal (T1a) from submucosal (T1b) 
tumours is crucial, as Griffin et al (2011) have recently demonstrated that 
the risk of lymph node metastases in oesophageal adenocarcinoma is 0% 
of the former but 12% of the latter.  On this basis therapeutic endoscopy is 
unsafe for submucosal (T1b) tumours (Griffin et al 2011). Endoscopic 
resection is appropriate for mucosal node negative (T1a N0) cancers and 
mucosal dysplasia (Allum et al 2011), where consistent 5-year disease-
free survival of 95% with low treatment-related morbidity has been 
reported (Takeshita et al 1997, Inoue et al 2002, Ciocirlan et al 2007).  
There is a lack of randomised controlled trial data comparing endoscopic 
therapy with surgical resection, with much of the evidence base derived 
from retrospective studies subject to treatment selection bias.  
Nevertheless, endoscopic therapy is associated with a similar overall 
survival to surgery, but significantly reduced treatment-associated 
morbidity when compared with surgery (Das et al 2008). 
1.10.2 Definitive chemoradiotherapy (dCRT) 
The optimum treatment for locally advanced oesophageal cancer in the 
UK is considered to be neoadjuvant chemotherapy followed by surgery. 
However, fewer than 30% of patients currently undergo surgery (NHS 
Information Centre 2010).  Long term survival following definitive 
chemoradiotherapy (dCRT) for squamous cell carcinoma and 
adenocarcinoma has been reported in a number of studies (Cooper et al 
1999, Gwynne et al 2011, Bedenne et al 2007, Stahl et al 2005, Chan et al 
1999, Coia et al 2000, Kaneko et al, 2003, Geh 2001, Chiu et al 2005).  
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Three randomised studies have found similar overall survival rates for 
squamous cell carcinoma treated with dCRT and surgery (Chiu et al 2005, 
Stahl et al 2006, Bedenne et al 2007), although they were underpowered 
to detect the equivalence of dCRT.  No randomised trials have yet 
compared dCRT to surgical based treatment for adenocarcinoma, 
although a recent stage-for-stage comparison for oesophageal cancer of 
all cell types from the S.E. Wales cancer network reported similar overall 2 
year survival following dCRT and surgery with or without neoadjuvant 
therapy (Morgan et al 2009).  Definitive chemoradiotherapy is a 
recommended treatment for localised squamous cell carcinoma, and is 
also considered a valid therapeutic option for patients with 
adenocarcinoma deemed unsuitable for surgery (Allum et al 2011).  
Treatment with dCRT is currently used in the UK in both of these 
scenarios (NHS Information Centre 2010).  An additional consideration 
when determining oesophageal cancer treatment is health related quality 
of life (HRQL).  Both treatment types have been reported to compromise 
HRQL in the first few months, but the effect is far greater for surgically 
based approaches than for dCRT.  However, by one year HRQL scores 
are similar for both treatment types (Avery et al 2007).  The role of dCRT 
in treating fit patients with potentially operable adenocarcinoma remains 
uncertain, and is clearly an area for further investigation. 
1.11 SERVICE CONFIGURATION 
The organisation of oesophagogastric cancer surgery services in the UK 
remains a subject of considerable controversy and contentious conflict.  
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The Calman-Hine report (The Expert Advisory Group on Cancer to the 
Chief Medical Officers of England and Wales 1995) was the first 
comprehensive cancer report to be produced in the UK, and set out 
principles for the organisation and delivery of cancer care.  It promoted a 
paradigm shift from a model of generalist delivered cancer surgery to a 
fully specialised service, and introduced the concepts of cancer centres 
and cancer units.  However, whilst the report provided a vision for cancer 
services it failed to establish any central plan for implementation. 
Subsequent NHS organisational change and the devolution of government 
within the UK in the late 1990s resulted in prolonged and patchy uptake of 
these recommendations.  Nevertheless, central support from the 
Department of Health in England continued for the development of 
national clinical standards in cancer care.  Specific NHS Executive (2001) 
guidance for upper GI cancer was published in 2001.  It recommended 
that surgical treatment of oesophagogastric cancer be centralised in units 
serving populations of at least one million.  Compliance with this guidance 
has been strongly supported and largely achieved in England but received 
lesser resource and support in Wales.  Indeed the most recent audit of 
oesophagogastric cancer surgery in Wales found that many surgeons’ 
case loads were small, staging strategies were idiosyncratic, open and 
close operations were common, operative mortality high and long term 
survival poor (Pye et al 2001). 
A wealth of evidence supports the relationship between surgeon or unit 
case volumes and short term outcomes in oesophagogastric resectional 
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surgery, particularly operative mortality (Matthews et al 1986, Birkmeyer et 
al 2003, Swisher et al 2000, Van Lanshot et al 2001, Bachmann et al 2002, 
Skipworth et al 2010, Anderson et al 2011).  There is also emerging 
evidence of an association between surgical volume and long term 
survival (Birkmeyer et al 2007, Van de Poll-Franse et al 2011).  However, 
most published reports are based on population studies, with little data on 
actual improvements following service reconfiguration.  Following almost a 
decade of negotiation between politicians, management from multiple 
health boards, and clinicians, an agreement was reached to centralise 
oesophagogastric cancer surgery for the S.E. Wales region on a single 
site in Cardiff.  The centralised service serves a population of 1.4 million 
and commenced in August 2010. 
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1.12 AIMS AND HYPOTHESES 
In light of the above areas of uncertainty, this thesis aims to address the 
following: 
1. To compare oesophageal cancer stage categorisation and survival 
using TNM6 and TNM7. 
2. To determine the influence of CT-PET in the staging algorithm of 
patients with potentially operable oesophageal cancer. 
3. To determine the relative incidence and pattern of oesophageal 
cancer recurrence following definitive chemoradiotherapy and surgery. 
4. To determine the prognostic significance of an involved circumferential 
resection margin (CRM+) after potentially curative oesophagectomy, 
to identify factors predictive of CRM+, and to assess the influence of 
differing neoadjuvant therapy regimes on CRM+ rates. 
5. To determine if early enteral nutrition following upper GI cancer 
resection improves clinical outcomes. 
6. To assess the outcomes of the first year of centralised 
oesophagogastric cancer surgery performed on a single site in S.E. 
Wales, compared with control data from the previous year. 
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The hypotheses tested are:  
1. The TNM7 staging system is a more accurate prognostic tool for 
oesophageal cancer than TNM6. 
2. The use of CT-PET upstages a significant number of patients with 
occult oesophageal cancer metastases, and avoids inappropriate 
radical treatment. 
3. Oesophageal cancer recurrence patterns differ following dCRT and 
surgery, but overall recurrence rates and survival are comparable for 
advanced stage disease. 
4. An involved CRM following oesophagectomy is associated with poorer 
survival and its incidence can be reduced with neoadjuvant 
chemoradiotherapy. 
5. Early enteral nutrition improves clinical outcomes following upper GI 
cancer resection. 
6. Centralisation of oesophagogastric cancer surgery in S.E. Wales is 
feasible and associated with improved clinical outcomes. 
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2.1 SUMMARY 
The aim of this study was to determine the influence of the new TNM7 
oesophageal cancer system on stage categorisation and survival when 
compared with historical controls. 
Two hundred and two patients with oesophageal cancer who underwent 
oesophagectomy (118 neoadjuvant chemotherapy) were studied. Patients 
originally classified and staged using TNM6 were retrospectively re-staged 
using TNM7. 
TNM7 re-classification resulted in stage re-categorisation in 11.9% of 
patients (9.9% down staged, 2.0% up staged) when compared with TNM6. 
Five year survival for stages I, II, and III was 78, 46 and 18% using TNM6, 
compared with 62, 51 and 18% respectively using TNM7. Univariate 
analysis revealed that histological grade (p=0.006), pT (p<0.0001), TNM6 
pN (p<0.0001), TNM7 pN (p<0.0001), number of lymph node metastases 
(p<0.0001), TNM6 stage group (p<0.0001), TNM7 stage group (p<0.0001) 
and TNM7 prognostic group (p<0.0001) were all associated with survival. 
Multivariate analysis revealed that only the TNM7 prognostic group was 
independently and significantly associated with survival. 
TNM7 is a better prognostic tool than TNM6 and represents an important 
advance in staging oesophageal cancer.  
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2.2 INTRODUCTION  
The Tumour, Nodes, Metastases (TNM) Classification system, published 
by the International Union Against Cancer (UICC) is the gold standard 
cancer staging system used worldwide (Sobin et al 2009).  Its objectives 
include assisting in the planning of therapy, informing prognosis, allowing 
evaluation of results and facilitating information exchange between 
treatment centres, and is updated periodically to incorporate evidence 
base evolution (Sobin et al 2009).  However, the 2002 TNM 6th Edition 
(TNM6) (Sobin and Wittekind 2002) has been considered to be a tool of 
limited prognostic value in oesophageal cancer, mainly because lymph 
node (N) stage was limited by definition as a binary variable (N0 or N1), 
regardless of the actual lymph node metastasis count.  
The recently published TNM 7th edition (TNM7) replaced TNM6 with effect 
from 2010, and incorporated major modifications with regard to 
oesophageal cancer in particular related to the individual T, N and M stage 
criteria, and stage groups (Sobin et al 2009).  Moreover, TNM7 introduced 
a new system of prognostic groups in which other prognostic variables are 
combined with T, N and M categories, for stage I and II tumours, which 
also differs for adenocarcinoma (ACA) and squamous cell carcinoma 
(SCC).  Prognostic grouping for both cell types takes account of tumour 
grade, but for SCC, the anatomical site within the thoracic oesophagus is 
now also incorporated (Sobin et al 2009).  However, the principal TNM7 
upgrade relates to the classification of lymph node stage, which has a 
major influence on defining specific stage groups.  The number of lymph 
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node metastases has long been considered to be the key and defining 
prognostic factor for patients diagnosed with oesophageal cancer 
(Kawahara et al 1998), and in addressing this issue TNM7 reclassifies 
lymph node positive tumours into 3 groups (N1-3) based on the relative 
burden of nodal metastases.   Anatomical stage groups have also been 
revised and expanded to account for this modified N stage.  A summary of 
TNM7 and the stage groupings is shown in Appendix 2.  
The aims of this study were to determine the influence of the new TNM7 
staging system on oesophageal cancer histopathological stage 
categorisation and related survival, when compared with historical control 
data derived with TNM6, and to determine the relative accuracy of TNM6 
and TNM7 in predicting prognosis.  The setting was a regional upper 
gastrointestinal cancer network in S.E. Wales serving a population of 1.4 
million. 
2.3 METHODS 
2.3.1 Details of the patients 
Consecutive patients who underwent potentially curative surgery for 
oesophageal cancer were identified from a prospectively maintained 
database.  Patients were excluded if there had been a complete 
pathological response to neoadjuvant treatment, involved longitudinal 
resection margins, high grade dysplasia in the absence of invasive 
malignancy, or if complete histological information on the numbers of 
involved lymph nodes was missing.  Complete pathological data were 
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available on 202 patients, all of whom underwent oesophagectomy 
between 1998 and 2010. The median age of the patients was 61 years 
(range 35 to 79).  There were 161 (79.7%) males and 41 (20.3%) females.  
One hundred and sixty-nine patients had adenocarcinomas (83.7%), and 
33 patients had squamous cell carcinomas (16.3%). 
2.3.2 Staging and surgery +/- neoadjuvant therapy 
Pre-operative staging involved computed tomography (CT) and 
endoluminal ultrasonography (EUS) and was in accordance with TNM6 
definitions.  All patients were discussed at a regional specialist multi-
disciplinary team meeting with management plans individually tailored 
according to factors relating to both comorbidity and tumour stage.  In 
general, fit patients with tumours of stage T3 and equivocal T4, N0 and N1 
were considered for neoadjuvant therapy prior to surgery.  Less fit patients 
and those with T1-2, N0 disease were considered for surgery alone.  One 
hundred and twenty-one patients underwent standard subtotal 
oesophagectomy as described by Lewis (1946) and Tanner (1947). 
Transhiatal resection, as described by Orringer (1985), was performed in 
81 patients.  This was employed selectively in patients with 
adenocarcinoma of the lower third of the oesophagus who had significant 
cardiorespiratory co-morbidity.  Neoadjuvant chemotherapy or 
chemoradiotherapy were given to 87 patients and 31 patients respectively. 
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2.3.3 Restaging using TNM7  
All patients were originally staged histopathologically in accordance with 
TNM6 and then retrospectively re-staged using TNM7.  The primary 
outcome measure was survival.   
2.3.4 Follow-up 
Patients were followed-up clinically at 3 monthly intervals for the first year 
following surgery, decreasing to 6 monthly intervals thereafter, for a total 
of 5 years or until death.  One hundred and eighty-seven patients (92.6%) 
were followed-up for 5 years or until death.  Death certification was 
obtained from the Office for National Statistics (ONS).  
The regional ethics committee was contacted regarding this study, but a 
formal application was deemed unnecessary. 
2.3.5 Statistical analysis 
Data were expressed as median (range) and non-parametric methods 
were used.  Cumulative survival was calculated according to the life-table 
method of Kaplan and Meier (1958), and differences in survival between 
groups of patients were analysed with the log rank test. Multivariate 
analysis of factors influencing survival was performed using Cox’s 
proportional hazards model (1972).  All data analysis was performed using 
SPSS version 18.0 (Chicago, USA). 
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2.4 RESULTS 
2.4.1 Stage re-categorisation 
The T and N stages, stage groups and prognostic groups of the patients 
are shown in Table 2.1, and the proportion of patients who changed 
stages when TNM7 was applied is summarised in Table 2.2.  There were 
no changes observed in oesophageal cancer pT stage, but significant 
changes were observed in pN stage.  Of the 110 patients (54.5%) with 
lymph node metastases classified as pN1 by TNM6, 56 (27.7%) remained 
pN1, 35 (17.3%) were re-classified as pN2, and 19 (9.4%) patients were 
re-classified as pN3 by TNM7.  With regard to stage groups, the number of 
patients with stage I disease almost doubled using TNM7, whilst in 
contrast the number of patients with stage II tumours was reduced by 
almost a third. The number of patients with stage III tumours increased 
slightly when classified by TNM7, whilst the number of patients with stage 
IV tumours remained unchanged.  Down stage re-categorisation occurred 
in 20 (9.9%) patients when classified by TNM7 (stage II to I). Up stage re-
categorisation occurred in 4 (2.0%) patients (stage II to III).  When TNM7 
prognostic group allocations were compared with TNM6 allocations, fewer 
were classified as stage I, and more were classified as stage II.  The 
numbers of patients with stages III and IV tumours remained unchanged. 
Eleven patients from the early period of this series could not be allocated a 
prognostic group because of pathology reports that failed to comment on 
tumour grade. 
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2.4.2 Survival 
Table 2.3 illustrates median and 5-year survival related to stage. Survival 
related to TNM7 is shown separately.  Figures 2.1 to 2.3 demonstrate 
Kaplan-Meier survival curves for oesophageal cancer by TNM6 and TNM 
7 stage groups, and TNM7 prognostic groups. 
For stage I oesophageal cancer, 5-year survival by TNM7 was poorer by 
16.1% when compared with TNM6.  In contrast stage II oesophageal 
cancer 5 year survival by TNM7 improved by 4.4%, and median survival 
improved by 17 months.  Survival for patients with stage III and IV tumours 
remained the same.  Allocation of TNM7 prognostic groups produced 
survival plots that were midway between those obtained with TNM6 and 
TNM7 stage groups for patients with stage I and II tumours, and were 
unchanged for patients with stage III and IV tumours. 
2.4.3 Univariate and multivariate analysis 
Univariate analysis of the factors associated with survival is shown in 
Table 2.4.  On multivariate analysis including the following variables – 
tumour grade, pT stage, TNM6 pN stage, TNM7 pN stage, TNM6 stage 
group, TNM7 stage group, TNM7 prognostic group, and the number of 
lymph node metastases – only TNM7 prognostic group emerged as 
significantly and independently associated with survival (Table 2.5). 
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Table 2.1 Details of the patients’ staging by TNM6 and TNM7 
T Stage (%) TNM6 TNM7 
T1 29 (14.4) 29 (14.4) 
T2 29 (14.4) 29 (14.4) 
T3 130 (64.4) 130 (64.4) 
T4 14 (6.9) 14 (6.9) 
N Stage (%)   
N0 92 (45.5) 92 (45.5) 
N1 110 (54.5) 56 (27.7) 
N2 N/A 35 (17.3) 
N3 N/A 19 (9.4) 
Stage Groupings (%)   
I 23 (11.4) 43 (21.3) 
II 80 (39.6) 56 (27.7) 
III 93 (46.0) 97 (48.0) 
IV 6 (3.0) 6 (3.0) 
Prognostic Groupings (%)   
I N/A 27 (13.4)  
II N/A 61 (30.2) 
III N/A 97 (48.0) 
IV N/A 6 (3.0) 
Not determined N/A 11 (5.4) 
2 TNM7 
 
60 
Table 2.2 Stage re-categorisation related to TNM7 classification 
 TNM7 Stage 
TNM6 
Stage 
 I II III IV 
I 23 0 0 0 
II 20 56 4 0 
III 0 0 93 0 
IV 0 0 0 6 
 
The shaded boxes represent patients with the same stage group under 
both TNM 6 and TNM 7
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Table 2.3 Stage-by-stage patient survival 
Survival 
TNM6 
Stage 
Groups 
TNM7 
Stage 
Groups 
TNM7 
Prognostic 
Groups 
Stage I     
Median (months) N/A 111 111 
5-year (%) 78.3 62.2 67.7 
Stage II    
Median (months) 47 64 48 
5-year (%) 46.3 50.7 48.6 
Stage III    
Median (months) 23 23 23 
5-year (%) 18.3 17.6 17.6 
Stage IV    
Median (months) 13 13 13 
5-year (%) 0 0 0 
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Table 2.4 Univariate analysis of factors influencing survival 
Variable Chi2 df p value 
Age 48.020 41 0.210 
Gender 1.039 1 0.308 
Histological cell type 1.300 1 0.254 
Histological tumour grade 10.260 2 0.006 
Operative approach (TT vs. TH) 0.795 1 0.373 
Neoadjuvant therapy 0.627 1 0.429 
T stage (same in TNM6 and TNM7) 21.514 3 <0.0001 
N stage (TNM6) 21.499 1 <0.0001 
N stage (TNM7) 37.509 3 <0.0001 
Number of lymph node metastases 61.677 12 <0.0001 
Stage groupings (TNM6) 36.587 4 <0.0001 
Stage groupings (TNM7) 50.531 7 <0.0001 
Prognostic groupings (TNM7) 47.147 7 <0.0001 
TT = trans thoracic, TH = trans hiatal. 
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Table 2.5 Multivariate analysis of factors influencing survival 
 
TNM7 Prognostic Stage Hazard 
Ratio 
95% CI p value 
Stage IA       Reference group  
Stage IB 3.901 1.034   -   14.721 0.045 
Stage IIA 5.994 1.586   -   22.659 0.008 
Stage IIB 4.346 1.303   -   14.503 0.017 
Stage IIIA 5.734 1.743   -   18.869 0.004 
Stage IIIB 10.838 3.244   -   36.211 <0.001 
Stage IIIC 13.130 3.873   -   44.511 <0.001 
Stage IV 11.565 2.743   -   48.760 <0.001 
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Figure 2.1 Oesophageal cancer survival related to TNM6 stage 
groups
 
 
Chi2 36.587, df 4, p<0.0001 
 
 
No. at risk 0m   12m 24m 36m 48m 60m 
Stage I 23 20 20 19 16 16 
Stage IIA 65 56 46 38 30 26 
Stage IIB 11 11 8 7 4 4 
Stage III 97 81 46 26 19 13 
Stage IVa 6 4 2 1 1 0 
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Figure 2.2 Oesophageal cancer survival related to TNM7 stage 
groups
 
 
Chi2 50.531, df 7, p<0.0001 
 
No. at risk 0m 12m 24m 36m 48m 60m 
Stage IA 23 20 20 19 16 16 
Stage IB 20 17 15 11 9 7 
Stage IIA 45 39 31 27 21 19 
Stage IIB 11 11 8 7 4 4 
Stage IIIA 43 37 27 19 15 11 
Stage IIIB 29 23 12 4 3 2 
Stage IIIC 25 21 7 3 2 0 
Stage IV 6 4 2 1 1 0 
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Figure 2.3 Oesophageal cancer survival related to TNM7 prognostic 
groups 
 
 
Chi2 47.147, df 7, p<0.0001 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
Stage IA 15 13 13 13 12 12 
Stage IB 12 11 9 9 7 5 
Stage IIA 12 9 7 4 3 3 
Stage IIB 49 45 36 30 22 20 
Stage IIIA 43 37 27 19 14 11 
Stage IIIB 29 23 12 4 3 2 
Stage IIIC 25 21 7 3 2 0 
Stage IV 6 4 2 1 0 0 
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2.5 DISCUSSION 
This study is the first to be carried out in a Westernised country to 
examine the outcome in patients using the new TNM7 staging system 
compared with TNM6 for oesophageal cancer.  The principal findings were 
that stage re-categorisation occurred in 11.9% of patients, and this 
resulted in significant artefactual change in survival rates for early stage 
disease (I and II), but no change in outcome for more advanced stage 
disease (III and IV).  Prognosis was better predicted by TNM7 when 
compared with TNM6, and specifically by the new prognostic groups 
incorporated in TNM7.  This data therefore provides strong support for the 
updated TNM7 staging system for oesophageal cancer, and lends further 
weight to the validity of the data-driven approach used to derive this 
radical update (Rice et al 2010).  
The study has several strengths. The patient numbers are relatively large 
by Western standards, and represent a consecutive series treated by a 
single UK cancer network.  All patients received stage-directed treatment 
by a specialist regional multidisciplinary team with considerable 
experience in the treatment of oesophagogastric cancer.  The surgery was 
performed by specialist upper GI surgeons whose results have been well 
audited (Morgan et al 2009) and shown to be equivalent or better than 
those reported in the UK based MRC OEO2 randomised trial (Morgan et al 
2009, MRC Oesophageal Cancer Working Group 2002).  The patients 
resided in a well defined geographical area, and the follow-up data are 
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especially robust with dates and causes of death obtained from the Office 
for National Statistics.  
Nevertheless, there are potential limitations.  Although the numbers of 
patients were large for a single UK region, they are relatively small when 
compared to the large multicentre study undertaken to derive TNM7 for 
oesophageal cancer (Rice et al 2010).  However, Rice et al (2010) 
describe a patient series who underwent surgery alone, whereas our 
patients were treated with neoadjuvant chemotherapy in line with current 
UK practice, where neoadjuvant chemotherapy is the standard of care for 
locoregionally advanced oesophageal cancer (MRC Oesophageal Cancer 
Working Group 2002).  In addition, total lymph node harvests were 
variable, with a median of 11 nodes (range 1-38) retrieved.  We have 
reported previously that the prognosis of surgically resected oesophageal 
cancer is highly dependent on the numbers of lymph nodes examined 
pathologically, again arguably due to stage migration effects (Twine et al 
2009b).  Hsu et al (2010) from Taiwan have recently reported a 
comparison of TNM6 vs. TNM7 in surgically resected oesophageal 
squamous cell carcinoma.  Their findings confirmed the predictive value of 
the new pN and pM stage criteria and they concluded that TNM7 
constituted an improvement over TNM6 in terms of informing outcome.  
However, although their sample size was large (392), as might be 
expected from its geographical origin, this study consisted exclusively of 
patients diagnosed with squamous cell cancer, and it is therefore 
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uncertain how applicable their conclusions are to patients diagnosed with 
adenocarcinoma, the predominant Western tumour.  
Improving the accuracy of any given staging system is a fundamental aim 
of modifying and upgrading prognostic models, and TNM7 appears to 
have been successful in this regard in relation to oesophageal cancer.  
Such a benefit must however be balanced against potential and inherent 
disadvantages of modifying histopathological staging.  The ‘Will Rogers 
Phenomenon’ is a perceived paradox named after a quote attributed to the 
US comedian and social commentator Will Rogers (1879-1935).  Referring 
to migration during the American economic depression of the 1930s, he 
allegedly said:  
“When the Okies left Oklahoma and moved to California, they raised the 
average intelligence level in both states.”  
An analogous phenomenon is the concept of cancer stage migration, 
whereby changes in staging result in apparent differences in group 
outcomes, yet individual patient outcomes remain unchanged.  The first 
report of this phenomenon described a cohort of lung cancer patients that 
had artefactually better stage specific survival than historical controls from 
the same institution (Feinstein et al 1985).  The difference was explained 
by the combination of both a prognostically favourable lead time bias, and 
stage migration, as a result of more advanced imaging techniques 
(Feinstein et al 1985).  Changes in the rules governing the grading of 
prostate cancer biopsies, and improved histopathological processing of 
2 TNM7 
 
70 
bladder cancer specimens, have produced similar stage migration effects 
in urological oncology (Gofrit et al 2008).  In the present study, significant 
yet purely artefactual changes in the survival of early stage oesophageal 
cancer have been demonstrated, through the application of the TNM7 
system, for the same reasons.  Such changes may not only be mistakenly 
attributed to the effects of treatment, but equally importantly they risk 
preventing meaningful comparison of patient outcomes with historical 
controls, including those published in clinical trials.  Indeed, this study 
indicates that it is now imperative for the results of clinical trials to be 
reported in relation to the TNM stage classification used.  There is also a 
responsibility upon the clinicians involved in revising and updating the 
TNM staging system to ensure that modifications are based on the best 
available evidence, using pathological criteria that are known to be 
reproducible, to justify any concomitant problems that an update may bring. 
In the case of the colorectal cancer TNM staging system, major concerns 
have been raised within the pathology community regarding modifications 
incorporated within TNM6 and TNM7 because of a perceived lack of a 
sound evidence base (Quirke et al 2007, Quirke et al 2010) and because 
of this, UK colorectal cancer staging continues to be classified by means 
of TNM5, more than a decade after its publication (Quirke et al 2010). 
2.6 CONCLUSION 
TNM7 is a better prognostic tool than TNM6 for oesophageal cancer, due 
predominantly to the inclusion of the lymph node metastases count.  
Moreover, the new system of prognostic grouping in TNM7, taking account 
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of tumour grade and site, has further refined staging accuracy when 
compared with the traditional anatomically based stage grouping. TNM7 
should therefore also form the basis for the radiological reporting and 
staging of all modalities for oesophageal cancer. Notwithstanding the 
significant benefit TNM7 provides, clinicians must be aware of the Will 
Rogers Phenomenon in the context of cancer staging, and avoid drawing 
misleading conclusions when comparing current patient outcomes with 
those of historical controls. 
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The influence of CT-PET in staging oesophageal cancer 
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3.1 SUMMARY 
The aim was to clarify the additional value of CT-PET imaging over and 
above CT and EUS in refining stage-directed therapy for oesophageal 
cancer, with particular emphasis on N and M stage. 
One hundred and fifty patients underwent CT, EUS and CT PET followed 
by multidisciplinary treatment.  Fifty-four patients underwent surgery, 40 
definitive chemoradiotherapy, 2 endoscopic mucosal resection, 53 
palliative therapy, and 1 died during staging.  The primary outcome 
measure was the relative accuracy of each modality in determining the 
radiological (r) TNM stage. 
The rN stage was upstaged by CT-PET in 6 (4.0%) patients, compared 
with combined CT and EUS.  The strength of agreement between 
radiological and histopathological N stage was fair for EUS (Kw=0.316, 
96% CI 0.000-0.591, p=0.044) but there was no agreement for CT-PET 
(Kw=0.041, 95% CI -0.104-0.211, p=0.604).  The sensitivity, specificity, 
positive predictive value and negative predictive value for CT-PET rN 
stage were 12.5%, 92.9%, 75.0% and 38.2%. In contrast rM stage was 
upstaged by CT-PET in 36 (24.0%) patients.  Failure of CT-PET to detect 
distant metastases occurred in 10 (6.7%) patients. 
CT PET materially altered the radiological perceived oesophageal tumour 
stage in 1 in 4 patients, with clear potential economic savings and must 
therefore become a mainstay of the contemporary pre-operative staging 
protocol.
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3.2 INTRODUCTION 
Accurate radiological staging of patients with oesophageal cancer is 
essential if stage directed multimodality treatment regimens are to be used 
appropriately and optimal outcomes achieved.  Staging must be able to 
identify those patients with distant metastases (M1 stage) at presentation, 
so that inappropriate aggressive treatment can be avoided.  In patients 
with early tumours, locoregional staging must be able to precisely identify 
the depth of tumour invasion (rT stage), so that endoscopic resection can 
be considered where appropriate (Allum et al 2011).  In patients with more 
advanced tumours the lymph node stage (rN stage) and the precise 
positions of any lymph node metastases proximal or distal to the primary 
tumour must be identified to establish the full extent of the disease.  This 
information informs not only the feasibility of surgical resection and the 
need for neoadjuvant therapy, but also facilitates the planning of newer 
non-surgical treatment options such as definitive chemoradiotherapy 
(Crosby et al 2004, Gwynne et al 2011). 
The principal modalities used in the past were computed tomography (CT), 
endoluminal ultrasonography (EUS), and where appropriate, staging 
laparoscopy.  Computed tomography is the first line investigation to 
exclude gross metastatic disease.  Computed tomography also provides 
limited information on rT and rN stage, and it’s accuracy in these respects 
has been reported to vary with body mass index (Twine et al 2009c).  
Furthermore, the assessment of lymph nodes by CT is entirely dependant 
on size criteria, with difficulty detecting metastases in lymph nodes of 
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normal size (van Vliet et al, 2008).  Endoluminal ultrasonography is 
considered the recommended gold standard for defining rT and rN stage 
(Allum et al 2011), exhibiting superior accuracy over CT in these areas 
(Kienle et al 2002, Blackshaw et al 2008), although it is constrained in the 
assessment of distant lymph nodes and viscera by it’s limited depth of 
penetration (Kienle et al 2002).  FDG-positron emission tomography (PET) 
provides metabolic tumour information, and has been shown to have 
superior sensitivity to CT in the detection of distant metastases (van 
Westreenen et al 2004, van Vliet et al 2008).  Integrated CT-PET scanning 
directly combines this metabolic information with the anatomical detail 
needed to accurately localise the sites of abnormality, and avoids the 
possibility of inaccurate co-registration encountered when information from 
independent PET and CT scans are combined.  Funding for integrated 
CT-PET imaging has been available for patients in S.E. Wales since 
January 2009.  The aim of this study was to assess the additional value of 
CT-PET in refining oesophageal cancer radiological stage. 
3.3 METHODS 
3.3.1 Staging and the utilisation of CT-PET    
The first one hundred and fifty consecutive patients to undergo CT-PET 
imaging in the S.E. Wales cancer network were included in the present 
study.  Patients proceeded to CT-PET imaging only if they were suitable 
for potentially curative treatment on the grounds of CT stage and 
performance status, and this was arranged concurrently with endoluminal 
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ultrasonography (EUS).  All CT-PET imaging took place between January 
2009 and June 2011.  The first 68 studies were performed at the 
Cheltenham Imaging Centre until August 2010 when the Wales CT-PET 
scanner became operational.  All subsequent imaging was provided at the 
University Hospital of Wales.  All staging investigations were reported in 
accordance with the UICC Tumour Nodes Metastasis (TNM) 6th Edition 
(Sobin and Wittekind 2002).  
3.3.2 Treatment modalities 
The algorithm for neoadjuvant and surgical treatment of oesophageal 
cancer in the S.E. Wales network has been described in Chapter 2. A 
small number of patients in this study with Siewert type III junctional 
tumours were treated by means of total D2 gastrectomy.  The protocols for 
definitive chemoradiotherapy (dCRT) have been described previously 
(Crosby et al 2004, Gwynne et al 2011) and are covered in more detail in 
Chapter 4. 
3.3.3 Statistical Analysis 
Grouped data were expressed as median (range) and non-parametric 
methods were used throughout.  The strength of agreement between 
radiological and histopathological staging was assessed using the 
weighted Kappa statistic (Kw). 
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3.4 RESULTS 
3.4.1 Radiological stage 
The clinical and radiological details of the patients are provided in Table 
3.1.  One hundred and forty (93.3%) patients had primary tumours that 
were demonstrated on CT-PET.  There were ten patients whose tumours 
could not be identified on CT-PET.  Of these, four were very early cancers 
of EUS stage rT1, for which the lack of FDG uptake by the tumour was 
attributed by the radiologist more to small size, rather than non avid 
tumours.  The remaining six tumours (4.0%) were more bulky yet non avid.  
All ten non-identified tumours were adenocarcinomas.  Details of the 
treatments prescribed and histopathological staging of the surgical 
patients are provided in Table 3.2. 
3.4.2 Influence of CT-PET on radiological T Stage 
Tumour stage was only reported on CT-PET in ten (6.7%) patients.  Of 
these ten patients 3 were upstaged by CT-PET when compared with the 
combined CT/EUS rT stage.  Two patients were upstaged from rT3 to rT4, 
and one from rT2 to rT3.  The remaining 140 (93.3%) patients had a rT 
stage that was either not formally assessed or reported as TX on CT-PET. 
3.4.3 Influence of CT-PET on radiological N Stage 
Combined CT/EUS N stage was upstaged from rN0 to rN1 in 6 (4.0%) 
patients by the addition of CT-PET (Table 3.3). 
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3.4.4 Comparative radiological vs. histopathological N Stage 
A comparison of CT, EUS and CT-PET perceived N stage with 
pathologically defined N stage, in a subgroup of 38 patients who had 
tumours crossed at EUS, and who underwent surgical resection is shown 
in Table 3.4.  The overall strength of agreement was fair for EUS 
(Kw=0.316, 95% CI 0.000-0.591, p=0.044).  In contrast there was poor 
agreement for both CT (Kw=0.064, 95% CI -0.156-0.304, p=0.601) and 
CT-PET (Kw=0.041, 95% CI -0.104-0.211, p=0.604).  Sensitivity, 
specificity, positive predictive value and negative predictive value, for the 
three staging modalities in terms of perceived rN stage are shown in Table 
3.5.  The number of lymph node metastases identified by EUS was not 
significantly different from the histopathological count [median 1 (0-18) vs. 
1 (0-11), p=0.095].  In contrast, the number of lymph node metastases 
identified by CT-PET was significantly lower than that reported 
histopathologically [median 0 (0-2) vs. 1 (0-11), p<0.0001]. 
3.4.5 Influence of CT-PET on M stage 
The rM stage was upstaged by CT-PET to rM1 in 36 (24.0%) patients.  
The sites of CT-PET identified metastases are listed in Table 3.6.  In 21 
patients (14.0%) the CT scan failed to identify distant metastases (M0).  In 
the remaining 15 patients (10%) CT had identified lesions that were 
equivocal for metastases (MX) and without the confirmation afforded by 
CT-PET, there would have been insufficient evidence to allow the MDT to 
deviate from potentially curative to palliative treatment intent.  The 
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treatment intent for all 36 patients changed to palliative as a direct result of 
the CT-PET.  False negative CT-PET rM0 stage occurred in 10 (6.7%) 
patients.  Four patients had peritoneal or liver metastases detected on 
staging laparoscopy and four had liver metastases apparent on 
laparotomy. The remaining two patients had cervical lymph node 
metastases (M1a) outside the surgical field identified on EUS, but not 
seen on CT-PET, both of which were confirmed by fine needle aspiration 
cytology.  The overall negative predictive value for CT-PET M stage was 
therefore 90.4%. 
3.4.6 Additional diagnostic workload 
A summary of the additional diagnostic workload generated as a 
consequence of the CT-PET imaging findings is shown in Table 3.7.  
Twenty-two patients (14.7%) underwent further investigations, most of 
which confirmed that the FDG uptake on CT-PET was physiological, or 
indicative of benign pathology.  One patient was subsequently diagnosed 
with a previously undetected early invasive breast cancer. 
3.4.7 Treatment 
Potentially curative treatment was attempted in 96 (64.0%) patients.  The 
reasons for palliative treatment, other than for those patients upstaged by 
CT-PET, included disease lengths considered too extensive for surgery or 
curative dCRT (5 patients), deterioration in performance status during 
staging (4), demonstration of direct liver infiltration on staging laparoscopy 
(1), and a patient declining potentially curative treatment (1). 
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Table 3.1 Clinical and radiological details of the patients 
 
Number 150 
Age (Y) 67 (36-82) 
Gender   M:F 111:39 
ACA : SCC : neuroendocrine 115 : 33 : 2 
Anatomical site (%)  
Upper third 3 (2.0) 
Middle third 33 (22.0) 
Lower third inc Siewert I 80 (53.3) 
Siewert II junctional 13 (8.7) 
Siewert III junctional 21 (14.0) 
CT T Stage (%)  
T1 10 (6.7) 
T2 20 (13.3) 
T3 99 (66.0) 
T4 21 (14.0) 
CT N Stage (%)  
N0 74 (49.3) 
N1 76 (50.7) 
CT M Stage (%)  
M0 122 (81.3) 
MX 28 (18.7) 
EUS attempted (%) 126 (84.0) 
EUS tumour crossed (%) 107 (71.3) 
EUS T Stage (%)  
T1 9 (6.0) 
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T2 7 (4.7) 
T3 75 (50.0) 
T4 16 (10.7) 
EUS N stage (%)  
N0 38 (25.3) 
N1 69 (46.0) 
EUS M1a stage (%) 2 (1.3) 
CT-PET T stage (%)  
T3 6 (4.0) 
T4 4 (2.7) 
TX or not reported 140 (93.3) 
CT-PET N stage (%)  
N0 97 (64.7) 
N1 53 (35.3) 
CT-PET M stage (%)  
M0 103 (68.7) 
M1 36 (24.0) 
MX 11 (7.3) 
ACA – adenocarcinoma, SCC – squamous cell carcinoma, 
Age is median (range). 
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Table 3.2 Details of treatment and histopathological staging 
 
Treatment (%)  
Surgery 54 (36.0) 
      Neoadjuvant chemotherapy 40 (26.6) 
      Surgery alone 14 (9.3) 
      Transthoracic oesophagectomy 21 (14.0) 
      Transhiatal oesophagectomy 
      Total D2 gastrectomy 
14 (9.3) 
10 (6.7) 
      Open and close laparotomy 9 (6.0) 
      Resection completed 45 (30.0) 
Definitive chemoradiotherapy 40 (26.7) 
EMR 2 (1.3) 
Palliation 53 (35.3) 
Died during staging 1 (0.7) 
Resected patients  
Histopathological T stage (%)  
CPR 1 (0.7) 
T1 5 (3.3) 
T2 14 (9.3) 
T3 24 (16.0) 
T4 1 (0.7) 
Histopathological N stage (%)  
N0 17 (11.3) 
N1 28 (18.7) 
EMR – endoscopic mucosal resection, CPR – complete 
pathological response. 
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Table 3.3 Combined CT/EUS vs. CT-PET perceived N stage 
 
  Stage by CT-PET 
  N0 N1 
Stage by combined N0 45 6 
CT EUS N1 52 47 
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Table 3.4 Radiological vs. histopathological N stage 
 
  Stage by histopathology 
  N0 N1 
Stage by CT N0 11 17 
 N1 3 7 
    
    
  Stage by histopathology 
  N0 N1 
Stage by EUS N0 10 9 
 N1 4 15 
    
    
  Stage by histopathology 
  N0 N1 
Stage by CT-PET N0 13 21 
 N1 1 3 
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Table 3.5 Radiological N stage sensitivity, specificity, PPV, NPV 
 
 CT EUS CT-PET 
Sensitivity 29.2 62.5 12.5 
Specificity 78.6 71.4 92.9 
PPV 70.0 78.9 75.0 
NPV 39.3 52,6 38.2 
  
PPV – positive predictive value, NPV – negative predictive 
value.  
 
 
 
Table 3.6 Sites of CT-PET detected occult metastases 
 
Site of metastasis Number (%) 
Lymph nodes outside surgical field 25 (16.7) 
Liver 9 (6.0) 
Musculoskeletal 6 (4.0) 
Lung / pleural 5 (3.3) 
Renal 3 (2.0) 
Adrenal 2 (1.3) 
Peritoneal 2 (1.3) 
Ocular 1 (0.7) 
Tongue / pharynx 1 (0.7) 
 
Some patients had metastases at more than one site. 
 
 
3 CT-PET 
86 
Table 3.7 Additional diagnostic workload generated by CT-PET 
 
Site of FDG uptake Number (%) Outcome 
Large bowel / rectum 9 (6.0) 5 polyps, 4 normal 
Pharynx / vocal cords 4 (2.7) All normal 
Prostate 4 (2.7) 3 benign, 1 not formally 
investigated 
Adrenal 3 (2.0) All benign 
Breast 1 (0.7) Breast cancer 
Hip joint capsule 1 (0.7 Normal 
Parotid gland 1 (0.7) Benign tumour 
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3.5 DISCUSSION 
This study investigated the contribution of CT-PET in the staging and 
treatment of a consecutive cohort of patients with oesophageal cancer.  
The principal finding was that CT-PET upstaged twenty-four patients to 
stage rM1 and consequently avoided inappropriate aggressive radical 
treatment with no prospect of cure.  Twenty-two (14.7%) patients required 
further, sometimes invasive, diagnostic testing on the basis of incidental 
CT-PET findings. 
There are major pitfalls associated with the use of FDG-PET in the 
assessment of rN stage.  Principally FDG uptake in perioesophageal 
lymph nodes that are anatomically close to the primary tumour is difficult 
to differentiate from uptake originating from the oesophagus itself, due to 
the limited spatial resolution of PET (Rice 2000, Chowdhury et al 2008).  
Indeed, it has been demonstrated that PET has greater accuracy in the 
identification of regional and distant nodal involvement, than in local lymph 
nodes (Flamen et al 2000, Yoon et al 2003).  In addition FDG uptake 
within lymph nodes can occur in benign disease, including granulomatous 
infection (Mackie and Pohlen 2005) and sarcoidosis (Maeda et al 2005) 
and in many cases this cannot be confidently distinguished from malignant 
disease.  
Numerous studies have examined the individual accuracy of EUS and 
PET in terms of oesophageal rN stage.  Radiological stage sensitivity and 
specificity for EUS range from 45% to 97% and 33% to 100%, and for PET 
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range from 22% to 82% and 60% to 100% (van Vliet et al 2008).  Very few 
studies have examined the accuracy of integrated CT-PET compared with 
separate CT and PET, although Yuan et al (2006) identified small 
improvements in rN stage sensitivity and specificity for integrated CT-PET 
compared with separate CT and PET.  Meta-analysis derived pooled 
sensitivity and specificity for EUS are 80% and 70%, and for PET 57% and 
85% (van Vliet et al 2008).  The results of this study demonstrate rN stage 
sensitivity for EUS (62.5%) and CT-PET (12.5%) fall short of these, 
however the trend of greater sensitivity with EUS compared with PET 
holds true.  In contrast rN stage specificity for EUS (71.4%) and CT-PET 
(92.9%) in this study are equivalent to reported meta-analysis figures for 
EUS, and are indeed better for PET.  However, the patient numbers in this 
study were relatively small and care must therefore be taken in the 
analysis of small differences in sensitivity and specificity.  It would appear 
reasonable though to suggest the results concur with the meta-analysis 
findings of greater sensitivity for EUS, yet greater specificity for PET, in the 
assessment of rN stage. 
The principal strength of PET based imaging is in the detection of occult 
distant metastases.  Meta-analysis derived pooled sensitivity and 
specificity rM stage for CT are 52% and 91%, and for PET 71% and 93%.  
A comparison of the results of the present study with these published 
sensitivity and specificity figures cannot be made as CT-PET imaging was 
not performed on all patients undergoing staging, but rather reserved only 
for a select cohort potentially suitable for curative treatment based on CT 
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stage.  However, the CT-PET influence in refining M stage in almost a 
quarter of patients in this study clearly demonstrates its superiority over 
CT in this regard.  The 6.7% of patients in this cohort with metastases 
undetected by both CT and CT-PET is comparable to a published rate of 
5% from a recent prospective trial (Meyers et el 2007), and therefore this 
modality is not without limitations in terms of rM stage.  One patient (0.7%) 
in this series had an unrelated synchronous cancer diagnosed on CT-PET, 
although a further patient had a suspected prostatic carcinoma that was 
not formally investigated due to extensive oesophageal metastases.  The 
identification of synchronous cancers is well documented for PET-based 
imaging and has been reported in as many as 5.5% of patients, of which 
the majority have malignant or premalignant colorectal lesions (van 
Westreenen et al 2005). 
The study has potential limitations.  The total number of patients was 
relatively high, yet the numbers who underwent surgical resection 
relatively small, limiting the accuracy of the radiological vs. pathological N 
stage comparison.  The accuracy of the EUS examinations was a little 
disappointing, and indeed higher strengths of agreement with pathological 
N stage have previously been reported in our unit (Kw=0.639 95% CI 
0.576-0.702, p = 0.0001, Twine et al 2009c).  The reasons for this are 
unclear but it may relate to the small numbers, and the use of neoadjuvant 
therapy.  However, it must be acknowledged that the predominant pattern 
of EUS inaccuracy in this series was in under, rather than over, staging N 
stage.    
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Aside from the obvious benefits for those patients avoiding inappropriate 
radical surgery, there will clearly be a substantial associated cost saving. 
However a formal cost analysis was not within the remit of this study.  
There is scope for further research, with larger patient numbers, to 
evaluate the differing accuracy of EUS and PET in identifying peritumoural 
vs. more distant regional lymph node metastases, and also to assess this 
within the framework of TNM7 defined N1, N2 and N3 subgroups. 
In contrast the study has several strengths.  The patients were a 
consecutive series.  All data were collected prospectively, and treatment 
was provided by an experienced MDT.  All imaging was carefully reviewed 
in a regional MDT setting, and the reasons for differing treatment 
decisions were clearly defined.  
3.6 CONCLUSION 
The addition of CT-PET to the staging algorithm for oesophageal cancer 
resulted in the upstaging of 24% of patients, in whom inappropriate 
aggressive curative treatment was avoided.  The principal strength of CT-
PET was in the assessment of M stage, with a very limited role in N stage.  
The roles of CT, EUS and CT-PET are complementary, and a combined 
staging approach utilising all three will optimise treatment decisions in 
oesophageal cancer. 
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The relative incidence and pattern of oesophageal cancer recurrence 
following definitive chemoradiotherapy and surgery 
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4.1 SUMMARY 
The aim of this study was to determine the relative incidence and pattern 
of oesophageal cancer recurrence following definitive chemoradiotherapy 
and surgery.  
Three hundred and eleven consecutive patients unsuitable for surgery on 
the grounds of performance status (n=137), bulky local disease (n=121) or 
personal choice (n=53) received definitive chemoradiotherapy (164 ACA, 
147 SCC), and 312 surgery (252 ACA, 60 SCC) (200 neoadjuvant 
chemotherapy).  The primary outcome measure was disease-free survival. 
Oesophageal cancer recurrence was diagnosed in 44.1% after definitive 
chemoradiotherapy compared with 40.7% after surgery (p=0.222). Loco-
regional recurrence was commoner after definitive chemoradiotherapy 
than surgery (24.1% vs. 9.3%, p<0.0001). Distant metastases were 
commoner after surgery than definitive chemoradiotherapy (22.8% vs. 
12.9%, p=0.001). The median times to recurrence after definitive 
chemoradiotherapy and surgery were 15 and 17 months respectively 
(p=0.052). Stage related disease-free 2-year survival after definitive 
chemoradiotherapy vs. surgery was: stage I (68.6 vs. 85.6%, p=0.069), II 
(36.9 vs. 47.4%, p=0.011), III (31.0 vs. 28.6, p=0.878), IVa (21.4 vs. 26.3%, 
p=0.710).  
These findings support the need for a randomised trial of definitive 
chemoradiotherapy vs. surgery in oesophageal cancer irrespective of 
histopathological cell type. 
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4.2 INTRODUCTION 
Oesophageal carcinoma is the 9th most common cancer in the UK, and 
has increased in incidence by more than 60% in males over the past 30 
years (Cancer Research UK 2007).  The optimum contemporary treatment 
in the UK is considered to be neoadjuvant chemotherapy followed by 
surgery (Medical Research Council Oesophageal Cancer Working Party 
2002), but the recent UK national audit suggested that fewer than 30% of 
all cases of oesophageal cancer undergo surgery (National Oesophago-
gastric Cancer Audit 2010).  Despite recent advances in physiological and 
radiological staging, anaesthesia and surgical techniques, outcomes 
remain poor, with operative morbidity and mortality rates of 30% and 4.5 to 
10.1% respectively, 2-year survival rates of 34 to 43%, and overall 5 year 
survival of 17 to 23% (Medical Research Council Oesophageal Cancer 
Working Party 2002, National Oesophago-gastric Cancer Audit 2010, 
Kelson et al 1998, Al-Sarira et al 2007).  Moreover surgery has a major 
detrimental impact on short term health-related quality of life, that persists 
at least six months following oesophagectomy (Avery et al 2007).  
Definitive chemoradiotherapy (dCRT) has been reported to result in long 
term survival of patients with both squamous cell carcinoma and 
adenocarcinoma of the oesophagus and championed as an alternative 
treatment for patients with squamous cell carcinoma (Cooper et al 1999, 
Crosby et al 2004, Gwynne et al 2011, Bedenne et al 2007, Stahl et al 
2005, Chan et al 1999, Coia et al 2000, Kaneko et al, 2003, Geh 2001, 
Chiu et al 2005).  Three randomised trials have compared dCRT to 
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surgery with or without neoadjuvant therapy for patients with squamous 
cell carcinoma, all of which reported similar overall survival rates 
(Bedenne et al 2007, Stahl et al 2005, Chiu et al 2005).  However, the 
trials were underpowered to examine the possible equivalence of dCRT 
compared to surgery and limited HRQL data were reported.  No well 
designed and conducted randomised trial has yet compared dCRT to 
surgery based treatment for oesophageal adenocarcinoma, and as such 
the role of dCRT in treating fit patients with potentially operable 
adenocarcinoma remains uncertain.   
A stage-for-stage comparison of dCRT and surgery for oesophageal 
cancer irrespective of pathological cell type, from the S.E. Wales regional 
cancer network, has demonstrated similar overall 2-year survival for 
patients treated with dCRT, surgery alone and neoadjuvant therapy 
followed by surgery (Morgan et al 2009).   However, criticism was received 
following publication for suspected poorer locoregional disease control 
after dCRT, relative to surgery (Clark et al 2010) and the lack of 
recurrence data in this study left this open to question. 
The aim of this study therefore was to determine the relative incidence and 
pattern of oesophageal cancer recurrence following dCRT and surgery in 
patients receiving stage directed therapy with curative intent. 
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4.3 METHODS 
4.3.1 Patient selection and radiological staging 
The study included consecutive patients diagnosed with potentially curable 
oesophageal carcinoma of any cell type between 1 January 1998 and 31 
October 2010, by a regional cancer network multidisciplinary team serving 
a population of 1.4 million.  Clinical and pathological information was 
collected on a prospectively maintained database.  Pre-operative staging 
involved computed tomography (CT), endoluminal ultrasonography (EUS) 
and if appropriate, laparoscopy.  More recently CT-PET imaging has been 
incorporated into the staging protocol, for patients diagnosed from early 
2009 onwards.  All staging was in accordance with the UICC Tumour 
Nodes Metastasis Classification (TNM) 6th Edition (Sobin et al 2002).  The 
EUS examinations were either performed or supervised by a single 
radiologist.  In addition to standard TNM criteria, and the primary tumour 
length, EUS examinations also reported the lymph node metastasis count 
(LNMC) and the EUS defined total length of disease (ELOD).  The latter 
was equal to the tumour length for patients staged N0. However, for 
patients with suspicious lymph node metastases ELOD was calculated 
according to the distance between the most proximal lymph node or 
tumour extent and the most distal lymph node or tumour extent.  Sixteen 
patients (2.5%) were excluded because their tumours were too stenotic to 
be crossed at EUS, and therefore a full and accurate radiological stage 
was not available. Ethical approval was sought from the regional ethics 
committee, but the chair confirmed that individual patient consent was not 
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required to report clinical outcomes alone and as such no formal approval 
was necessary. 
4.3.2 Surgery +/- neoadjuvant therapy 
Management plans were individually tailored according to patient factors 
and disease stage.  In general, fit patients with tumours of stage T3 and 
equivocal T4, N0 and N1 were considered for neoadjuvant therapy prior to 
surgery.  Prior to 2002 patients were treated with neoadjuvant 
chemoradiotherapy.  Following the publication of the MRC OE02 trial 
(Medical Research Council Oesophageal Cancer Working Party, 2002) 
patients received neoadjuvant chemotherapy.  Less fit patients and those 
with T1-T2, N0 disease were considered for surgery alone.  Most patients 
underwent standard subtotal oesophagectomy as described by Lewis and 
Tanner (Lewis 1946, Tanner 1947).  Transhiatal resection, as described 
by Orringer (Orringer 1985), was used selectively in patients with 
adenocarcinoma of the lower third of the oesophagus who had significant 
cardiorespiratory co-morbidity.  Oesophageal resection was defined as 
potentially curative when all visible tumour had been removed and both 
proximal and distal resection margins were free from tumour on 
histological examination.  Involvement of the circumferential resection 
margin was defined as the presence of tumour within 1mm of the 
circumferential margin. 
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4.3.3 Definitive chemoradiotherapy 
Patients deemed unsuitable for surgery on grounds of co-morbidities 
and/or performance status, locoregional disease considered too extensive 
for curative resection or personal choice received dCRT.  They received 
four cycles of cisplatin (60 mg/m2) and a fluoropyrimidine over 12 weeks, 
with cycles 3 and 4 given concurrently with 50 Gy conformal radiotherapy 
delivered in a single phase in 25 fractions.  The dCRT protocol which has 
evolved over time has been described in detail previously (Crosby et al 
2004, Gwynne et al 2011, Morgan et al 2009).  Toxicity related to 
oncological therapy was graded using the National Cancer Institute 
common criteria for adverse events (National Cancer Institute, 2003).   
4.3.4 Follow-up and Disease Recurrence 
After completion of dCRT a CT scan was carried out to assess the 
response and to establish a baseline after treatment.  Repeat endoscopy 
was not routinely carried out after treatment.  All patients were reviewed 
every 3 months for the first year after dCRT or oesophagectomy, and 
every 6 months thereafter.  Definitive chemoradiotherapy patients were 
deemed to have progressive local disease where there was a failure to 
respond to treatment, defined as disease progression within 6 weeks from 
the date of completion of treatment.  Disease recurrence was suspected 
clinically and confirmed with investigations, usually CT or endoscopy.  
Patterns of recurrence were defined as locoregional (L), distant (D) 
(metastatic) or both locoregional and distant (L and D), when both were 
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diagnosed at the same time.  The time of recurrence was taken as the 
date of the confirmatory investigation.  Follow-up until 5 years or death 
was available for 539 (86.5%) patients.  Death certification was obtained 
from the Office for National Statistics. 
4.3.5 Statistical Analysis 
Analysis was based on intention to treat.  The primary outcome measures 
were oesophageal cancer recurrence, disease-free survival and overall 
survival.  Grouped data were expressed as median (range) and non 
parametric methods were used.  Disease-free survival for all patients was 
calculated using similar methodology to both the MRC OEO2 (Medical 
Research Council Oesophageal Cancer Working Party, 2002) and US 
Intergroup (Kelson, 1998) randomised trials, by measuring the period from 
a landmark time of 6 months after diagnosis (6 months from time of 
randomisation in the trials) to the date of recurrence. This approach was 
adopted for the trials, to allow for the variable interval to surgery following 
diagnosis, depending on whether neoadjuvant therapy was prescribed. As 
in the randomised trials, events resulting in a failure to complete curative 
treatment such as not proceeding to surgery, open and close laparotomy, 
palliative resection, in-hospital mortality, and disease progression during 
dCRT, were assumed to have occurred at this landmark time, to maintain 
the intention to treat analysis. Overall survival was measured from the 
date of diagnosis.  Cumulative survival was calculated according to the 
life-table method of Kaplan and Meier, and differences between groups 
were analysed with the log rank test.  Univariate analyses examining 
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factors influencing survival were initially examined, and those with 
associations found to be significant retained in a Cox’s proportional 
hazards model.  The final multivariate model also included gender, age 
and histological cell type, to correct for baseline differences between the 
groups.   
4.4 RESULTS 
4.4.1 Details of the patients and treatment prescribed 
Six hundred and twenty-three patients were included in the study, and 
their details related to treatment modality are shown in Table 4.1.  Of the 
623 patients, 311 were deemed unsuitable for surgery on the basis of co-
morbidity and/or performance status (137, 44.1%), extensive locoregional 
disease (121, 38.9%) or personal choice (53, 17.0%) and received dCRT.  
Of these 311 patients, 70 (22.5%) had disease that progressed despite 
dCRT treatment.  No patients died during treatment with dCRT.  The 
remaining 312 patients were deemed suitable for surgical treatment.  
Neoadjuvant chemotherapy and chemoradiotherapy was given to 150 
(48.9%) and 50 (16.3%) patients respectively.  
4.4.2 Details of the surgery 
The operative approach was trans thoracic in 167 (53.5%) and transhiatal 
in 107 (34.3%).  Six patients (1.9%) failed to proceed to surgery following 
neoadjuvant therapy due to disease progression. Resection was 
potentially curative (R0) in 254 (81.7%) and palliative (R1 or R2) in 20 
(6.4%).  Circumferential resection margin (CRM) status was negative in 
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155 (49.7%), involved in 99 (31.7%) and not reported in 20 patients (6.4%) 
from early in the series.  Thirty-two patients (10.3%) underwent open and 
close laparotomy.  The operative mortality (deaths within 30 days) was 12 
(3.8%) and the in-hospital mortality rate was 14 (4.5%).  In total 72 
patients (23.1%) failed to complete potentially curative surgical treatment 
for these reasons.      
4.4.3 Treatment related morbidity 
The overall rate of operative morbidity in the surgical group was 38.5% 
(120 patients).  In comparison the rates of grade III and IV toxicity in the 
dCRT patients were 42.1% (131 patients) and 7.1% (22 patients).  
4.4.4 Disease recurrence 
Data on cancer recurrence related to treatment type are shown in Table 
4.2.  There was no significant difference in the overall rate of recurrence. 
Locoregional recurrence was two and half times commoner after dCRT 
than surgery.  In contrast distant recurrence was nearly twice as common 
after surgery.  Definitive chemoradiotherapy was associated with a trend 
towards a 2 month reduction in time to recurrence (p=0.052), and non-
significant 3 and 4 month reductions in time to locoregional and distant 
recurrence respectively, when compared with surgery. 
4.4.5 Disease-free and overall survival 
For patients with all stages of disease, surgery was associated with 
significantly better disease-free survival (median 14 vs. 9 months, 2-year 
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39.8 vs. 33.0%, p=0.003) and overall survival (median 28 vs. 22 months, 
2-year 56.2 vs. 45.4%, p=0.001) than dCRT.  Stage-for-stage median and 
2-year disease-free survival for surgery versus dCRT was: stage I (n/a vs. 
59 months, 85.6 vs. 68.6%, p=0.069), stage II (24 vs. 12 months, 47.4 vs. 
36.9%, p=0.011), stage III (9 vs. 6 months, 28.6 vs. 31.0%, p=0.878) and 
stage IVa (0 vs. 3 months, 26.3 vs. 21.4%, p=0.710).  (See Figures 4.1 - 
4.4)  Stage-for-stage median and 2-year overall survival for surgery versus 
dCRT was: stage I (n/a vs. 68 months, 85.6 vs. 68.6%, p=0.236), stage II 
(41 vs. 26 months, 67.2 vs. 51.3%, p=0.013), stage III (22 vs. 17 months, 
46.2 vs. 41.8%, p=0.377) and stage IVa (19 vs. 15 months, 31.6 vs. 42.9%, 
p=0.665). 
A subanalysis of the same parameters including only patients with 
oesophageal ACA demonstrated broadly similar results for patients with 
SCC and ACA.  Disease-free survival was significantly better following 
surgery than dCRT for stage I (n/a vs. 45 months, 88.1 vs. 68.6%, 
p=0.008) and stage II (24 vs. 14 months, 2-year 48.0 vs. 33.7%, p=0.036), 
but comparable to dCRT for stage III (8 vs. 5 months, 24.3 vs. 30.5%, 
p=0.593) and stage IVa (0 vs. 3.0 months, 20.0 vs. 20.0%, p=0.915).  
Overall survival was better following surgery than dCRT for stage I (n/a vs. 
68 months, 88.1 vs. 68.6%, p=0.078) and non significantly better for stage 
II (34 vs. 25 months, 66.8 vs. 50.0%, p=0.062), but comparable to dCRT 
for stage III (22 vs. 17 months, 43.9 vs. 41.2%, p=0.721) and stage IVa 
(19 vs. 12 months, 26.7 vs. 33.3%, p=0.577). 
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4.4.6 Influence of histological cell type 
The patients were analysed in relation to histological cell type, irrespective 
of the treatment modality prescribed.  Patients with SCC had significantly 
more advanced stages of disease than patients with ACA (stage I: 3.4 vs. 
6.0%, stage II:  27.1 vs. 37.5%, stage III: 61.4 vs. 49.3%, stage IV: 8.2 vs. 
7.2%, p=0.017), and a greater proportion received dCRT than surgery 
(71.0 vs. 39.4%, p<0.0001).  Recurrence occurred in 85 (41.1%) patients 
with SCC and 179 (43.0%) patients with ACA (p=0.860).  There was a 
greater incidence of locoregional recurrence in patients diagnosed with 
SCC compared with patients diagnosed with ACA (46 vs. 58, 22.2 vs. 
13.9%, p=0.009).   In contrast, distant recurrence was more common for 
patients with ACA than patients with SCC (85 vs. 26, 20.4 vs. 12.6%, 
p=0.016).  Disease-free survival was comparable for patients with ACA 
and SCC (12 vs. 11 months, 35.6 vs. 38.0%, p=0.847).  Overall survival 
was also comparable for patients with ACA and SCC (25 vs. 25 months, 
50.7% vs. 50.8%, p=0.817, respectively).    
4.4.7 Influence of neoadjuvant therapy 
One hundred and twelve patients underwent surgery alone (S), and 200 
patients underwent surgery following neoadjuvant therapy (CS, 50 
chemoradiotherapy, 150 chemotherapy).  Surgery following neoadjuvant 
therapy was associated with poorer disease-free survival (median 12 vs. 
24 months, 2 year 34.2 vs. 49.4%, p=0.039) and overall survival (median 
25 vs. 41 months, 2 year 50.8 vs. 65.6%, p=0.049) than surgery alone.  
4 Recurrence Patterns 
103 
There was a trend towards failure to complete curative treatment for the 
CS patients when compared with S (53 vs. 19 patients, 26.5% vs. 17.0%, 
p=0.068).  There was no significant difference in the incidence of cancer 
recurrence following CS when compared with S (82 vs. 45 patients, 41.0% 
vs. 40.2%, p=0.887).  Similarly, there were no significant differences in the 
patterns of cancer recurrence following CS and S [local recurrence 20 
(10.0%) vs. 9 (8.0%), distant recurrence 48 (24.0%) vs. 23 (20.5%), both 
local and distant 13 (6.5%) vs. 12 (10.7%) and site unspecified 1 (0.5%) vs. 
1 (0.9%), overall p=0.486]    
4.4.8 Univariate and multivariate analysis 
A univariate analysis of factors influencing disease-free survival is shown 
in Table 4.3.  A multivariate analysis of the factors significant on univariate 
analysis, and corrected for gender, age and histological cell type, identified 
EUS T stage and EUS defined LNMC to be independently and significantly 
related to disease-free survival (Table 4.4). 
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Table 4.1 Details of the patients 
 
 Surgery dCRT p value 
Number 312 311  
Gender   M:F 244:68 172:139 <0.0001 
Median Age (Y) (range) 62 (31-79) 69 (39-85) <0.0001 
Age <70:≥70 242:70 159:152 <0.0001 
Histology   ACC:SCC 252:60 164:147 <0.0001 
Site of Tumour (%)   <0.0001 
Upper third 0 12 (3.9)  
Middle third 53 (17.0) 123 (39.5)  
Lower third & GOJ 259 (83.0) 173 (55.6)  
Unknown 0 3 (1.0)  
Radiological Stage (%)  <0.0001 
I 22 (7.1) 10 (3.2)  
II 126 (40.4) 86 (27.7)  
III 145 (46.5) 187 (60.1)  
IVa 19 (6.1) 28 (9.0)  
EUS T Stage (%)   <0.0001 
T1 26 (8.3) 12 (3.9)  
T2 52 (16.7) 39 (12.5%)  
T3 209 (67.0) 178 (57.2)  
T4 25 (8.0) 82 (26.4)  
EUS N Stage (%)   <0.0001 
N0 128 (41.0) 85 (27.3)  
N1 184 (59.0 226 (72.7)  
EUS M1a (%) 19 (6.1) 28 (9.0) 0.169 
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Median ELOD (range) 6 (0-20) 7 (0-26) <0.0001 
ELOD ≤ 5cm (%) 116 (37.2) 92 (29.6) 0.017 
ELOD ≤ 7cm (%) 173 (55.4) 138 (44.3) 0.011 
ELOD ≤ 10cm (%) 226 (72.4) 192 (61.7) <0.0001 
ELOD not reported (%) 51 (16.3) 43 (13.8) 0.380 
ELOD – EUS defined total disease length in cm 
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Table 4.2 Outcomes related to treatment type 
 
 Surgery dCRT p value 
Progressive disease despite 
dCRT (%) 
- 70 (22.5) - 
No surgery / palliative 
resection / in hospital 
mortality (%) 
72 (23.1) - - 
Disease free (%) 113 (36.2) 104 (33.4) 0.467 
Recurrence (%) 127 (40.7) 137 (44.1) 0.222 
Site of recurrence (%)    
Locoregional 29 (9.3) 75 (24.1) <0.0001 
Distant 71 (22.8) 40 (12.9) 0.001 
Both 25 (8.0) 22 (7.1) 0.657 
Unspecified 2 (0.6) 0 0.157 
Median time to recurrence 
(range) 
17 (2-74) 15 (5-162) 0.052 
Median time to locoregional 
recurrence (range) 
18 (7-50) 15 (6-65) 0.134 
Median time to distant 
recurrence (range) 
16 (2-74) 12 (5-162) 0.175 
Time to recurrence in months. 
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Table 4.3 Univariate analysis of factors influencing disease-free 
survival 
Factor Chi2 df p value 
Age 58.251 50 0.198 
Age group (10 years) 3.190 3 0.363 
Gender 1.510 1 0.219 
Histological cell type 0.037 1 0.847 
EUS T stage 34.543 3 <0.0001 
EUS N stage 30.800 1 <0.0001 
EUS defined tumour length 26.934 16 0.042 
EUS defined disease length 41.198 24 0.016 
EUS defined LNMC 36.711 11 <0.0001 
LNMC – lymph node metastasis count 
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Table 4.4 Multivariate analysis of factors influencing disease-free 
survival 
 Hazard 
Ratio 
95% CI p value 
EUS defined LNMC 1.066 1.022 1.112 0.003 
EUS T Stage  
T1 Reference group 
T2     1.959 1.017 3.774 0.044 
T3 2.477 1.343 4.567 0.004 
T4 2.566 1.304 5.050 0.006 
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Figure 4.1 Stage I disease-free survival related to treatment 
 
 
 
 
Chi2 3.316, df 1, p=0.069 
 
 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
Surgery 22 15 15 12 11 11 
dCRT 10 8 6 4 3 1 
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Figure 4.2 Stage II disease-free survival related to treatment 
 
 
 
 
Chi2 6.535, df 1, p=0.011 
 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
Surgery 126 72 54 44 39 34 
dCRT 86 41 28 21 12 10 
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Figure 4.3 Stage III disease-free survival related to treatment 
 
 
 
 
 
Chi2 0.023, df 1, p=0.878 
 
 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
Surgery 145 56 36 30 25 21 
dCRT 187 68 51 39 30 24 
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Figure 4.4 Stage IV disease-free survival related to treatment 
 
 
 
 
 
Chi2 0.138, df 1, p=0.710 
 
 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
Surgery 19 6 5 4 3 3 
dCRT 28 9 6 5 2 2 
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4.5 DISCUSSION 
This study represents the largest single centre prospective cohort 
comparative series of dCRT and surgery for oesophageal cancer in the 
United Kingdom. The principal finding was that overall rates of 
oesophageal cancer recurrence were comparable for surgery and dCRT, 
but the patterns and distribution of recurrence differed in relation to 
treatment type.  Chemoradiotherapy was associated with rates of 
locoregional recurrence that were two and a half times more common than 
after surgery, but in contrast distant metastatic recurrence was more than 
one and a half times commoner after surgery than dCRT.  Disease-free 
and overall survival were better following surgery than dCRT for patients 
diagnosed with early stage (I and II) oesophageal cancer, but were similar 
for patients with advanced stage (III and IVa) cancer.  The 311 patients 
undergoing dCRT were significantly older with associated 
cardiorespiratory comorbidities, were more likely to have squamous cell 
carcinomas, and had longer and more locally advanced tumours than 
patients undergoing surgery.  Nevertheless these patients had an overall 
median survival of 22 months, with 45.4% and 23.9% of patients being 
alive at 2 and 5 years respectively.  Even patients with T4 disease 
survived for a median of 13 months, with a 2 year survival of 32.6%.  
Based on historical control data, such patients in the past would have 
been offered only palliative therapy with a likely 2 year survival of some 5 
to 10%.  
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Relatively few randomised control trials have directly compared dCRT with 
surgery in the management of oesophageal cancer and definitive 
conclusions are therefore uncertain.  Chiu et al from China (2005) 
randomised 80 patients with SCC to dCRT or surgery and found little 
difference in disease-free survival (54.5 vs. 58.3 after S or dCRT 
respectively, p=0.45).  Patients treated with S had a slightly higher 
proportion of recurrence in the mediastinum whereas patients treated with 
dCRT sustained a higher proportion of recurrence in the cervical or 
abdominal regions (Chiu et al 2005).  Similarly, Carstens et al (2007) from 
Sweden randomised 91 patients with both ACA and SCC to dCRT or S 
and reported 4 year survival of 29% and 23% respectively (not significant, 
no recurrence data quoted, no p value quoted).  Conversely, Badwe et al 
(1999) from India randomised 99 patients with SCC to radiotherapy alone 
(50 Gy in 25 fractions with a 15 Gy boost to the tumour bed) versus S 
alone and reported a significant survival advantage in favour of surgery 
(p=0.002), but again no recurrence data was quoted.  Two further 
randomised trials have compared dCRT alone with neoadjuvant 
chemoradiotherapy (CRT) followed by surgery, in patients with exclusively 
oesophageal squamous cell carcinomas (Bedenne et al 2007, Stahl et al 
2005).  Neither demonstrated significant differences in overall survival 
between treatment types.  Stahl et al reported 2-year locoregional 
disease-free rates of 64.3% for CRT followed by surgery and 46.7% for 
dCRT, commenting that the addition of surgery improved local disease 
control but not overall survival (Stahl et al 2005).  This is similar to the 
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findings of this study but Stahl et al do not provide any data on recurrence 
at other sites, namely distant metastases. Bedenne et al (2007) reported 
comparable 2-year recurrence rates of 56.7% for CRT followed by surgery 
and 59.6% for dCRT.  Local recurrence was significantly more frequent 
after dCRT, but there was no significant difference in the rate of distant 
recurrence between the groups (Bedenne et al 2007).  A British feasibility 
study of patients is currently underway to establish whether a full 
multicentre randomised trial of dCRT versus surgically based treatment is 
possible in the UK, although only patients with squamous cell carcinoma 
will be studied (Blazeby 2011).   
The study has several potential limitations.  This was a non-randomised, 
observational comparison of two treatment modalities allocated on a per 
patient basis, and therefore is potentially vulnerable to selection bias. 
Consequently the groups were unbalanced in terms of age, performance 
status, histopathological cell type, and length and stage of disease. 
Furthermore, there was a predominance of squamous cell carcinoma in 
the dCRT cohort, which is perceived to have greater radiosensitivity than 
the predominant adenocarcinoma, and these patients are less likely to be 
surgical candidates due to a combination of the site of the oesophageal 
tumour (high oesophagus) and co-morbidity related to aetiological factors 
that are in common with the cancer.  Nevertheless, comparable long term 
survival has been reported with dCRT for adenocarcinoma (Geh 2001). 
However, histopathological cell type was not found to be associated with 
disease-free survival on univariate analysis.  Moreover, the stage-for-
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stage subanalysis of the patients with oesophageal adenocarcinoma found 
that surgery and dCRT remained associated with comparable disease-free, 
and overall survival rates, for stage III and IV cancers, after exclusion of 
the data related to squamous carcinomas.  However, such subgroup 
analysis can introduce further bias, and a consequence of reducing patient 
numbers is the possibility of inadequate statistical power to detect real 
differences.  Of the patients receiving neoadjuvant chemotherapy and 
failing to progress to surgery (1.9%); the current series included a number 
of borderline resectable patients at diagnosis, in whom it was hoped that 
neoadjuvant chemotherapy might result in down staging, facilitating 
surgery.  In the course of neo-adjuvant treatment, there always exists a 
proportion of patients whose disease progresses, or who become 
physiologically too unwell for surgery. In the US Intergroup 0116 (Kelson 
et al 1998) and the MRC OE02 (Medical Research Council Oesophageal 
Cancer Working Party 2002) trials, the corresponding numbers of patients 
randomised to pre-operative therapy that underwent resection were 180 of 
213, and 360 of 401, respectively.  Data was not available on quality of life, 
as this is not usually recorded in routine clinical practice. 
In contrast, the present study has several strengths in that it represents 
the largest series of consecutive patients treated over 12 years in a single 
upper gastrointestinal cancer network, by an experienced multidisciplinary 
team based on state of the art radiological staging in each patient, with the 
surgery performed by specialist surgeons (Morgan et al 2007b and 2009 
and Adams et al 2007).  The integrity of a stage-for-stage approach to 
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analysis, with the inclusion of patients treated non-surgically, is highly 
dependant on accurate radiological staging.  All patients included in this 
study had complete EUS examinations, with well documented radiological 
expertise and user reliability (Weaver et al 2004).  The patients reside in a 
stable and well defined geographical area, and consequently the follow-up 
data is particularly robust.  The findings of this study cannot be explained 
on the basis of poorer than expected results from the surgery.  The in-
hospital mortality rate (4.5%) is comparable to large trial data (6-10%) 
(Kelson et al 1998, Medical Research Council Oesophageal Cancer 
Working Party, 2002) and the 2010 UK National Audit (4.5%) (National 
Oesophago-gastric Cancer Audit 2010).  The overall survival rates 
following surgery (median 28 months, 2 year 56.2%) compare favourably 
with the results from both the MRC OE02 (median 13.3 to 16.8 months, 2 
year survival 34 to 43%) (Medical Research Council Oesophageal Cancer 
Working Party, 2002) and the US Intergroup (median 14.9 to 16.9 months, 
2 year survival 35 to 37%) (Kelson et al 1998) trials.  Disease-free survival 
can also be directly compared to these trials, given the similar statistical 
methodology employed in this study. Whilst neither trial presents detailed 
data on disease-free survival, median and 2 year disease-free survival can 
be extrapolated from the published Kaplan-Meier plots (Medical Research 
Council Oesophageal Cancer Working Party 2002, Kelson et al 1998).  
The disease-free survival in the surgical patients in this study (median 14 
months, 2 year 39.8%) compares very favourably to both OE02 (0 to 6 
months, 20%, Medical Research Council Oesophageal Cancer Working 
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Party 2002) and the US Intergroup trial (0 months, 22%, Kelson et al 
1998).  The overall survival rates following dCRT (median 22 months, 2-
year 45.4%) compare favourably with other published series, which have 
shown consistent overall survival (median 14-18 months, 2-year 35-40%) 
in both SCC and ACA (Cooper et al 1999, Bedenne et al 2007, Stahl et al 
2005, Chan et al 1999, Coia et al 2000, Kaneko et al 2003, Geh 2001). 
4.6 CONCLUSION 
In conclusion, the results of this study have again shown that dCRT is an 
effective and well tolerated treatment for patients diagnosed with 
oesophageal cancer of any histopathological cell type.  Survival rates were 
similar to those reported in surgical series; supporting the view that dCRT 
should be considered in all patients, particularly those at higher risk from 
surgery due to co-morbidity and stage III disease in whom an R0 resection 
is less likely.  Relapses were predominantly local after dCRT but 
metastatic after surgery. Indeed, locoregional disease was a component of 
treatment failure in 70.8% of cases after dCRT compared with 42.5% after 
surgery, whereas metastases were a component in 45.3% of cases after 
dCRT compared with 75.6% after surgery.  The overall local failure rate 
after dCRT of 31.2% is similar to other studies but seems higher than that 
reported after surgery.  Most sites of first recurrence after dCRT were 
within the radiation field, suggesting a need for intensifying local therapy 
allied to improving systemic therapy.  Further research to optimise dCRT 
technique, focusing on recent advances such as intensity-modulation 
radiotherapy may allow safe dose escalation.  Improved systemic therapy 
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with targeted agents such as anti-epidermal growth factor receptor 
inhibitors have shown promise when combined with radiotherapy in other 
tumour sites (Bonner et al, 2006) and are currently under investigation in 
the UK National Cancer Research Institute SCOPE 1 study of dCRT for 
oesophageal cancer (Crosby 2009).  A prospective randomised trial is 
needed to directly compare outcomes after dCRT and surgically based 
therapy for oesophageal cancer, but the difficulties of satisfying both 
patient and surgeon preferences would be considerable (Blazeby 2011).  
The feasibility study underway at present is examining whether it is 
possible to recruit patients into a randomised control trial comparing 
diverse treatments (Blazeby et al 2011).  The above trial is proposed in 
oesophageal SCC but the data from this study suggest that it may also be 
able to incorporate patients diagnosed with ACA, making the feasibility of 
such a trial more likely. 
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The prognostic significance of involvement of the circumferential 
resection margin following oesophagectomy and influence of 
differing neoadjuvant therapy regimens 
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5.1 SUMMARY 
The optimum multimodal treatment for oesophageal cancer, and the 
prognostic significance of histopathological tumour involvement of the 
circumferential resection margin (CRM+) are uncertain.  The aims of this 
study were to determine the prognostic significance of CRM+ after 
oesophagectomy and to identify endosonographic (EUS) features that 
predict CRM+. 
Two hundred and fifty six consecutive patients underwent potentially 
curative oesophagectomy [118 neoadjuvant chemotherapy (CS) and 42 
chemoradiotherapy (CRTS)].  The primary outcome measures were 
overall and disease-free survival (DFS). 
A positive CRM was reported in 93 (38.0%) of all patients, and in 85 
(62.4%) of the pT3 patients.  Multivariate analysis of pathological factors 
revealed: lymphovascular invasion (HR 2.437, 95%CI 1.633-3.636, 
p<0.0001) and CRM+ (HR 1.878, 95%CI 1.266-2.785, p=0.002) to be 
independently and significantly associated with DFS.  Multivariate analysis 
revealed EUS T stage (T3 or T4, OR 34.560, 95%CI 9.032-132.241, 
p<0.0001) and the use of CRTS (OR 0.099, 95% CI 0.029-0.334, 
p<0.0001) to be independently and significantly associated with CRM+.   
A positive CRM was a better predictor of disease-free survival than 
standard pTNM stage, and these results support the need for a 
randomised trial of CRTS vs. CS in patients with oesophageal cancer of 
radiological T3 or T4 stage. 
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5.2 INTRODUCTION 
The significance of pathological involvement of the circumferential 
resection margin (CRM) following surgery for rectal cancer is well 
established.  An involved rectal CRM has a proven association with local 
recurrence and poor survival (Quirke et al 1986, Adam et al 1994, Birbeck 
et al 2002), and as such patients deemed radiologically to be at high risk 
are offered pre-operative chemoradiotherapy (Theodoropoulos et al 2002, 
Klautke et al 2005).  In contrast, the significance of pathological CRM 
involvement in oesophageal cancer is far less certain.  Sagar et al (1993) 
first demonstrated an association between an involved CRM and local 
recurrence after oesophagectomy.  A number of heterogeneous studies 
have since sought to further illuminate this issue and investigate the 
influence of oesophageal CRM involvement on survival (Dexter et al 2001, 
Khan et al 2003, Griffiths et al 2006, Sujendran et al 2008, Scheepers et al 
2009, Saha et al 2009, Mirnezami et al 2010).  Many have demonstrated 
CRM involvement to impact negatively on overall survival (Dexter et al 
2001, Sujendran et al 2008, Scheepers et al 2009, Saha et al 2009), 
although other studies have found no association with survival at all (Khan 
et al 2003), no influence on survival when only T3 tumours were analysed 
(Griffiths et al 2006), and no independent association with survival 
(Mirnezami 2010).  The relevance of an involved CRM therefore remains 
uncertain. 
The majority of patients with oesophageal cancer in the UK present with 
locoregionally advanced disease.  The aims of neoadjuvant treatment in 
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this patient cohort are to increase the probability of a complete (R0) 
resection and to improve survival.  Since the publication of the MRC OE02 
randomised trial almost a decade ago, neoadjuvant chemotherapy 
followed by surgery has remained the mainstay of contemporary treatment 
in the UK (MRC Oesophageal Cancer Working Group 2002).  However, 
less than 30% of patients in the UK are suitable for this treatment (NHS 
Information Centre 2010), and even for those that are, 5-year survival is 
poor at just 23% (Allum et al 2009).  Few studies have examined the 
influence of different neoadjuvant treatment regimes on oesophageal CRM 
involvement rates specifically.  Sujendran et al (2008) report a significant 
reduction in CRM involvement rate associated with neoadjuvant 
chemotherapy compared with surgery alone for T3 tumours, yet even after 
this reduction, 31% still had a positive CRM.  The overall incidence of 
CRM involvement is 29% in the 2010 UK National Oesophago-gastric 
Audit (NHS Information Centre 2010), and ranges from 20 to 47% in the 
published series (Sagar et al 1993, Dexter et al 2001, Khan et al 2003, 
Griffiths et al 2006, Sujendran et al 2008, Scheepers et al 2009, Saha et al 
2009, Mirnezami et al 2010). 
Neoadjuvant chemoradiotherapy can result in tumour downstaging in more 
than 90% of patients, (Reynolds et al 2007) and complete pathological 
response in 15 to 29% (Rohatgi et al 2005, Reynolds et al 2007, Stahl et 
al 2009, Donahue et al 2009, Courrech Staal et al 2010), offering the 
possibility of increased R0 resection rates.  However, this treatment 
modality has fallen out of favour in the UK due to a combination of 
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concerns about increased surgical morbidity and mortality, the publication 
of the results of the OE02 trial promoting neoadjuvant chemotherapy, and 
on going patient recruitment into the MRC OE05 trial.  The use of EUS 
criteria to pre-operatively estimatate the risk of a circumferentially 
incomplete resection (R1) has the potential to guide the choice of 
neoadjuvant therapy prescribed.  However, this possibility has not been 
studied to date. 
The aims of this study were three-fold:  
1. To identify the relative prognostic significance of CRM involvement 
after potentially curative oesophagectomy.  
2. To assess the strength of pre-operative EUS derived factors in 
predicting subsequent CRM involvement. 
3. To identify the influence of differing neoadjuvant modalities on CRM 
involvement rates. 
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5.3 METHODS 
5.3.1 Patient selection and staging 
Consecutive patients treated for oesophageal cancer between 1 January 
1998 and 31 October 2010 by the regional S.E. Wales upper GI cancer 
network were studied.  Patient exclusion criteria were as follows:  1. 
Treatment  for high grade dysplasia in the absence of invasive malignancy.  
2. Open and close surgery.  3. Pathological involvement of the longitudinal 
resection margins.  4. Missing pathological TNM stage information.  
Consequently, 256 patients underwent potentially curative 
oesophagectomy and were included in the study.  Clinical, radiological and 
pathological information was collected on a prospectively maintained 
database.  Pre-operative staging was in accordance with the UICC 
Tumour Nodes Metastasis (TNM) 6th Edition (Sobin and Wittekind 2002), 
using the algorithm described in Chapter 4.  All EUS examinations were 
either performed or supervised by a single radiologist (Weaver et al 2004). 
5.3.2 Surgery +/- neoadjuvant therapy 
All patients had individually tailored management plans.  In general, fit 
patients with tumours of stage T3 and equivocal T4, N0 and N1 were 
considered for neoadjuvant therapy.  Prior to 2002 patients were treated 
with neoadjuvant chemoradiotherapy.  They received two cycles of 
cisplatin (60mg/m2) with 300mg/m2 per day of infusional 5-fluorouracil (5-
FU) before 45Gy radiotherapy delivered in 25 fractions.  Following the 
publication of the OE02 trial, patients were treated with neoadjuvant 
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chemotherapy.  They received either two cycles of cisplatin (80mg/m2) and 
5-FU (1000mg/m2) or four cycles of epirubicin (50mg/m2), cisplatin and 5-
FU (200mg/m2).  The operative approach was transthoracic for 152 
(59.4%) patients, and transhiatal for 104 (40.6%).  All surgery was 
performed by specialist upper GI surgeons.  Oesophageal resection was 
defined as potentially curative when all visible tumour had been removed 
and both proximal and distal resection margins were free from tumour on 
histological examination. Operative mortality was defined as death 
occurring within 30 days of surgery. 
5.3.3 Circumferential margin assessment 
Pathological involvement of the circumferential resection margin was 
defined according to the Royal College of Pathologists, as the presence of 
tumour within 1mm of the circumferential margin (Mapstone 1998). 
5.3.4 Follow-up 
All patients were reviewed every 3 months for the first year and then 6 
monthly.  Suspected disease recurrence was investigated with CT and/or 
endoscopy.  The time of recurrence was taken as the date of the 
confirmatory investigation.  Follow-up until 5 years or death was available 
for 210 (82%) patients.  Death certification was obtained from the Office 
for National Statistics. 
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5.3.5 Statistical analysis 
Grouped data were expressed as median (range) and non-parametric 
methods were used.  Overall survival was calculated in months from the 
date of diagnosis.  Disease-free survival was also calculated in months 
from the data of diagnosis, with either the confirmation of disease 
recurrence or death constituting the end point.  Cumulative survival was 
calculated according to the life-table method of Kaplan and Meier, and 
differences between groups were analysed with the log rank test.  
Multivariate analysis of factors found to be significant on univariate 
analysis was performed with Cox regression.  Analysis of pre-operative 
factors influencing CRM status was performed using binary logistic 
regression.  
5.4 RESULTS 
5.4.1 Clinical, radiological and pathological details of the patients 
The clinical and radiological details of the patients related to neoadjuvant 
treatment type are shown in Table 5.1, and pathological details in Table 
5.2.  There were progressive increases in the radiological T and N stages 
of the patients treated with surgery alone, neoadjuvant chemotherapy and 
neoadjuvant chemoradiotherapy.  A complete pathological response 
occurred in more than one third of patients who received 
chemoradiotherapy, but was a relatively rare event in those treated with 
chemotherapy.  CRM status was reported in 245 (95.7%) patients, of 
which 93 (38.0%) had an involved CRM. 
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5.4.2 Overall and disease-free survival   
Figures 5.1 and 5.2 show Kaplan-Meier survival curves for overall and 
disease-free survival related to CRM status, for all patients included in this 
study.  A negative CRM was associated with significantly better overall 
survival (median 66 vs. 25 months, 2-year 70.5 vs. 53.2%, p<0.0001) and 
disease-free survival (median 52 vs. 18 months, 2-year 65.7 vs. 34.5%, 
p<0.0001).  Figures 3 and 4 show similar survival curves for overall and 
disease-free survival related to CRM status, for patients of pT3 stage.  In 
this pT3 subgroup a negative CRM was associated with significantly better 
overall survival (median 36 vs 26 months, 2-year 65.1 vs 57.4%, p=0.025) 
and disease-free survival (median 30 vs 19 months, 2-year 59.1 vs 37.1, 
p=0.013) when compared with a positive CRM. 
A univariate analysis of clinical and pathological factors influencing both 
overall and disease-free survival is shown in Table 5.3.  The same six 
factors were identified as significant for both measures of survival, and 
were entered into multivariate analyses, with individual models for overall 
and disease-free survival (Table 5.4).  Lymphovascular invasion retained 
an independent association with both survival measures, but CRM+ was 
only independently associated with disease-free survival. 
5.4.3 CRM status related to radiological T stage 
The overall rates of CRM involvement related to EUS defined T stage 
were T1 (0), T2 (6 of 43, 14.0%), T3 (78 of 159, 49.1%) T4 (6 of 16, 
37.5%).  For patients treated with surgery alone these CRM involvement 
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rates were T1 (0), T2 (2 of 31, 6.5%), T3 (27 of 37, 73.0%) and T4 (N/A). 
For patients treated with neoadjuvant chemotherapy the equivalent rates 
were T1 (0), T2 (4 of 11, 36.4%), T3 (47 of 89, 52.8%) and T4 (5 of 9, 
55.6%).  For patients treated with neoadjuvant chemoradiotherapy the 
rates were T1 (N/A), T2 (0), T3 (4 of 33, 12.1%) and T4 (1 of 7, 14.3%).  
The reduced CRM involvement rate for EUS T3 tumours following 
chemoradiotherapy (12.1%) compared with surgery alone (73.0%) and 
chemotherapy (52.8%) was highly statistically significant (p<0.0001). 
5.4.4 CRM status related to pathological T stage  
The overall rates of CRM involvement related to pT stage were T1 (0), T2 
(4 of 43, 9.3%), T3 (85 of 135, 63.0%), T4 (4 of 5, 80%).  The rates of 
CRM involvement in the 135 patients with pT3 tumours related to 
neoadjuvant treatment type were surgery (27 of 41, 65.9%), neoadjuvant 
chemotherapy (54 of 80, 67.5%) and neoadjuvant chemotherapy (4 of 14, 
28.6%, p=0.022). 
5.4.5 Influence of EUS derived factors on CRM involvement  
The results of univariate and multivariate binary logistic regression 
analysis of the association between various EUS derived factors and 
subsequent CRM involvement are presented in Table 5.5.  Neoadjuvant 
treatment type was also included in this analysis because of its significant 
influence on CRM outlined above.  The multivariate model included all 
factors significant on univariate analysis.  The only EUS variable that 
retained an independent association with CRM involvement was EUS T 
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stage, with an almost 35-fold increased risk of CRM involvement once a 
tumour was T stage T3 or greater by EUS criteria.  Neoadjuvant treatment 
type also emerged as independently significant on multivariate analysis.  
There was a non-significant trend towards a reduced risk of CRM 
involvement associated with neoadjuvant chemotherapy compared with 
surgery alone, but a highly significant reduction in risk conferred by 
neoadjuvant chemoradiotherapy. 
5.4.6 Operative morbidity and mortality 
The overall rates of all operative morbidity after surgery alone, 
neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy were 42 
(47.7%), 51 (46.8%) and 21 (50.0%) respectively (p=0.939).  The 
equivalent operative mortality was 5 (5.2%), 1 (0.8%) and 5 (11.9%) 
respectively (p=0.009).  The overall operative mortality rate was 11 (4.3%). 
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Table 5.1 Details of the patients 
 S CS CRTS  p value 
Number 96 118 42  
Gender   M:F 75:21 92:26 31:11 0.836 
Median age (Y) 
(range) 
66 (35-79) 62 (36-74) 55 (31-71) <0.0001 
Histology 
ACC:SCC 
73:23 98:20 30:12 0.219 
EUS T Stage (%)   <0.0001 
T1 23 (24.0) 2 (1.7) 0  
T2 31 (32.3) 11 (9.3) 1 (2.4)  
T3 41 (42.7) 92 (78.0) 34 (81.0)  
T4 1 (1.0) 10 (8.5) 7 (16.7)  
Not crossed 0 3 (2.5) 0 0.169 
EUS N Stage (%)   <0.0001 
N0 63 (65.6) 42 (36.0) 10 (23.8)  
N1 33 (34.4) 73 (62.0) 32 (76.2)  
Not crossed (%) 0 3 (2.5) 0 0.169 
EUS M1a (%) 2 (2.1) 5 (4.2) 3 (7.1) 0.358 
EUS tumour 
length (range) 
3 (0-15) 5 (1-12) 5 (1-11) <0.0001 
EUS disease 
length (range) 
3 (0-15) 7 (1-19) 5 (1-16) <0.0001 
EUS tumour 
thickness in 
(range) 
0.9 (0-1.7) 1.3 (0.5-3.0) 1 (0.5-2.0) <0.0001 
     
Length and thickness parameters are median cm (range).   S – surgery 
alone, CS – neoadjuvant chemotherapy, CRTS – neoadjuvant 
chemoradiotherapy. 
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Table 5.2 Pathological details of the patients 
 S CS CRTS p value 
CPR (%) n/a 3 (2.5) 15 (35.7) <0.0001 
pT stage (%)    <0.0001 
T1 31 (32.3) 9 (7.6) 4 (9.5)  
T2 17 (17.7) 20 (17.0) 6 (14.3)  
T3 47 (50.0) 82 (69.5) 15 (35.7)  
T4 1 (1.0) 4 (3.4) 2 (4.8)  
pN stage (%)    <0.0001 
N0 49 (51.0) 40 (33.9) 30 (71.4)  
N1 47 (49.0) 78 (66.1) 12 (28.6)  
Tumour grade (%)    0.075 
Well 13 (13.5) 7 (5.9) 1 (2.4)  
Moderate 47 (49.0) 52 (44.1) 9 (21.4)  
Poor 27 (28.1) 51 (43.2) 11 (26.2)  
Not reported 9 (9.4) 5 (4.2) 6 (14.3)  
CRM (%)    <0.0001 
Negative 61 (63.5) 55 (46.6) 36 (85.7)  
Positive 29 (30.2) 59 (50.0) 5 (12.0)  
Not reported 6 (6.3) 4 (3.4) 1 (2.4)  
LV invasion (%)    0.023 
Yes 43 (44.8) 56 (47.5) 27 (64.3)  
No 30 (31.3) 50 (42.4) 7 (16.7)  
Not reported 23 (24.0) 12 (10.2) 8 (19.0)  
 
S – surgery alone, CS – neoadjuvant chemotherapy, CRTS – neoadjuvant 
chemoradiotherapy, CPR – complete pathological response to 
neoadjuvant therapy, LNMC – lymph node metastasis count, CRM – 
circumferential resection margin, LV – lymphovascular. 
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Table 5.3 Univariate analysis of factors influencing survival 
Factor Disease-free survival Overall survival 
 Chi2 df p value Chi2 p value 
Age 50.786 42 0.166 41.108 0.510 
Gender 1.408 1 0.235 1.767 0.184 
Path cell type 1.089 1 0.297 1.034 0.309 
Neo treatment type 0.950 2 0.622 0.892 0.604 
pT stage 27.963 4 <0.0001 23.164 <0.0001 
pN stage 27.161 1 <0.0001 24.060 <0.0001 
Tumour grade 12.526 2 0.002 13.208 0.001 
CRM involvement 26.212 1 <0.0001 21.004 <0.0001 
LV invasion 38.257 1 <0.0001 31.757 <0.0001 
LNMC 70.308 14 <0.0001 68.184 <0.0001 
 
Path – pathological, Neo – neoadjuvant, LV – lymphovascular, LNMC – 
lymph node metastasis count. 
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Table 5.4 Multivariate analysis of factors influencing survival 
 
 Hazard 
Ratio 
95% CI p value 
Overall Survival 
Lymphovascular invasion 2.184 1.428 - 3.342 <0.0001 
LNMC 1.082 1.024 - 1.143 0.005 
 
Disease-free Survival 
Lymphovascular invasion 2.437 1.633 - 3.636 <0.0001 
CRM involvement 1.878 1.266 - 2.785 0.002 
 
LNMC – lymph node metastasis count 
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Table 5.5 Binary logistic regression analysis of pre-operative factors 
associated with an involved circumferential margin 
 
Factor Odds Ratio 95% CI p value 
Univariate analysis 
EUS T stage     T1/T2  Reference group 
                         T3/T4 9.385 3.856 - 22.841 <0.0001 
EUS N stage    N0 Reference group 
                         N1 1.773 1.040 - 3.024 0.035 
EUS tumour length 1.165 1.045 - 1.299 0.006 
EUS disease length 1.077 1.020 - 1.158 0.043 
EUS tumour thickness 1.869 0.993 - 3.516 0.053 
EUS LNMC 1.169 1.040 - 1.313 0.009 
Neoadj Rx        S     Reference group 
                        CS 2.256 1.270 - 4.009 0.006 
                        CRTS 0.292 0.104 - 0.822 0.020 
 
 
   
Multivariate analysis  
EUS T stage    T1/T2 Reference group 
                        T3/T4 34.560 9.032 - 132.241 <0.0001 
Neoadj Rx        S Reference group 
                        CS 0.529 0.227 - 1.232 0.140 
                        CRTS 0.099 0.029 - 0.334 <0.0001 
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Figure 5.1 Overall survival related to CRM status for all patients 
 
 
 
 
Chi2 21.004, df 1, p<0.0001 
 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
CRM –ve 152 125 96 80 66 58 
CRM +ve 93 66 39 21 16 11 
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Figure 5.2 Disease-free survival related to CRM status for all patients 
 
 
 
 
Chi2 26.212, df 1, p<0.0001 
 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
CRM –ve 152 118 90 76 63 56 
CRM +ve 93 57 25 17 14 10 
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Figure 5.3 Overall survival related to CRM status for pT3 patients 
 
 
 
 
 
Chi2 5.058, df 1, p=0.025 
 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
CRM –ve 50 45 31 22 19 15 
CRM +ve 83 60 39 21 16 10 
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Figure 5.4 Disease-free survival related to CRM status for pT3 
patients 
 
 
 
 
Chi2 6.229, df 1, p=0.013 
 
 
 
 
No. at risk 0m 12m 24m 36m 48m 60m 
CRM –ve 50 43 28 20 17 13 
CRM +ve 83 52 25 17 14 10 
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5.5 DISCUSSION 
 
This work represents the third largest study of the prognostic significance 
of CRM following oesophagectomy, and one of only two that assess 
disease-free survival.  Furthermore, it is the only study to date to examine 
the value of EUS factors in predicting subsequent CRM involvement.  The 
principal findings were that a positive CRM is associated with poorer 
overall and disease-free survival, for patients of all pT stages, as well as 
for those with only pT3 stage tumours, and is independently associated 
with disease-free survival.  A number of EUS factors predicted a positive 
CRM, but EUS T stage was the strongest, with half of all patients with EUS 
defined T3 tumours subsequently having a positive CRM.  A positive CRM 
was significantly less common after neoadjuvant chemoradiotherapy than 
chemotherapy for EUS stage T3 tumours, on a stage for stage basis. 
The significance of involvement of the oesophageal CRM is crucial in 
making treatment decisions, and informing prognosis, yet remains poorly 
understood, due largely to the relative lack of contemporary literature, and 
inconsistency therein.  The eight published studies on this subject vary in 
many regards, including study design, the use of neoadjuvant therapy, 
surgical techniques, differences in pathological specimen handling and 
processing, and the rates of CRM involvement quoted (Sagar et al 1993, 
Dexter et al 2001, Khan et al 2003, Griffiths et al 2006, Sujendran et al 
2008, Scheepers et al 2009, Saha et al 2009, Mirnezami et al 2010).  
Despite these differences only two of the studies have failed to 
demonstrate any independent survival association with CRM status, both 
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of which had the largest sample sizes of all those published.  Khan et al 
(2003) found no association between CRM and survival in 329 patients.  
However, their series of patients were treated between 1987 and 1996, 
with none receiving any form of neoadjuvant treatment, yet despite this 
their reported CRM positivity rate was only 20%, the lowest of all the 
published series.  This calls into question the accuracy of the histological 
assessment of the CRM in this study.  More recently, a series of 314 
patients (Mirnezami et all 2010) identified CRM status to be positively 
associated with survival on univariate testing, but not independently 
significant.  However, this series differed from most in that it included 
patients with positive longitudinal resection margins, and this latter factor 
consequently emerged as one of the factors independently associated 
with survival on multivariate analysis.  Several studies have demonstrated 
that a positive CRM had a greater influence on survival for tumours with a 
low lymph node burden (Dexter et al 2001, Griffiths et al 2006), whilst 
another demonstrated an adverse influence on survival for T3 tumours 
irrespective of nodal stage (Sujendran et al 2008).  Subanalysis of pT3 
tumours in this study on the basis of pathological nodal stage, identified 
definite trends towards poorer overall and disease-free survival with a 
positive CRM, with and without lymph node metastases, but these didn’t 
reach significance, possibly due to underpowered sample sizes. 
The reasons for the stronger prognostic influence of CRM status on 
disease-free survival than overall survival in this study are unclear.  For a 
tumour such as oesophageal carcinoma, where relapse following surgery 
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is common, and for which there is little or no prospect of further curative 
treatment, it is logical to consider disease-free and overall survival to be 
very closely related.  Clearly both are clinically important outcome 
measures.  However, disease-free survival takes into account both the 
physical and psychological burden of tumour recurrence, and subsequent 
associated palliative treatment.  In the present study, lymphovascular 
invasion was the strongest prognostic factor for both overall and disease-
free survival, which is in keeping with the literature which recognises both 
venous and lymphatic invasion to be highly significant prognostic markers 
(Theunissen et al 1991, Paraf et al 1995, Zafirellis et al 2002, von Rahden 
et al 2005). 
From a histopathology perspective the assessment of the oesophageal 
CRM is controversial.  Whilst the debate continues as to the significance 
of CRM, pathological lymph node stage is an established prognostic factor 
(Theunissen et al 1991, Kawahara K 1998, Khan et al 2003).  It has been 
said that accurate assessment of both lymph node stage and CRM status 
are incompatible, and therefore a compromise is required to satisfy both 
requirements (Mapstone et al 2007).  In particular, the dissection of lymph 
nodes from the resected specimen by some surgeons renders meaningful 
assessment of the CRM impossible (Mapstone et al 2007).  The precise 
definition used to define a positive CRM is yet another issue of uncertainty.  
In the UK, a positive CRM is defined as tumour within 1mm of the CRM by 
the Royal College of Pathologists (Mapstone et al 1998), whilst the 
American College of Pathologists use a definition of tumour present at the 
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margin itself (Washington et al 2009).  Comparative studies have identified 
differences in the relative prognostic value of CRM status, depending on 
the definition used, in favour of the American system (Deeter et al 2009, 
Verhage et al 2011, Chao et al 2011). 
This study reinforces the substantial incidence of positive CRMs after 
potentially curative oesophagectomy.  Most patients in the UK present with 
T3 disease, for which neoadjuvant chemotherapy followed by surgery is 
the current standard of care.  Based on these results such patients have a 
52.8% chance of having a circumferentially incomplete (R1) resection.  
The results of this study also suggest the possibility of significantly 
improved odds (87.5%) of a circumferentially complete (R0) resection 
when treated with neoadjuvant chemoradiotherapy, a treatment which is 
considered the neoadjuvant modality of choice in the USA (Hingorani et al 
2011).  Provided acceptable toxicity, morbidity and mortality can be 
achieved with this aggressive treatment, there exists the possibility of 
improved outcomes.  A complete pathological response is known to occur 
in up to a third of patients treated with chemoradiotherapy prior to surgery 
and this provides a well established survival advantage. (Courrech Staal et 
al 2010).  Neoadjuvant chemotherapy and chemoradiotherapy have each 
been extensively compared with surgery alone in a number of meta-
analyses (Urschel et al 2003, Sjoquist et al 2011), yet there is little high 
quality data comparing these two modalities with each other.  Only two 
randomised trials, one German (Stahl et al 2009) and the other Australian 
(Burmeister et al 2011) have addressed this question.  Meta-analysis of 
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both showed a trend towards improved survival with chemoradiotherapy 
but this was not significant (Sjoquist et al 2011).  Both trials closed early 
and were underpowered.  There was no association between the type of 
neoadjuvant treatment and the risk of post-operative mortality (Sjoquist et 
al 2011).  The clear need exists for an adequately powered randomised 
trial of these two neoadjuvant regimes, and this has recently been 
proposed in the UK (Hingorani et al 2011).  The results of the present 
study lend further support to this, and suggest that such a trial should 
focus on patients with EUS T3 tumours. 
The present study has several weaknesses.  The reporting of histological 
factors was undertaken by three separate pathology departments within 
the cancer network, and there could therefore be discrepancies in the 
reporting of CRM, particularly considering the many difficulties already 
discussed in relation to this.  However, the rates of CRM involvement lie 
within the range reported in published series, and it therefore seems 
unlikely that CRM involvement has been substantially under-reported.  
The number of patients in this study are relatively large, yet are not 
sufficient to enable a meaningful subgroup analysis of exclusively patients 
with EUS T3 tumours.  Such a subgroup analysis would be of value in 
establishing the relative influence of the radiological factors other than 
EUS T stage that were predictive of CRM involvement on univariate 
analysis.  The comparison of different neoadjuvant modalities is open to 
bias, as these treatments were allocated on a non-randomised, per patient 
basis, and based on MDT practice at the time. 
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In contrast, the present study has several strengths.  All the treatment was 
provided by an MDT experienced in the management of oesophageal 
cancer, and whose results have been well audited (Morgan et al 2007b).  
The EUS part of the study is particularly original work, and the only study 
yet to compare EUS factors with CRM status, and to relate this to the 
effects of differing neoadjuvant treatments.  All EUS examinations were 
performed or supervised by a radiologist with considerable esperience and 
expertise in this staging technique.  The follow-up data is robust for the 
reasons discussed in Chapter 4. 
5.6 CONCLUSION 
Involvement of the oesophageal CRM is an independently significant 
predictor of disease-free survival.  Its occurrence can be estimated from 
several EUS variables, but T stage is the strongest predictor.  Its incidence 
can be reduced by neoadjuvant chemoradiotherapy.  There is an urgent 
need for a trial of chemoradiotherapy vs. chemotherapy in operable 
oesophageal cancer and the results of this study suggest T3 and T4 
tumours should be targeted. 
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Early enteral nutrition following upper gastrointestinal surgical 
resection 
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6.1 SUMMARY 
The aim of this study was to determine if early enteral nutrition (EEN) 
improved clinical outcomes and shortened length of hospital stay. 
This was a prospective multicentre randomised controlled trial within the S.E. 
Wales cancer network.  One hundred and twenty-one patients with suspected 
operable upper gastrointestinal cancer (54 oesophageal, 38 gastric, 29 
pancreatic) were studied.  Patients were randomised to receive EEN (n=64) 
or standard care post-operatively (nil by mouth and IV fluid, n=57).  Analysis 
was based on intention to treat and the primary outcome measure was length 
of hospital stay. 
Operative morbidity was less common after EEN (32.8%) than Control 
management (50.9%, p=0.044), due to fewer wound infections (p=0.017), 
chest infections (p=0.036) and anastomotic leaks (p=0.055). Median length of 
hospital stay was 16 days (IQ=9) after EEN compared with 19 (IQ=11) days 
after Control management (p=0.023). 
EEN was associated with significantly shortened length of hospital stay and 
improved clinical outcomes.  These findings reinforce the potential benefit of 
early oral nutrition as evidenced by enhanced recovery after surgery 
programmes, and such strategies deserve further research in upper GI 
surgery. 
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6.2 INTRODUCTION 
Gastrointestinal surgery involving intestinal resection and anastomosis 
commonly entails long periods of starvation or “nil by mouth”, while new 
anastomoses heal.  This strategy is designed to allow time for intestinal 
motility to return to normal, and to protect anastomoses from the stress of 
introducing oral fluids and diet (Lewis et al 2009).  Upper gastrointestinal 
cancer surgery in particular, is frequently performed in malnourished 
patients (Nygren et al 2003) which if severe, can be associated with a 
higher incidence of post-operative complications, which may in turn 
impede recovery (Weimann et al 2006). 
Oesophageal, gastric and pancreatic cancer represent the 7th, 8th and 
10th commonest causes of death from cancer in the UK, accounting for 
approximately 19,000 deaths per annum (Cancer Research UK).  Surgical 
resection remains the mainstay of curative treatment (Allum et al 2011) but 
is complex in nature and frequently associated with post-operative 
morbidity and mortality, even in well nourished patients (NHS Information 
Centre 2010).  Traditional post-operative management often involves 
intravenous fluids for 7 to 10 days, with ad hoc additional nutritional 
support, often delayed, and frequently utilising parenteral nutrition (PN).  
Enteral nutrition (EN) has been reported to preserve gut structure and 
function (Maxton et al 1989), enhance gut mediated immunity (Kudsk et al 
2002) and to be feasible in over 90% of patients undergoing 
gastrointestinal surgery (Braga et al 2002).  Moreover randomised 
comparisons have reported that EN is superior to PN with regard to clinical 
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outcomes (Bozzetti et al 2001) because of fewer associated septic 
complications (Moore et al 1986, Mochizuki et al 2000) and shorter lengths 
of hospital stay (Aiko et al 2001). 
However, contemporary opinion is that EEN should not be recommended 
for routine clinical practice because firstly the above benefits remain 
unproven (Lewis et al 2009) and secondly because the method of enteral 
delivery is controversial.  Nasojejunal tubes may be unreliable and poorly 
tolerated by patients (Hoffmann et al 2001) and surgical jejunostomy 
placement is not only invasive, but also associated with major 
complications (Hoffman et al 2001).  Nevertheless, a recent meta-analysis 
concluded that early feeding may be beneficial after elective 
gastrointestinal resection, but emphasised the need for an adequately 
powered trial to confirm or refute the findings observed in previous small 
trials (Lewis et al 2009). 
The aim of this study was to determine if EEN was well tolerated, safe and 
whether or not it improved clinical outcomes in terms of post-operative 
morbidity, mortality, fluid balance and length of hospital stay.  The setting 
was a UK regional upper GI cancer network serving a population of 1.4 
million. 
6.3 METHODS 
6.3.1 Study design 
This open, prospective, pragmatic RCT was conducted in three NHS 
hospitals, which were part of the S.E. Wales upper gastrointestinal cancer 
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network.  Data were collected over 30 months, and the trial closed in July 
2006.  All adult patients admitted with a suspected upper gastrointestinal 
malignancy and referred for major elective surgery, were eligible for 
participation. Exclusion criteria were: age under 18 years; unable or 
unwilling to give informed consent; pregnancy; pre-operative infection; 
previous intestinal surgery resulting in residual small intestine length of 
less than 100cm. 
Approval was obtained from the S.E. Wales NHS Ethics Committee, and 
the trial was registered with the National Research Register and UK 
Clinical Research Network (UKCRN ID: 1730).  All trial participants 
provided written informed consent.  Copies of the Ethics Committee 
approval letter and the consent form used are presented in Appendix 3.  
All surgical and nursing staff associated with patient care were given 
detailed information about the study protocol.  Outcome data were 
assessed and collected by two members of the research team who were 
trained in the details of the data collection requirements. 
After the operating surgeon had confirmed that a potentially curative 
operative procedure had been performed, patients were randomised to 
receive either Early Enteral Nutrition (EEN) or Control (CON). 
Randomisation was stratified within each centre, and the randomisation 
sequence was generated by computer in permuted blocks of 30.  The 
code was kept in opaque, sealed envelopes labelled with sequential study 
numbers in a locked box at the co-ordinating research site.  
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This was an unblinded study.  Placebo was considered, but for the 
purpose of this study was not used.  One study (Schloerb et al 2004) 
attributed major and even fatal complications when hypotonic solutions 
were delivered via jejunostomies and therefore this placebo was 
considered by research team to have a potential biological effect.  It was 
considered difficult to conceal treatment allocation by any practical means, 
given the nature of the intervention.  However, data entry was completed 
blinded to group allocation. 
6.3.2 Baseline evaluation and general management 
After patients consented to participate in the trial, a pre-operative baseline 
medical, physiological and nutritional assessment was completed.  Pre-
operative staging was in accordance with TNM and as described in earlier 
chapters. 
6.3.3 Details of post-operative nutritional support 
All patients in the study had a needle catheter feeding jejunostomy (Freka 
Fresnius, Cheshire, UK) inserted at operation. 
Control management consisted of patients being kept nil by mouth, with 
hydration maintained by means of intravenous fluids, which continued until 
the introduction of oral fluids and diet. These patients also received 
10ml/hour of sterile water via the jejunostomy, and this was continued until 
the introduction of oral fluids.  Patients who had undergone 
oesophagectomy or total gastrectomy underwent a radiological contrast 
swallow between day 7 and 10 after surgery, and provided this 
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demonstrated no anastomotic dehiscence, oral fluids and diet were 
introduced gradually over 2 to 5 days.  After the radiological contrast 
swallow, if patients were diagnosed with radiological anastomotic leaks, 
they received either enteral or parenteral nutritional support at the 
discretion of the consultant surgeon until deemed safe to commence oral 
fluids.  Nutritional requirements were calculated based on 30 kcal per kg 
per day (Elwyn et al 1980). 
Early Enteral Nutrition was delivered via the jejunostomy. Nutritional 
support was commenced within 12 hours of surgery at 20ml/hour of a 
standard 1 kcal/ml commercial whole protein enteral feed for the first 24 
hours in patients undergoing oesophagogastric resection, with the rate 
increasing as tolerated by 10ml/hour every 12 hours, until the maximum 
feed target rate of 80ml/hour was achieved. Patients undergoing 
pancreatic resection were commenced on 10ml/hours of a 1.3kcal/ml 
commercial semi-elemental enteral feed on the first post-operative day, 
which was then steadily increased as for the oesophagogastric patients. 
The aim was to achieve a minimum of half of nutritional requirements 
(Elwyn et al 1980) by the fifth post-operative day.  Intravenous fluids were 
administered in addition to the enteral feeding, as necessary to maintain 
fluid balance.  Once oral intake was established, patients commenced a 
1.5 kcal/ml enteral feed and converted to overnight enteral nutrition via the 
jejunostomy over 12 hours.  This continued until it was deemed that 75% 
of nutritional requirements were being achieved orally. Nutritional 
requirements were calculated as for control patients (Elwyn et al 1980). 
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Patients allocated EEN also underwent radiological contrast swallow 
between day 7 and 10 after surgery. 
6.3.4 Details of the surgery 
Oesophagectomy  
Fifty-four patients underwent oesophageal resection, with the choice of 
operative approach and use of neoadjuvant chemotherapy as described in 
Chapters 3, 4, and 5. Thirty patients underwent standard subtotal 
oesophagectomy (Lewis 1946, Tanner 1947). Transhiatal resection 
Orringer 1985) was performed in 24 patients.  Neoadjuvant chemotherapy 
with 5-FU and Cisplatin was given to 34 patients. 
Gastrectomy 
Thirty-eight patients underwent gastric resection.  The type of surgery was 
determined by the anatomical location of the tumour.  Subtotal 
gastrectomy was performed in patients with antral tumours and total 
gastrectomy was performed for tumours of the cardia (Siewert type III), 
body and linitis plastica. Thirty patients underwent modified radical D2 
resection (preserving the pancreas and the spleen where possible) as 
originally described by Sue-Ling et al (1993).  Eight patients underwent a 
selective D1 lymphadenectomy as chosen by individual surgeons for 
elderly patients with medical co-morbidities or patients with early tumours 
on CT criteria, who it was considered would benefit from a quicker, simpler 
operation. 
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Pancreatectomy 
Twenty-nine patients underwent pancreatic resection.  Twenty-six patients 
underwent Pylorus Preserving Pancreaticoduodenectomy as described by 
Transverso and Longmire (1978), and 3 patients underwent total 
pancreactectomy as described by Rockey (1943).  
6.3.5 End points 
The primary endpoint for the study was length of hospital stay (LOHS), 
which was defined as the time from the date of the index operation to the 
date the operating surgeon assessed that the patient was medically fit for 
discharge, or death.  This definition controlled for any administrative 
factors that may prolong discharge, for example, waiting for social support 
packages.  Strict and precise criteria were used to define when patients 
were fit for discharge.  These criteria included the ability to: mobilise out of 
bed and ambulate, prepare a drink or food and get to the lavatory in their 
home.  Secondary endpoints were operative morbidity, operative mortality 
and fluid balance.  Patients were reviewed at 6 and 12 weeks post-
discharge, and readmission rates during that period were documented. 
6.3.6 Sample Size 
The study hypothesised that a mean reduction in length of hospital stay of 
3 days, without any deterioration in clinical outcomes, would constitute a 
clinically important difference in outcome (Aiko et al 2001).  Fifty-five 
patients per group were needed to detect such a difference based on a 
power calculation with alpha set at 0.05 and 80% power.   
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6.3.7 Statistical analysis 
All data were presented as median and interquartile range (IQR), and non-
parametric tests were used throughout. Overall survival was analysed 
according to Kaplan and Meier, and differences assessed with the log rank 
test.  Overall survival was calculated in months from the date of diagnosis.  
The data were analysed on an intention to treat basis.   
6.4 RESULTS 
From 192 consecutive recruited patients, 34 declined participation (Table 
6.1).  In general there were no striking differences between the patients 
who provided consent and the patients who declined to consent.  
However, patients with more advanced disease were more likely to opt for 
participation.  An additional 37 patients were excluded as they were found 
to have disseminated disease at the time of laparotomy.  The study was 
intended to include only patients who underwent potentially curative 
surgery for randomisation (CONSORT diagram, Figure 6.1).  The details 
of the patients related to treatment allocation and baseline nutritional 
parameters are shown in Table 6.2.  The groups were deemed 
comparable at baseline other than the discrepancy regarding ASA grade. 
6.4.1 Length of hospital stay and readmission 
The median LOHS for patients after EEN was 16 days (IQR 9 days) 
compared with 19 days (IQR 11 days) after CON therapy (p = 0.023). 
These data are presented in Figure 6.2, which demonstrates a clear 
advantage for EEN for the first 30 days.  Intention to treat analysis with the 
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operative deaths removed, did not alter the primary outcome (EEN group 
16 days vs. CON 19 days, p=0.039).  There were no statistically 
significant differences between the two groups for hospital readmissions 
after EEN within 6 weeks of discharge (EEN 4 patients, vs. CON 6 
patients, p=0.501), or between 6 and 12 weeks after discharge (EEN 1 
patient vs. CON 2 patients, p=0.237). 
6.4.2 Operative morbidity and mortality  
Details of the operative morbidity are shown in Table 6.3.  Operative 
morbidity occurred in 50 patients (41.3%) of the total population, and was 
less common after EEN therapy (21 patients, 32.8%) compared with CON 
therapy (29 patients, 50.9%, p=0.044, Table 6.3).  There were 3 operative 
deaths (within 30 days of surgery, 2.4%).  All deaths (3 patients, 4.7%) 
occurred in patients randomised to receive EEN.  One patient died on the 
first post-operative day following portal vein haemorrhage after pancreatic 
resection, prior to commencing EEN.  The other two patients died after 
oesophagectomy; one on the 8th post-operative day as a result of chest 
sepsis and respiratory failure, and the other on the 20th post-operative 
day as a results of anastomotic leak followed by chest sepsis and 
respiratory failure.  Neither of these deaths were attributed to the enteral 
nutrition, and the complications developed on the second and third post 
operative days respectively.  
Fewer EEN patients were discharged on continuing enteral nutrition, but 
this difference was not statistically significant (EEN 5 patients (7.8%) vs. 
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12 patients (21.1%) after CON, p=0.092).  These patients were not 
achieving their target nutritional requirements orally.  
6.4.3 Jejunostomy complications 
There were no reported major jejunostomy related complications, such as 
catheter site infections, leakage or displacement. Although there were 
several reports of transient catheter occlusions, these did not interfere 
with feed delivery for more than 24 hours.  Fifty-four patients randomised 
to EEN (84.3%) had uninterrupted enteral feeding during the 1st post-
operative week.  
6.4.4 Nutritional intake 
The median percentage daily nutritional requirement achieved by the end 
of the first post operative week in patients receiving EEN was 69% (IQR 
53) compared with zero % (IQR 0) in control patients.  The median calorie 
intake during the first post-operative week was 7627kcal (IQR 4123) for 
patients receiving EEN compared with zero kcal (IQR 0) in control 
patients. The median protein intake during the first post-operative week 
was 328g (IQR 175) for patients receiving EEN compared with zero g 
(IQR 0) in control patients. 
6.4.5 Fluid balance 
The median IV fluid intake during the first post-operative week was 
12125ml (IQR 6791) for patients receiving EEN compared with 19210ml 
(IQR 4150) in control patients (p<0.0001).  The median volume of feed 
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administered during the first post-operative week was 7260ml (IQR 4488) 
for patients receiving EEN compared with 0ml (IQR 0) in control patients. 
(p<0.0001).  The total fluid intake of the patients, by all routes of 
administration, during the first post-operative week was 20383ml (IQR 
5132) for patients receiving EEN compared with 21180ml (IQR 4270) for 
control patients (p=0.673).  The median cumulative fluid balance at the 
end of the first post-operative week was 4213ml positive (IQR 3438) for 
patients receiving EEN compared with 4464ml positive (IQR 4978) for 
control patients (p=0.935).  Peripheral oedema during the first post-
operative week was identified in 4 (6.3%) patients receiving EEN 
compared with 15 (26.3%) control patients (p=0.002). 
6.4.6 Overall survival 
There was no significant difference in long term survival for the patients 
who received EEN compared with the control patients.  Median, 2-year 
and 5-year overall survival were 41 months, 60.6% and 36.4% for the 
patients who received EEN, compared with 33 months, 61.2% and 41.4% 
for the control patients (p=0.807). 
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Table 6.1 Details of the patients related to consent to randomisation 
 Consent declined Consent to 
randomisation 
Number 34 121 
Median age (IQR) 62.5 (18) 64 (15) 
Gender M:F 16:18 83:38 
Site of tumour (%)   
Oesophageal 10 (29.4) 54 (44.6) 
Gastric 14 (41.2) 38 (31.4) 
Pancreatic 10 (29.4) 29 (23.9) 
Radiological TNM stage (%)   
I 10 (29.4) 12 (9.9) 
II 17 (50.0) 55 (45.5) 
III 7 (20.6) 51 (42.1) 
IVa 0 3 (2.5) 
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Table 6.2 Details of the patients and surgery 
 CON EEN Total 
Median age (Y) (IQR) 63 (16) 64.5 (14) 64 (15) 
Gender M:F 40:17 43:21 83:38 
Pathological TNM stage (%)    
0 5 (8.8) 5 (7.8) 10 (8.3) 
I 14 (24.6) 17 (26.6) 31 (25.6) 
II 15 (26.3) 19 (29.7) 34 (28.1) 
III 20 (35.1) 23 (35.9) 43 (35.6) 
IVa 3 (5.3) 0 3 (2.5) 
Histological diagnosis    
Oesophageal (%)    
ACA 19 (33.3) 23 (35.9) 42 (34.7) 
SCC 4 (7.0) 4 (6.3) 8 (6.6) 
Carcinosarcoma 0 1 (1.6) 1 (0.8) 
Anaplastic carcinoma 1 (1.8) 0 1 (0.8) 
High grade dysplasia 1 (1.8) 1 (1.6) 2 (1.7) 
Gastric (%)    
ACA 15 (26.3) 21 (32.8) 36 (29.8) 
GIST 1 (1.8) 0 1 (0.8) 
Benign ulcer 0 1 (1.6) 1 (0.8) 
Pancreatic (%)    
ACA 7 (12.3) 7 (10.9) 14 (11.6) 
Cholangiocarcinoma / 
ampullary tumour 
4 (7.0) 2 (3.1) 6 (5.0) 
Neuroendocrine 0 1 (1.6) 1 (0.8) 
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Intraductal papillary 
mucinous tumour 
1 (1.8) 0 1 (0.8) 
Adenoma 0 1 (1.6) 1 (0.8) 
Chronic pancreatitis 2 (3.5) 2 (3.1) 4 (3.3) 
Duodenal adenoma 2 (3.5) 0 2 (1.7) 
Surgical procedure (%)    
Transhiatal oesophagectomy 10 (17.5) 14 (21.9) 24 (19.8) 
Ivor Lewis oesophagectomy 15 (26.3) 15 (23.4) 30 (24.8) 
Subtotal D1 gastrectomy 2 (3.5) 4 (6.3) 6 (5.0) 
Subtotal D2 gastrectomy 6 (10.5) 6 (9.4) 12 (9.9) 
Total D1 gastrectomy 0 2 (3.1) 2 (1.7) 
Total D2 gastrectomy 8 (14.0) 10 (15.6) 18 (15.0) 
PPPD 15 (26.3) 11 (17.2) 26 (21.5) 
Total pancreatectomy 1 (1.8) 2 (3.1) 3 (2.5) 
ASA grade (%)    
I 0 1 (1.6) 1 (0.8) 
II 39 (68.4) 25 (39.1) 64 (52.5) 
III 18 (31.6) * 38 (59.4) * 56 (46.0) 
Pre-operaitive BMI Kg/m2 
(IQR) 
24.4 (5.7) 25.6 (4.9) 25.4 (5.4) 
Pre-operative weight Kg 70 (17) 76 (18) 73 (18) 
Unintentional weight loss % 
(IQR) 
6.1 (10.1) 5.6 (11.6) 6.1 (11.1) 
Pre-op NRI (%)    
Borderline malnutrition 43 (75.5) 47 (73.4) 90 (74.4) 
Moderate malnutrition 8 (14.0) 8 (12.5) 16 (13.2) 
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Severe malnutrition 6 (10.5) 9 (14.0) 15 (12.4) 
    
  
ACA – adenocarcinoma 
SCC – squamous cell carcinoma 
GIST – gastro intestinal stromal tumour 
PPPD – pylorus preserving pancreaticoduodenectomy 
ASA – American Society of Anaesthesiologists 
*p=0.004 
BMI – body mass index 
NRI – nutritional risk index (Veterans Affair, 1991) 
Unintentional weight loss was during 6-12 weeks prior to admission for 
surgery.        
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Table 6.3 Details of operative morbidity  
Complication CON  EEN  p value 
Infective Complications (%)    
Wound infection 16 (28.1)  7 (10.9) 0.017 
Chest infection  12 (21.1) 5 (7.8) 0.036 
Anastomotic leak 7 (12.2) 2 (3.1) 0.055 
Urinary tract infection  3 (5.3)  1 (1.6)  
Bacteramia 3 (5.3) 2 (3.1)  
Non Infective Complications (%)    
Pleural effusion 10 (17.5) 10 (15.6)  
Myocardial infarction 1 (1.8) 0  
Major haemorrhage 2 (3.5) 0  
Chylothorax 0 1 (1.6)  
Rec. laryngeal nerve palsy 0 1 (1.6)  
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Figure 6.1 CONSORT diagram 
 
 
 
 
 
 
 
 
 
Allocated to EEN n=64 
Received EEN n=58 
No EEN n=6 
Reasons: 
n=1 died 1st post op day 
n=3 nasojejunal feeding 
tube placed (at surgeon’s 
preference) 
n=1 re-laparotomy 
unrelated to EEN 
n=1 commenced PN after 
1st week because of 
chylothorax 
Recruited 
158 
 
158 
Palliative 
37 
Randomised 
121 
Allocated to CON n=57 
Received CON n=53 
No CON n=4 
Reasons: 
n=4 EN 1st post op week 
 
n=24 commenced delayed 
EN after 1st post op week 
Assessed as eligible 
192 
Declined consent 
34 
All patients included in ITT analysis 
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 Figure 6.2 Length of hospital stay related to randomisation  
 
 
Log Rank Chi2 2.386, df 1, p=0.122 
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6.5 DISCUSSION 
This study represents the first adequately powered prospective 
randomised control trial of early enteral nutrition versus standard care in 
patients undergoing upper gastrointestinal resectional surgery in the UK.  
The principal findings were that EEN delivered within 12 hours of leaving 
the operating theatre was feasible, safe, and associated with significantly 
better clinical outcomes.  Post-operative morbidity was far less common, 
and septic and anastomotic complications in particular, were on average 
less than half and one third as common respectively after EEN.  These 
findings resulted in durations of hospital stay that were strinkingly different 
for the two randomised groups.  Patients who received EEN had hospital 
stays that were three days shorter than those of the control patients, 
despite the fact that the EEN patients were of significantly poorer 
performance status.  Moreover, peripheral oedema was less than one 
quarter as common after EEN compared with CON, despite the two 
groups having seemingly comparable total fluid intake and cumulative fluid 
balance. 
Preventing complications after oesophagectomy, gastrectomy and 
pancreatectomy is as important, if not more so, than the rapid and pro-
active management of complications which do occur, if outcomes are to be 
improved.  Enteral nutritrion has been reported in a number of randomised 
control trials to be associated with fewer septic complications than 
standard care (Kudsk et al 1996, Aiko et al 2001) and shorter LOHS, but 
none have had the statistical power to prove benefit.  Consequently Koretz 
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et al (2009) reported that EN has been accepted and implemented into 
clinical practice without convincing scientific support.  Designing and 
conducting pragmatic clinical trials, particularly in surgical patients with 
complex and diverse needs, are fraught with limitations and this study is 
typical in this regard. Precise definition of the primary outcome measure 
(LOHS) is crucial but controversial.  LOHS is influenced by many factors 
including patient age and performance status, and intra-operative factors 
such as type of surgical procedure, level of lymphadenectomy and blood 
loss (Clearly et al 1991, Greenfield et al 1993).  In the few previous RCTs 
which included clear definitions of LOHS, emphasis has focused on the 
time from index operation to hospital discharge, which may be criticised 
unless robust discharge criteria are agreed because patients often remain 
in hospital for non-medical reasons. In the UK, delays in agreeing social 
care packages frequently cause delays in hospital discharge.  The 
cumulative LOHS curve (Figure 6.2) demonstrates an early EEN 
associated benefit until 30 days after surgery.  Any benefit beyond this is 
difficult to assess, because durations of stay over 30 days, by definition 
occurred in patients who had suffered serious complications and would 
consequently have received therapeutic EN irrespective of randomisation.  
Furthermore, a major criticism of studies which report length of hospital 
stay as a primary outcome is the failure to address the issue of rates of 
hospital readmission.  One of the strengths of this study is that hospital 
readmission rates were similar regardless of randomisation during the 
initial 3-month follow up period.  
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There are several potential criticisms of this study.  Firstly, the patients 
studied had heterogenous diagnoses and underwent different surgical 
procedures.  However, this may suggest that the benefit of EEN was 
independent of the cancer site and type of operation.  Oesophagectomy, 
gastrectomy and pancreatectomy clearly differ, but the complexity and 
duration of the surgery, and the subsequent risk of morbidity and mortality 
were comparable (Allum et al 2011, Kotwall et al 2002).  Treatment 
allocation was not concealed, and this approach has been reported to 
exaggerate treatment effects.  No placebo was used because of the risk of 
placebo associated physiological effect, producing false atypical results, 
and possible detrimental risk to control patients.  Beier-Holgersen et al 
(1996) reported a study of saline placebo vs. enteral feeding after major 
elective gastrointestinal surgery.  Enterally fed patients had improved 
outcomes, but placebo patients had unusually high complication rates, 
possibly associated with either the lack of enteral feed or saline use.   
With regard to post-operative fluid therapy, EEN patients received on 
average 7 litres less intravenous fluid (37%) than control patients over the 
first post-operative week, but the total fluid therapy received (including 
enteral feed) was comparable (3.9% greater volume after CON, p=0.673).  
Moreover, the cumulative fluid balance over the entire first post-operative 
week was also similar (6.0% greater volume after CON, p=0.935).  
GIFTASUP consensus guidance (Powell-Tuck et al 2009) suggests that 
adult maintenance fluid requirements should be approximately 1.5 to 2.5 
litres per 24 hours (25 to 35 ml/Kg/24h).  Control patients in this study 
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received on average 2800ml of IV fluid per 24/h, which is some 12% 
greater than the maximum guidance.  However these patients had all 
undergone complex upper GI resectional surgery for cancer and would 
arguably have therefore required replacement of extra fluid losses.  Data 
regarding the types of intravenous fluids administered to patients was not 
collected prospectively.  The possibility therefore exists that some of the 
benefits witnessed after EEN may have been derived from them receiving 
less sodium, as a consequence of lower intravenous fluid intakes, than 
control patients.  The adverse effects of excess sodium administration are 
well documented (Lobo 2004, Allison 2004, Powell-Tuck et al 2009).  The 
four-fold higher rate of peripheral oedema in CON patients compared with 
EEN, is highly relevant, as peripheral oedema is known to correlate with 
delayed return of gut function, prolonged hospital stay and post-operative 
complications after major abdominal surgery (Itobi et al 2006). 
Complications related to the feeding jejunostomy were conspicuous by 
their absence in this study.  In contrast, the National Oesophago-Gastric 
Cancer Audit 2010 reported complications such as chest sepsis (15.1%), 
wound sepsis (4.7%), and anastomotic leaks (8.3%) to occur more 
frequently in patients receiving a feeding jejunostomy, necessitating re-
operation in 11.7% of patients (NHS Information Centre 2010).  However, 
this data must be interpreted with caution as patients receiving feeding 
jejunostomies in the above audit may have been more malnourished and 
no data were provided as to whether the jejunostomies were actually 
utilised for feeding purposes.  The operative morbidity reported in this 
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study is high, certainly when compared with the above national 
oesophagogastric audit; although anastomotic leak rates were comparable 
(oesophagectomy 9.3% vs. 8.3%; gastrectomy 2.6% vs. 5.9%).  For 
wound (oesophagectomy 20% vs. 3.9%, gastrectomy 10.5% vs. 3.3%) 
and respiratory infection (oesophagectomy 24.1% vs. 12.9%, gastrectomy 
7.9% vs. 7.3%) the rates in this study are higher than the national UK 
figures (NHS Information Centre 2010).  However, this study used broad 
and inclusive definitions of complications.  Furthermore, the patients in this 
trial were very carefully scrutinised for complications, in contrast to third 
person audit data collection (contributed in part by Cancer Networks, and 
cross-referenced with other databases, such as Hospital Episode 
Statistics in England) used to compile the national audit, and this may help 
to explain some of these differences.  In contrast, overall oesophagectomy 
and gastrectomy operative mortality in this study compared favourably 
with national data (3.7% vs. 3.8% and 0 vs. 4.5% respectively, NHS 
Information Centre 2010).  
6.6 CONCLUSION 
This randomised clinical trial has shown an important and clinically 
significant improvement in outcomes associated with EEN by means of 
feeding jejunostomy in patients undergoing major upper gastrointestinal 
surgical resection.  This is associated with major clinical implications for 
individual tailored integrated care pathways and broader economic 
implications for healthcare systems.  The findings are also in keeping with 
the conclusions of both Lewis et al (2001 and 2009) meta-analyses.  
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Recent discussion has focused on early volitional oral intake in the first 
few post-operative days following upper gastrointestinal surgery (Lassen 
et al 2008) and this again reinforces the argument to abandon the 
traditional nil by mouth strategy.  Certainly, contemporary enhanced 
recovery after surgery programmes no longer prescribe prolonged periods 
of post-operative starvation, and the effect of this may in itself contribute to 
reductions in length of hospital stay equivalent to those described in this 
study.  The advantageous shorter length of stay associated with EEN 
might not therefore be as marked, if a more contemporary comparison 
was made between EEN and early oral introduction of feed, such as sip 
feeds, and early free diet.  However, such an approach is not always 
appropriate in patients who have undergone oesophagectomy or total 
gastrectomy and who require contrast swallows to check on the integrity of 
the anastomosis prior to commencing oral intake.  Huge scope remains for 
refining peri-operative nutritional intervention to maximise the benefits for 
patients, allied to minimising risk and cost.  Furthermore, increased 
research efforts are required into the complex and interdependent 
mechanisms whereby nutritional interventions enhance recovery after 
surgery. 
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Upper gastrointestinal cancer surgery centralisation in South East 
Wales 
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7.1 SUMMARY 
The aim of this study was to determine the influence of a reconfigured 
centralised surgical model of care allied to an ERAS programme, when 
compared with historical control outcomes. 
The details of 664 consecutive patients diagnosed with UGI cancer over a 
2 year period were collected prospectively and the outcomes before 
(n=266) and after centralisation (n=398) inception compared. The primary 
outcome measure was length of hospital stay (LOHS).  
Following centralisation, the proportion of patients treated with potentially 
curative intent increased from 63 (23.7%) to 152 (38.2%), p<0.0001. The 
critical care (CC) cancellation rate fell from 15.7% to 2.3% (p=0.003), and 
CC bed usage fell from a median and total of 1 and 250 to 1 and 152. UGI 
cancer operative mortality and morbidity (Clavien-Dindo >III) were 3.0 and 
33.3% before compared with 1.7 and 16.7% after centralisation 
respectively. Total length of hospital stay (LOHS) shortened from 17.5 to 
14 days, p=0.037. On multivariate analysis, ERAS (HR 2.485, 95% CI 
1.499 to 4.122, p<0.0001), operative morbidity (HR 0.260, 95% CI 0.156 to 
0.432, p<0.0001), and operation type (overall p <0.0001) were 
independently associated with LOHS.  
These outcomes demonstrate the potential patient safety and quality 
improvements achievable by compliance with NHS executive 
commissioning guidelines.  
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7.2 INTRODUCTION 
Upper gastrointestinal cancer service reconfiguration and centralisation 
consistent with the guidelines for commissioning cancer services 
(Department of Health 2001), strongly supported and largely achieved in 
England, has received lesser resource and support in Wales. Indeed the 
most recent audit of activity related to oesophagogastric management 
demonstrated that many surgeons’ case loads remained small, staging 
strategies were idiosyncratic, open and close operations were performed 
in 23% of cases, operative mortality was 12%, and 2-year survival was 
42% following oesophagectomy and 43% following gastrectomy (Pye et al 
2001). 
Upper gastrointestinal surgery has, by tradition, been within the domain of 
the general surgeon and historically, a notional district general surgeon 
might expect to deal with fewer than 25 people with oesophageal cancer 
and 40 with gastric cancer per year (Pye et al 2001).  The last decade, 
however, has witnessed significant changes in practice in general surgery 
and sub-specialisation for major oncological work is now the accepted 
routine.  This is in keeping with NHS published guidance, one of whose 
key recommendations was that specialist teams be established, serving 
populations of greater than one million (Department of Health 2001).  
Moreover, Enhanced Recovery After Surgery (ERAS) protocols have also 
recently been championed to improve outcomes after major colorectal 
surgery but have not been tested in the surgical management of upper GI 
cancers (Basse et al 2000). 
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Specialist multidisciplinary team expertise has been described to improve 
outcomes for patients in sporadic reports (Siewert and Roder 1992, Sue-
Ling et al 1993, McCulloch 1994, Stephens et al 2006), but these 
hypotheses have not been tested by means of randomised control trials. In 
addition, case volume per surgeon or per unit has also been reported to 
be an important factor determining outcome of treatment of a raft of 
cancers (Matthews et al 1986, McCulloch 1994, Steele 1996, Swisher et al 
2000, Van Lanshot et al 2001, Bachmann et al 2002, Birkmeyer et al 2003, 
Skipworth et al 2010, Anderson et al 2011), yet data regarding the factual 
impact of reconfiguring and centralising cancer surgery is scarce, if not 
absent altogether.  
The aim of this study, therefore, was to determine the influence of a new 
clinical model comprising reconfigured centralised surgery encompassing 
a revised critical care admission protocol (commenced August 2010) and 
allied to ERAS (commenced October 2010), when compared with the 
historical control outcomes of three local hospital sites over the previous 
year. The setting was a UK regional cancer network serving a population 
of 1.4 million.    
7.3 METHODS 
7.3.1 S.E. Wales service reconfiguration 
The S.E. Wales region has a population of approximately 1.4 million, 
which is served by three NHS Health Boards.  These are Cardiff and Vale 
University Health Board (catchment population 450,000), Aneurin Bevan 
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Health Board (catchment population 600,000) and Cwm Taf Health Board 
(catchment population 325,000).  Together these health boards run six 
acute hospitals: four district general hospitals and two teaching hospitals, 
and this area constitutes the South East Wales Upper GI cancer network.  
Prior to August 2010 the surgical care of patients with oesophagogastric 
cancer was delivered by 8 surgeons undertaking surgery at 4 different 
hospital sites.  After a protracted period of negotiation between health care 
commissioners, health board management, involved clinicians and other 
stakeholders, an agreement was reached in December 2009 to 
reconfigure and centralise the upper GI surgical service on a single site at 
the University Hospital of Wales (UHW), in Cardiff, with an agreed start 
date of August 2010.  The new model was based on 5 specialist upper 
gastrointestinal surgeons performing all the resectional surgery; three of 
the surgeons were based at the surgical centre, whilst the other two were 
to operate on an in-reach basis.  One of the Cardiff based surgeons 
provided an outreach MDT and outpatient service at the Royal Gwent 
Hospital, Newport, for the Aneurin Bevan Health Board catchment 
population.  The facility existed for joint consultant operating, where 
necessary.  Diagnosis and staging continued to be undertaken locally 
within each health board, coordinated via three local weekly MDTs, and all 
cases deemed suitable for curative treatment were discussed at the 
existing weekly regional S.E. Wales MDT.  The new surgical service 
commenced on 1st August 2010.   
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7.3.2 Enhanced recovery after surgery 
Allied to the new surgical configuration was the establishment of an 
enhanced recovery after surgery (ERAS) programme in October 2011, 
based on the well established principles introduced by Kehlet and 
colleagues in the arena of colorectal surgery (Basse et al 2000).  In 
addition policies regarding the planned admission of patients to critical 
care post-operatively were updated, and took account of the results of 
cardiopulmonary exercise testing (CPET), which was performed in all 
patients proceeding to surgery following centralisation.  Provided CPET 
was satisfactory, patients due to undergo oesophagectomy were booked 
into the high dependency unit (HDU), rather than intensive care (ITU), and 
patients due to undergo gastrectomy were booked to return to the ward, 
rather than HDU. 
7.3.3 Data collection 
The oesophageal and gastric cancer caseload referred to the MDTs during 
the year preceding the start of centralisation (August 2009 to July 2010) 
was compared with the following year (August 2010 to July 2011).  The 
pre-centralisation year data across the three health boards was collected 
using a combination of a prospectively maintained database (for two of the 
three health boards) in combination with MDT records and retrospective 
review of hospital records.  The post-centralisation year data was collected 
prospectively.  Measures of outcome included numbers of new patients 
diagnosed with oesophagogastric cancer and gastrointestinal stromal 
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tumours (GISTs), the numbers treated with curative intent, details of the 
surgery, post operative morbidity and mortality, theatre utilisation, critical 
care bed occupancy, length of hospital stay and readmission rates 
following discharge. 
7.3.4 Surgical treatment +/- neoadjuvant therapy 
Management plans were individually tailored according to patient related 
factors and their stage of disease. The tumours were staged using 
computed tomography (CT), endoscopic ultrasound (EUS), computed 
tomography positron emission tomography (CT-PET) and staging 
laparoscopy as appropriate.  The S.E. Wales MDT treatment algorithms 
for oesophageal and gastric cancer have been described in Chapter 6.  
Recent changes in gastric cancer management have included the 
increased use of peri-operative chemotherapy in patients with 
locoregionally advanced tumours.  The surgery for gastric GISTs included 
local resection, sleeve gastrectomy or partial gastrectomy, as deemed 
appropriate. 
Operative morbidity was graded in accordance with the Dindo-Clavien 
classification (Dindo and Clavien 2004).  Particular emphasis was placed 
on the incidence of morbidity of Dindo-Clavien grade III or higher, as this 
represented a complication that required an endoscopic, radiological or 
surgical intervention.  In contrast, morbidity of Dindo-Clavien grade I or II 
required only pharmacological treatment. 
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7.3.5 Statistical analysis 
Surgical outcomes were analysed in two ways.  Firstly, outcomes were 
analysed on an intention to treat basis in the two cohorts.  Secondly the 
patients who completed potentially curative surgery for oesophagogastric 
cancer (excluding open and close, palliative surgery and GIST surgery) 
were analysed separately.  Grouped data were expressed as median 
(range) and non-parametric methods were used throughout. Univariate 
and multivariate analyses of factors influencing length of hospital stay 
were performed using the log rank test and Cox regression respectively.   
7.4 RESULTS 
7.4.1 Details of the patients 
The global caseloads presented to the regional MDTs were 271 and 425 
patients for the years pre and post centralisation respectively.  Table 7.1 
shows the details of the patients.  The perceived radiological stage groups 
of the patients pre and post centralisation were:  Stage I, 24 (9.0%) and 33 
(8.3%), Stage II, 40 (15.0%) and 53 (13.3%), Stage III, 75 (28.2%) and 
110 (27.6%) and Stage IV, 105 (39.5%) and 144 (36.2%). The remaining 
patients [22 (8.3%) and 58 (14.6%)] were not formally staged radiologically, 
either because of advanced age such that the MDT group felt their 
management would be palliative irrespective of stage, or because of 
diagnoses such as high grade dysplasia, GIST or lymphoma, for which a 
TNM stage is not appropriate. 
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7.4.2 Details of treatment 
Treatment was potentially curative in 63 (23.7%) and 152 (38.2%) patients 
pre and post centralisation respectively (p<0.0001).  Potentially curative 
treatment consisted of surgery [51 (19.1%) vs. 87 (21.9%)], definitive 
chemoradiotherapy [12 (4.5%) vs. 31 (7.8%)], endoscopic mucosal 
resection [0 vs. 12 (3.0%)], and haematological chemotherapy for 
lymphoma (1 patient post centralisation).  In addition 21 (5.3%) patients 
with oesophagogastric cancer were either awaiting a date for surgery, or 
receiving neoadjuvant therapy, with the probability of subsequent surgery, 
at the end of July 2011.   
The details of the surgery are shown in Table 7.2.  The rates of open and 
close laparotomy for oesophagogastric cancer were similar at 13.7% and 
13.6% pre and post centralisation respectively (p=0.988).  
7.4.3 Operative morbidity and mortality 
Surgical outcome and length of stay data are presented in Table 7.3, both 
for the surgical cohorts from each year as a whole, and as a subgroup 
analysis of the patients who completed a potentially curative resection for 
oesophagogastric cancer (excluding open and close, palliative surgery 
and GISTs).  The cause of the in-hospital death pre centralisation was 
myocardial infarction following total gastrectomy.  The causes of the two in 
hospital deaths post centralisation were multi-organ failure secondary to 
conduit necrosis following Ivor Lewis oesophagectomy, and sepsis 
secondary to abdominal collections following subtotal gastrectomy.  
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Morbidity was classified according to the Dindo-Clavien classification 
(2004).  There were non-significant 50% reductions in the incidence of 
serious (Dindo-Clavien ≥ III) morbidity for all the surgical patients and the 
oesophagogastric cancer resection group.  Anastomotic leaks occurred in 
3 (9.1%) and 5 (7.5%) of the cancer resection patients pre- and post- 
centralisation respectively (p=0.910). 
The morbidity rates were also analysed according to whether or not 
patients were treated within the ERAS program.  Enhanced recovery was 
associated with non-significant 50% reductions in the incidence of serious 
(Dindo-Clavien ≥ III) morbidity for all the patients (20.3% vs. 10.7%, 
p=0.089) and for the oesophagogastric cancer resection group (31.0% vs. 
15.7%, p=0.067).  
7.4.4 Critical care utilisation and length of hospital stay 
For all patients centralisation resulted in a significant reduction in ITU 
(p<0.0001) and critical care (p=0.038) stays.  For the oesophagogastric 
cancer resection patients the same pattern remained (ITU stay p<0.0001, 
critical care stay p<0.0001), but in addition, median length of total hospital 
was significantly shortened by 3.5 days (p=0.037).  The total ITU and HDU 
bed days utilised were 166 vs. 39 and 84 vs. 113 pre and post 
centralisation respectively.  The overall critical care bed days utilised were 
250 and 152 pre and post centralisation respectively.  The 30-day hospital 
readmission rates were 5.9% and 9.1% pre- and post- centralisation 
respectively (p=0.499). 
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The influence of ERAS on the lengths of stay was also examined.  For all 
patients ERAS was associated with a significant reduction in ITU stay 
[median 0 (0-70) vs. 0 (0-12), p=0.003).  There were non significant 
differences in HDU stay [median 1 (0-11) vs. 1 (0-9), p=0.400], critical care 
stay [median 1 (0-70) vs. 1 (0-20)] and overall hospital stay [median 14 (2-
72) vs. 12 (3-36), p=0.131].  For the oesophagogastric cancer resection 
patients ERAS was associated with significant reduction in ITU stay 
[median 0 (0-70) vs. 0 (0-12), p=0.002] and critical care stay [median 2 (0-
70) vs. 1 (0-20), p=0.035] but non-significant reductions in HDU stay 
[median 1 (0-11) vs. 1 (0-9), p=0.304] and overall hospital stay [median 16 
(5-72) vs. 14 (7-36), p=0.056].  Thirty day hospital readmission rates were 
6.3% and 9.3% pre and post ERAS respectively (p=0.603). 
7.4.5 Additional surgical workload 
In addition to the major resectional surgery, staging laparoscopy and the 
insertion of feeding jejunostomies, to facilitate nutrition during neoadjuvant 
therapy, placed an additional burden on the surgical service at the main 
centre (UHW).  During the year following centralisation, 69 staging 
laparoscopy procedures and 15 feeding jejunostomies were performed 
across the network, of which 39 and 11 respectively were undertaken at 
UHW.   
7.4.6 Operating theatre list utilisation and cancellation 
In terms of surgical resources, after taking into account bank holidays and 
consultant leave, a total of 120 all day upper GI theatre lists were available 
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during the year following centralisation at UHW.  Of these 78 (65.0%) were 
used for at least one, and in some cases two, major cancer resections.  
Cancellation of major resection cases in the post centralisation year 
occurred on only two occasions (2.2%) due to lack of an ITU bed, and 
both patients underwent surgery the following week.  In comparison 
cancellation during the pre centralisation period occurred on eight 
occasions (15.6%, p=0.005). 
7.4.7 Univariate and multivariate analysis 
A univariate analysis of factors influencing length of hospital stay, for the 
oesophagogastric cancer resection subgroup of patients, is shown in 
Table 7.4. A multivariate analysis, with the model incorporating all factors 
significant on univariate analysis, is shown in Table 7.5. 
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Table 7.1 Details of the patients 
 Pre Centralisation Post Centralisation 
Patients Referred to MDT 271 425 
New diagnoses 266 398 
Recurrent disease 5 27 
   New Diagnoses (%) 
Cardiff and Vale Health 
Board 
92 (34.6%) 126 (31.7%) 
Aneurin Bevan Health 
Board 
120 (45.1%) 177 (44.5%) 
Cwm Taf Health Board 54 (20.3%) 95 (23.9%) 
Median age (Y) (range) 73 (32-97) 71 (32-95) 
Male : Female 175:91 257:141 
Oesophageal 139 225 
HGD 0 8 
ACA 87 152 
SCC 50 56 
Neuroendocrine tumour 1 1 
Undifferentiated 
carcinoma 
0 6 
Small cell carcinoma 1 1 
Lymphoma 0 1 
Gastric 112 144 
HGD 0 2 
ACA 109 137 
Undifferentiated 
carcinoma 
1 1 
Neuroendocrine tumour 1 1 
Small cell carcinoma 1 0 
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Lymphoma 0 3 
GIST 13 24 
Gastric 10 20 
Oesophageal 1 1 
Jejunal 2 3 
Duodenal 2 5 
ACA 2 4 
Adenoma with HGD 0 1 
   
HGD – high grade dysplasia, ACA – adenocarcinoma, SCC – squamous 
cell carcinoma 
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Table 7.2 Details of the surgery 
 
 Pre 
Centralisation 
Post 
Centralisation 
p value 
Overall Number (%) 51 88  
Ivor Lewis 
Oesophagectomy 
14 (27.5) 11 (12.5)  
Trans Hiatal 
oesophagectomy 
4 (7.8) 14 (15.9)  
Three stage 
oesophagectomy 
0 3 (3.4)  
Total gastrectomy 7 (13.7) 16 (18.2)  
Subtotal gastrectomy 9 (17.6) 16 (18.2)  
Palliative bypass 1 (2.0) 5 (5.7)  
Open and close 7 (13.7) 12 (13.6) 0.988 
GIST Surgery (%) 
Distal or sleeve 
gastrectomy 
5 (9.8) 5 (5.7)  
Local gastric excision 3 (5.9) 3 (3.4)  
Small bowel resection 1 (2.0) 1 (1.1)  
Omentectomy 0 1 (1.1)  
Open and close 0 1 (1.1)  
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Table 7.3 Surgical outcomes and length of stay 
 Pre 
Centralisation 
Post 
Centralisation 
p value 
ALL PATIENTS (%) 
Number 51 88  
Operative (30 day) 
mortality 
1 (2.0) 1 (1.1) 0.694 
In hospital mortality 1 (2.0) 2 (2.3) 0.903 
Any morbidity 16 (31.4) 35 (39.8) 0.220 
Morbidity of Dindo-
Clavien Grade ≥ 3 
11 (21.5) 10 (11.4) 0.105 
Dindo-Clavien 
grades of 
morbidity (%) 
  0.015 
No morbidity 35 (68.6) 53 (60.3)  
Grade I 0 5 (5.7)  
Grade II 5 (9.8) 20 (22.7)  
Grade IIIa 3 (5.9) 0  
Grade IIIb 0 3 (3.4)  
Grade IVa 3 (5.9) 4 (4.5)  
Grade IVb 4 (7.8) 1 (1.1)  
Grade V 1 (2.0) 2 (2.3)  
Length of stay 
ITU stay 0 (0-70) 0 (0-12) <0.0001 
HDU stay 1 (0-11) 1 (0-9) 0.233 
Critical care stay  1 (0-70) 1 (0-20) 0.038 
Total hospital stay 14 (2-72) 12.5 (3-49) 0.238 
 
CURATIVE OESOPHAGOGASTRIC CANCER RESECTION (%) 
Number 33 60  
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Operative (30 day) 
mortality 
1 (3.0) 1 (1.7) 0.664 
In hospital mortality 1 (3.0) 2 (3.3) 0.937 
Any morbidity 16 (48.4) 29 (48.3) 0.989 
Morbidity of Dindo-
Clavien Grade ≥ 3 
11 (33.3) 10 (16.7) 0.066 
Dindo-Clavien 
grades of 
morbidity (%) 
  0.043 
No morbidity 17 (51.5) 31 (51.7)  
Grade I 0 3 (5.0)  
Grade II 5 (15.2) 16 (26.7)  
Grade IIIa 3 (9.1) 0  
Grade IIIb 0 3 (5.0)  
Grade IVa 3 (9.1) 4 (6.7)  
Grade IVb 4 (12.1) 1 (1.7)  
Grade V 1 (3.0) 2 (3.3)  
Length of stay    
ITU stay 0 (0-70) 0 (0-12) <0.0001 
HDU stay 2 (0-11) 1 (0-9) 0.108 
Critical care stay  2 (0-70) 1 (0-20) <0.0001 
Total hospital stay 17.5 (5-72) 14 (7-49) 0.037 
 
Lengths of stay are median in days (range) 
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Table 7.4 Univariate analysis of factors influencing length of hospital 
stay 
 
 
 
 
Table 7.5 Multivariate analysis of factors influencing length of 
hospital stay 
 
Variable Hazard 
Ratio 
95% CI p value 
Operative morbidity 0.260 0.156 0.432 <0.0001 
ERAS program 2.485 1.499 4.122 <0.0001 
Operation type  
Subtotal gastrectomy Reference group 
Total gastrectomy 0.281 0.147 0.535 <0.0001 
Trans hiatal 
oesophagectomy 
0.194 0.092 0.409 <0.0001 
Trans thoracic 
oesophagectomy 
0.207 0.108 0.396 <0.0001 
 
Variable Chi2 df p value 
Age 83.890 37 <0.0001 
Cancer site (oesophageal vs gastric) 16.803 1 <0.0001 
Radiological stage group of cancer 3.948 4 0.413 
Operation type 34.229 3 <0.0001 
Unit surgery performed in 5.803 2 0.055 
Centralisation 7.006 1 0.008 
ERAS program 6.491 1 0.011 
Operative morbidity 34.916 1 <0.0001 
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7.5 DISCUSSION 
The organisation of oesophagogastric cancer surgery services in the UK 
remains a subject of considerable controversy.  In 2001, in recognition of 
traditionally poor short and long term outcomes, the Department of Health 
recommended that the surgical treatment of oesophageal and gastric 
cancer be centralised in units serving populations of at least 1 million 
(Department of Health 2001).  A wealth of evidence now exists 
internationally to support the inverse relationship between hospital and 
surgeon volumes and short term outcomes, particularly operative mortality, 
following oesophagogastric resection (Matthews et al 1986, Swisher et al 
2000, Van Lanshot et al 2001, Bachmann et al 2002, Birkmeyer et al 2003, 
Skipworth et al 2010, Anderson et al 2011).  There is also recent evidence 
of the positive impact of concentrating oesophagogastric surgery on long 
term survival (Birkmeyer et al 2007, Van de Poll-Franse et al 2011).  
Nevertheless, opinions regarding the optimum service configuration 
remain divided in the UK, with Gillison et al (2002) finding no evidence of 
improved short or long term survival related to higher surgeon operative 
caseloads.  Dickson et al (2001) have highlighted the disadvantages of 
centralising oesophageal surgery, most notably the deterioration of 
surgical services and capabilities in district general hospitals, potentially 
disadvantaging patients with other surgical diagnoses requiring upper GI 
expertise.  Furthermore, there is no agreed threshold for defining what 
constitutes a high workload volume. 
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Most published studies on volume/outcome interactions are population 
based, with very few demonstrating actual improvements after 
centralisation of surgery (Birkmeyer et al 2007).  The principal finding of 
this study was that the centralisation of upper GI cancer surgery at the 
University Hospital of Wales was feasible, safe and resulted in significant 
reductions in the use of critical care resources. 
There are limitations to this study.  The data on the control year prior to 
centralisation was collected largely retrospectively, relies to a large extent 
on the accurate identification of patients from MDT records, and therefore 
will inevitably be less robust than the prospective data from the following 
year.  This may partly explain both the lower number of patients identified 
from the year preceding centralisation and the lower number of patients 
with recurrent disease identified relative to the following year.  Therefore, 
some caution must be exercised in over-interpretation of the absolute 
numbers prior to centralisation.  However, to a degree this method of data 
collection for the surgical patients is mitigated by two factors.  Firstly, all 
the patients who underwent surgery prior to centralisation from two of the 
three local health boards, and therefore the majority of the surgical 
patients, had been entered into a prospectively maintained database 
which included surgical outcomes.  Secondly, computerised records at the 
three health boards accurately record dates of hospital stay on different 
wards, operation notes, discharge documentation and all radiological and 
pathological test results.  It is therefore unlikely that any surgical patients 
7 Centralisation 
192 
have been missed or that any major errors exist in terms of outcomes and 
particularly length of stay. 
The reconfigured surgical service and the introduction of an ERAS 
programme are inextricably linked in the results of this study and it is 
difficult to be certain of the relative influence of each on the outcomes 
studied.  In the present study, multivariate analysis analysis identified 
ERAS to be independently related to the length of hospital stay, whilst the 
effect of centralisation was highly significant on univariate analysis.  There 
is considerable evidence from colorectal surgery which suggests ERAS is 
likely to contribute to reduced complication rates and shortened hospital 
stay.  Key input from the Intensive Care Department to update the new 
surgical model with a critical care admission protocol had an impact on 
ITU bed utilisation and this was independent of ERAS.  Moreover, the well 
documented effects of increased surgical volume on outcomes in the 
literature offer a further possible explanation for the improved outcomes 
demonstrated.  Specifically, the possibility of joint consultant operating, 
whilst possible pre-centralisation, has been made more accessible within 
the centralised service, and this may have delivered its own benefits in 
particularly difficult cases.  It is likely that the reasons for the demonstrated 
improvements are multifactorial, and further work is warranted to establish 
the influence of ERAS, and refine its application in upper GI surgery.   
The significant reductions in ITU and overall critical care bed occupancy 
are certain to have resulted in considerable financial cost savings to the 
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cancer network.  However, it was not within the remit of this study to 
formally assess cost effectiveness. 
It is generally accepted that most patients prefer to undergo medical 
treatment in their local hospital where possible.  It is therefore important to 
assess patient satisfaction when introducing a centralised clinical service.  
Whilst the results of this survey are awaited at present, patient feedback 
has been very favourable, no complaints have been received, and patients 
continue to undergo their diagnostic and staging investigations at their 
local hospitals. 
The present study has several strengths.  It is one of very few UK reports 
of outcomes following centralisation of oesophagogastric surgery.  The 
data for the year following centralisation was collected prospectively by the 
author.  This involved attendance at almost all MDT meetings and 
prospective review of all surgical patients during their hospital admission, 
and for these reasons the data is highly robust.   
At the time of writing, only two other UK studies have reported outcomes 
after centralising oesophagogastric cancer surgery.  In 2004 Branagan et 
al reported the early impact of centralisation within Wessex, and found 
similar overall complication rates but a significant reduction in operative 
mortality (5 of 33 vs 0 of 40, p=0.022).  Pathology reporting and mean 
lymph node harvest were also noted to have improved in the centralised 
unit.  The patient numbers treated were relatively small, and the operative 
mortality prior to centralisation (5 of 33, 15.2%) would be considered 
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excessive today.  These findings contrast to our experience, where 
operative mortality rates were low before centralisation, making such a 
dramatic improvement unlikely to be realised in S.E. Wales.  In 2006, 
Forshaw et al reported their experience of oesophagogastric resection 
within an efficient high volume unit in London.  They reported good 
cancer-related results, without a detrimental impact on the benign elective 
workload, although they do not present a historical control group for 
comparison.  Our experience in terms of cancer management is in many 
ways in common with this.  However, in contrast to Forshaw et al, there 
will have almost certainly been an adverse impact on local benign upper 
GI waiting times, as 65.0% of theatre lists were utilised wholly or in part for 
cancer surgery.  This effect was not examined as part of this study.   
The Association of Upper Gastrointestinal Surgeons (2010) has recently 
recommended that an ideal oesophagogastric unit would consist of 4-6 
surgeons, each performing a minimum of 15-20 resections per year and 
serving a population of 1-2 million.  The reconfigured service in S.E. Wales 
is in line with all of these recommendations. 
7.6 CONCLUSION 
Centralisation of oesophagogastric cancer surgery, allied to ERAS, is 
feasible in S.E. Wales within the limited resources available, and 
demonstrates the patient safety and quality improvements achievable by 
compliance with NHS guidelines. 
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GENERAL DISCUSSION AND FUTURE STUDIES 
This thesis is concerned with examining key areas of the treatment of 
oesophagogastric cancer where uncertainty exists.  These include: 
1. Whether the latest update of TNM represents an advance in 
oesophageal cancer stage categorisation.  
2. Whether CT-PET imaging contributes to the contemporary staging 
algorithm. 
3. Whether definitive chemoradiotherapy and surgery are associated with 
differing rates and patterns of oesophageal cancer recurrence. 
4. Whether an involved oesophageal circumferential resection margin 
has prognostic significance and how neoadjuvant therapy regimes 
impact on this. 
5. Whether early enteral nutrition following resectional surgery improves 
clinical outcomes. 
6. Whether centralisation of surgical services is feasible and improves 
clinical outcomes.  
Despite contemporary multidisciplinary, stage-directed treatment of 
oesophagogastric cancer, outcomes remain poor when compared with 
many other malignancies, and this relates largely to late presentation with 
advanced stage disease.  However, the treatments themselves are 
associated with substantial morbidity and mortality.  Chemotherapy and 
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chemoradiotherapy regimes are associated with significant toxicity, whilst 
surgical approaches for oesophagogastric cancer are among the most 
physiologically stressful of all operations. 
The treatment of oesophageal cancer must provide the best chance of 
cure, the lowest risk of morbidity and mortality, and the smallest impact on 
health related quality of life.  Accurate radiological staging is fundamental 
in determining the most appropriate multimodal treatment option where the 
possibility of cure exists, and avoiding inappropriate aggressive treatment 
in those patients with disseminated disease.  Successful staging relies on 
knowledge of the relative strengths and weaknesses of emerging staging 
modalities, and how such modalities are best incorporated into existing 
staging algorithms.  Furthermore, the TNM criteria used to define stage 
must be able to accurately predict prognosis, and evolve with the evidence 
base.  The morbidity of surgically based treatment continues to stimulate 
the search for refinement of potentially curative non-surgical options.  The 
limits of surgery alone in curing oesophageal cancer must be appreciated, 
neoadjuvant therapy used where appropriate and optimum regimes 
defined.  Principles of peri-operative care and surgical service 
configuration must continue to develop. 
8.1 TNM7 
The development of the 7th edition of TNM introduced major changes for 
oesophageal cancer staging, particularly with regard to stratified nodal 
staging.  The updates were not only evidence-based, but a novel data 
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driven approach was used to accurately redefine stage groupings (Rice et 
al 2010).  The findings reported in Chapter 2 demonstrated that the 
utilisation of TNM7 to redefine histopathological stage resulted in stage re-
categorisation and provided a more accurate determination of prognosis. 
The benefits of TNM7 are equally applicable to clinical stage as well as 
final pathological stage.  It is now vital that all radiological modalities report 
stage in accordance with TNM7, particularly with regard to the number of 
lymph node metastases.  Furthermore, published research must be 
interpreted in the context of the edition of TNM used, as the stage re-
categorisation effect demonstrated prevents meaningful comparison with 
data derived from an outdated edition of TNM.   Correct interpretation of 
published data is particularly important in the context of large randomised 
trials where the time interval from study development through to 
publication of results can be considerable, and there is the possibility of 
TNM revision during this period.  
8.2 STAGING CT-PET  
The incorporation of CT-PET in the staging algorithm for oesophageal 
cancer upstaged a quarter of patients and prevented inappropriate 
treatment (Chapter 3).  This benefit alone justifies the on-going routine use 
of CT-PET.  However, the accuracy of CT-PET in determining N stage was 
disappointing when compared with EUS, particularly in terms of sensitivity.  
Further work is needed to establish the reasons for the poor N stage 
accuracy, so that multidisciplinary teams can be aware of specific 
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situations in which CT-PET N stage may be particularly inaccurate.  
Specifically, further studies should define the relative accuracy of 
peritumoural vs. more distant regional lymph node assessment, compared 
with histopathological N stage, with large numbers of patients.  Such a 
study would require accurate prospective reporting of the precise location 
of lymph node metastases identified on CT-PET, in combination with more 
detailed pathological reporting of lymph node sites, in order to allow 
comparison.  In the future it may be the case that EUS is taken as the 
definitive assessment of peritumoural lymph nodes, whilst CT-PET is used 
specifically to refine examination of more distant regional nodes. 
Furthermore, the influence of CT-PET in the determination of total disease 
length must be investigated, as this is crucial for the planning of both 
surgery and chemoradiotherapy, and may have prognostic value. In 
particular the relative prognostic value of EUS and CT-PET defined length 
of disease remains to be identified.  The impact of SUV of the primary 
tumour on overall accuracy of all aspects of CT-PET staging remains to be 
determined.  There may exist a critical SUV level, below which CT-PET 
staging should be interpreted with caution, or even disregarded 
completely.  Finally the influence of CT-PET on oesophageal cancer 
survival should be studied, as the up-stage re-categorisation 
demonstrated in this thesis would be expected to result in improved stage 
specific survival. 
The centralisation of resectional surgery in the S.E. Wales network will 
facilitate such research, as large numbers of oesophageal resections will 
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be undertaken and standardised histopathology provided by a single 
department.  
8.3 OESOPHAGEAL CANCER RECURRENCE PATTERNS 
Stage for stage examination of long term outcomes following definitive 
chemoradiotherapy and surgery for oesophageal cancer in Chapter 4 
demonstrated similar overall rates of disease recurrence, but very different 
patterns of relapse.  Furthermore, survival was better following surgery 
than dCRT for early stage disease, but similar for more advanced stage III 
and IV tumours, with which the majority of patients present in the UK.  
Some surgeons continue to advocate surgically based treatment for 
advanced stage oesophageal cancer, largely on the basis of improved 
locoregional control (Stahl et al 2005, Clark et al 2010), yet the findings in 
this thesis demonstrate this cannot be justified, as any such benefit in 
surgically treated patients is offset by the two-fold increased rate of distant 
recurrence. 
The next major goal with regard to the role of dCRT is a randomised 
controlled trial of this treatment modality compared to surgically based 
treatment in fit patients with stage III oesophageal cancer of any cell type.  
However, the potential difficulties in running such a trial are considerable.  
Early results from a 3 centre feasibility trial (Blazeby 2011) confirm that the 
proportion of patients with squamous cell carcinoma recruited are small, 
and therefore running a full trial, although theoretically feasible, would 
require participation from a large number of centres (Strong et al 2011). 
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Further research will undoubtedly refine dCRT techniques.  Radiotherapy 
techniques continue to evolve, and in tandem with improved disease 
localisation radiologically, may enable better local disease control.  
Radiotherapy targeting is particularly difficult in patients where EUS has 
failed to cross the primary tumour, and CT-PET may enhance disease 
localisation in this situation.  As knowledge of tumour biology expands on 
a molecular level, the use of novel monoclonal antibodies, such as 
Trastuzumab and Cetuximab, allied to conventional chemotherapy agents, 
may improve the systemic effects of dCRT treatment.  Targeted molecular 
therapies, tailored to individual patients, are likely to form a mainstay of 
treatment for many cancers in the future, and may eventually replace 
conventional cytotoxic chemotherapy.  Patients with oesophageal cancer, 
who frequently present with advanced disease, for whom surgical 
treatment is unsuitable in the majority, may benefit substantially from such 
developments.  
8.4 CIRCUMFERENTIAL RESECTION MARGIN 
The results reported in Chapter 5 demonstrated that involvement of the 
CRM following oesophagectomy was an independently significant 
prognostic marker, and of stronger prognostic value than pathological 
lymph node stage for disease-free survival.  The majority of published 
studies on CRM status report an association with survival, in common with 
this thesis, although in contrast two of the largest studies failed to identify 
any such independent survival association.  Involvement of the CRM is 
likely therefore to be one of a number of important pathological prognostic 
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markers following oesophagectomy.  The pathological processing of 
oesophagectomy specimens is controversial, but irrespective of this, a 
positive CRM is a common occurrence in contemporary UK practice, 
occurring in 29% of patients (NHS Information Centre 2010).  Assuming 
appropriately radical surgery has been performed by specialist surgeons, it 
is reasonable to consider a positive CRM as more a reflection of locally 
advanced disease than suboptimal surgery.  The only conceivable means 
of significantly reducing CRM positive rates are through the use of more 
aggressive neoadjuvant therapy regimes.  Although Sujendran et al (2007) 
have shown neoadjuvant chemotherapy reduces the incidence of CRM 
involvement, the finding reported in this thesis was only a non-significant 
trend towards the same on multivariate analysis.  However, neoadjuvant 
chemoradiotherapy substantially reduced CRM positive rates in this study, 
and therefore the issue of CRM status is an integral part of the much wider 
argument regarding the optimum neoadjuvant therapy regime in 
oesophageal cancer.  High complete resection rates are a feature of many 
studies of neoadjuvant chemoradiotherapy, including the most recent 
randomised trial, in which 92.3% of patients treated with 
chemoradiotherapy had an R0 resection (Gasst et al 2010). 
The next major research goal must therefore be a randomised trial of 
neoadjuvant chemoradiotherapy vs. chemotherapy prior to surgery for T3+ 
tumours, with close scrutiny of treatment safety, R0 resection rates, 
survival and health related quality of life.  Treatment safety is of paramount 
concern in this context.  Chemoradiotherapy is arguably more 
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physiologically stressful and toxic than chemotherapy alone, and this has 
a potential knock-on effect on both the chances of patients remaining fit 
enough to proceed to surgery, and on maintaining sufficient physiological 
reserve to proceed to oesophagectomy with acceptable morbidity and 
mortality.  Such a trial must utilise standardised physiological assessment, 
ideally incorporating cardiopulmonary exercise testing before and after 
neoadjuvant treatment.  This will enhance patient selection and provide 
objective evidence of the relative impact of chemoradiotherapy and 
chemotherapy regimes. 
A further question that remains to be answered is the need for surgery in 
the one third of patients who have a complete pathological response to 
neoadjuvant chemoradiotherapy.  Clearly, identification of a complete 
response radiologically is difficult, as EUS has been shown to be 
unreliable following radiotherapy, even in complete pathological response 
(Bowrey et al 1999) and the role of CT-PET in this regard is yet to be 
defined.  Nevertheless, if radiological staging evolves to the point where 
the degree of pathological response can be accurately determined, this is 
an issue that will need to be addressed. 
8.5 EARLY ENTERAL NUTRITION 
The principal findings of Chapter 6 were that early enteral nutrition (EEN) 
within 12 hours of surgery, delivered via a feeding jejunostomy, was safe 
and associated with improved clinical outcomes.  Concerns remain 
regarding the safety of feeding jejunostomy placement (NHS Information 
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Centre 2010), and sceptics feel the only material benefit is the facility to 
enterally feed patients who develop serious post-operative complications. 
For these reasons early jejunostomy feeding is not routine practice in all 
UK centres (Allum et al 2011).  The most recent UK oesophagogastric 
cancer guidelines recommend that some form of nutrition be provided in 
line with National Institute for Health and Clinical Excellence (2006) 
guidance, and that preferably this should be enteral where possible.  Early 
enteral nutrition makes sense as a concept, when considered within the 
wider framework of Enhanced Recovery After Surgery (ERAS).  The 
principles of ERAS, widely advocated and well accepted in patients 
undergoing colorectal surgery, must now be tested as a complete package 
in upper gastrointestinal surgery.  Arguably there are even greater 
potential gains for patients undergoing oesophagogastric resection within 
an ERAS protocol, given the greater magnitude of physiological stress and 
more prolonged deficit of gut and body function, when compared with 
colorectal resection.  There is enormous scope for refining the ERAS 
protocol to make it applicable for patients with upper gastrointestinal 
anastomoses, for whom early oral intake may not be appropriate.  The 
enteral feeding regime studied in Chapter 6 aimed to provide 50% of 
nutritional requirements by day 5, yet it may be feasible to aim for greater 
provision, and consequently further reduce the need for intravenous fluids, 
with the attendant risk of volume and electrolyte imbalances.  The 
significant reduction in peripheral oedema reported in Chapter 6 in 
patients randomised to EEN occurred despite no significant difference in 
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overall cumulative fluid balance, suggesting the route of fluid 
administration is important.  Further studies in the context of EEN, within 
an ERAS protocol, are needed to more accurately quantify the interplay 
between enteral nutrition and fluid balance. Sophisticated research 
techniques, such as bioimpedance analysis, have been shown to 
accurately predict the development of oedema following major abdominal 
surgery, and consequently identify those at risk of delayed return of gut 
function, prolonged hospital stay and post-operative morbidity (Itobi et al 
2006).  Clearly the application of such techniques in the clinical setting 
warrants further research, ideally within the context of an ERAS protocol.  
Ultimately the traditional period of nil by mouth for 5 to 7 days, prior to 
routine contrast radiography for all patients following oesophagectomy and 
total gastrectomy may be questioned, raising the possibility of early oral 
fluid and feed intake in selected patients. 
8.6 CENTRALISATION OF SURGERY 
Subspecialisation of general surgery in the UK has developed rapidly over 
the last decade, and is now the accepted routine for major oncological 
surgery.  The move towards centralisation of low volume but high 
complexity cancer surgery was recommended by NHS Executive 
guidance, but progress has been sporadic and slow.  The results of 
centralisation of surgery in S.E. Wales, reported in Chapter 7, 
demonstrated that such reconfiguration was feasible and associated with 
improvements in clinical outcomes.  This stands alone as the only large 
scale comparison of the outcomes before and after service 
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reconfiguration, in a UK regional cancer network, and will lend support to 
reconfiguration efforts in other geographical areas and surgical 
specialities. 
The establishment of a high volume surgical centre will facilitate high 
quality prospective research in all areas of oesophagogastric practice.  
Specifically, further research effort is needed to establish if centralisation 
of oesophagogastric surgery is associated with any survival benefit, and to 
further clarify the individual influences of surgery in a high volume centre 
and an ERAS protocol.  Furthermore, accurate physiological staging for 
patients suitable for curative treatment is now at a critical juncture, with the 
increasing availability of cardiopulmonary exercise testing (CPET), the 
prospect of ever more intensive neoadjuvant chemoradiotherapy regimes 
on the horizon, and the emerging role of non-surgical curative treatment 
options for high risk patients.  A prospective study of CPET in relation to 
treatment decisions and oesophagogastric surgical outcomes is urgently 
needed, and the centralised unit would form an ideal setting for such work. 
Finally, the centralisation of regional oesophagogastric surgery in a single 
high volume centre has major potential benefits for specialist training for 
the full spectrum of multidisciplinary team members and facilitates national 
randomised trial recruitment. 
8.7 CONCLUSION 
Oesophagogastric cancer is still considered by many clinicians to be a 
“sentence of death”.  However, all aspects of staging, physiological 
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assessment, oncological treatment, surgery and peri-operative care are 
constantly improving, and this view must be challenged.  The cornerstone 
of oesophagogastric cancer management will continue to be accurate 
stage-directed treatment, specifically tailored to individual patients.  
Further research must strive to improve outcomes for patients diagnosed 
with the most rapidly increasing cancer in the Western world. 
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APPENDIX 2 
 
2.1 TNM7 for oesophageal cancer 
 
 
Tumour stage 
 
Tis Carcinoma in situ / high grade dysplasia 
 
T1a Invasion of lamina propria or muscularis mucosae 
T1b Invasion of submucosa 
 
T2 Invasion of muscularis propria 
 
T3 Invasion of adventitia 
  
T4a Invasion of pleura, pericardium, diaphragm or adjacent peritoneum 
T4b Invasion of other structures e.g. aorta, vertebral bofy, trachea 
 
 
Nodal stage 
 
N0 No regional lymph node metastases 
 
N1 1 to 2 regional lymph node metastases 
 
N2 3 to 6 regional lymph node metastases 
 
N3 >6 regional lymph node metastases 
 
 
Metastasis stage 
 
M0 No distant metastases 
 
M1 Distant metastases 
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2.2 TNM7 anatomical stage groups for oesophageal cancer 
 
 
   T   N   M 
 
Stage IA  T1   N0   M0 
 
Stage IB  T2   N0   M0 
 
Stage IIA  T3   N0   M0 
 
Stage IIB  T1, T2   N1   M0 
 
Stage IIIA  T4a   N0   M0 
   T3   N1   M0 
   T1, T2   N2   M0 
 
Stage IIIB  T3   N2   M0 
 
Stage IIIC  T4a   N1, N2  M0 
   T4b   Any N   M0 
   Any T   N3   M0 
 
Stage IV  Any T   Any N   M1 
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2.3 TNM7 prognostic stage groups for oesophageal squamous cell 
carcinoma 
 
 
  T     N       M            Grade            Location 
 
Stage IA T1     N0       M0  1,X    Any 
 
Stage IB T1     N0       M0  2,3    Any 
  T2,T3     N0       M0  1,X    Lower 
 
Stage IIA T2,T3     N0       M0  1,X    Upper, Middle 
  T2,T3     N0       M0  2,3    Lower 
 
Stage IIB T2,T3     N0       M0  2,3    Upper, Middle 
  T1,T2     N1       M0  Any    Any 
 
Stages IIIA, IIIB, IIIC and IV are as per anatomical stage groups 
 
 
Grades: 1 = well differenciated, 2 = moderately differenciated, 3 = poorly 
differenciated, X = not determined.   
 
Locations are upper, middle or lower third of oesophagus. 
 
 
 
 
2.4 TNM7 prognostic stage groups for oesophageal adenocarcinoma  
 
 
  T       N           M          Grade    
 
Stage IA T1       N0          M0   1,2,X   
 
Stage IB T1       N0          M0   3     
  T2       N0          M0   1,2,X     
 
Stage IIA T2       N0          M0   3         
 
Stage IIB T3       N0          M0   Any     
  T1,T2       N1          M0   Any     
 
Stages IIIA, IIIB, IIIC and IV are as per anatomical stage groups 
 
 
Grades: 1 = well differenciated, 2 = moderately differenciated, 3 = poorly 
differenciated, X = not determined.   
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APPENDIX 3 
 
Documents related to early enteral nutrition trial 
 
3.1 Patient consent form 
 
To be issued on Hospital Trust headed paper 
 
A STUDY COMPARING TWO TYPES OF NUTRITION AFTER MAJOR 
SURGERY 
 
I (name of patient) 
 
Of (address of patient) 
 
 
 
Voluntarily agree to participate in this study. 
 
I confirm that I have been given a full explanation of the purpose of the 
study by my doctor and/or the lead investigator and have had adequate 
opportunity to ask questions. I have been made aware of the procedures 
involved, any potential risk to my health and well-being and what is 
expected of me during the study. 
 
I understand that I am free to withdraw from this study at any time, without 
explanation, and that such withdrawal will not affect my future treatment. 
 
I understand that all reasonable steps will be taken to protect my 
confidentiality and that my name will not be disclosed to any unauthorised 
person or be referred to in any report concerning this study. 
 
I agree to my doctor informing my GP about my participation in the trial. 
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SIGNATURE OF PATIENT 
 
Signed ________________________________________________ 
   
Date  ________________________________________________ 
  
Name  ________________________________________________ 
 
 
SIGNATURE OF INVESTIGATOR 
 
Signed _______________________ Date ____________________ 
 
 
SIGNATURE OF WITNESS 
 
Signed ________________________________________________ 
 
Date  ________________________________________________ 
 
Name  ________________________________________________ 
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